ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  1  
 This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise  agreed  to in writing,  by accepting  or reviewing  these  documents,  you agree to hold this information  in 
confidence and not copy or disclose it to others (except where required by applicable law) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.   
 
 
 
A PHASE 3 PROSPECTIVE, RANDOMIZED, MULTICENTER, OPEN- LABEL, 
CENTRAL  ASSESSOR -BLINDED,  PARALLEL  GROUP,  COMPARATIVE  STUDY 
TO DETERMINE THE EFFICACY, SAFETY AND TOLERABILITY OF 
AZTREONAM -AVIBACTAM (ATM -AVI) ±METRONIDAZOLE (MTZ) VERSUS 
MEROPENEM ±COLISTIN (MER ±COL) FOR THE TREATMENT OF SERIOUS 
INFECTIONS DUE TO GRAM -NEGATIVE BACTERIA, INCLUDING  
METALLO -Β-LACTAMASE  (MBL)  – PRODUCING  MULTIDRUG  RESISTANT 
PATHOGENS, FOR WHICH THERE ARE LIMITED OR NO TREATMENT 
OPTIONS  
 
 
Investigational Product  Number:  PF-06947387  
Investigational Product  Name:  Aztreonam  -Avibactam  
United  States  (US)  Investigational New 
Drug (IND) Number:  
European  Clinical Trials  Database 
(EudraCT) Number:  2017- 002742 -68 
Protocol Number:  C3601002  
Phase:  3 
 
 

ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  2  
 Document  History  
 
Document  Version  Date  Summary of Changes and Rationale  
Amendment  2 18 May  2022  Increased sample size from “approximately 375 
subjects” to “up to approximately 425 subjects”. This 
change is reflected in the Protocol Summary, Section 3 (Study Design) and Section 9 (Data Analysis/Statistical Methods). This increase in patient 
numbers is in response to a slower than anticipated recruitment in another ATM-AVI Phase III protocol. The change will help ensure that there is a minimum of patients  on the ATM -AVI treatment  arm across  the 
program.  
 
• Section 1.5 and Section 16: Updated Single Reference  Safety  Document  and References  list to 
reflect current and additional sources of study drugs or comparators (update as per PACLs dated 05-Aug-2020, 26- Mar-2021) 
• Section 1.6: Updated risk/benefit language to replace “Drug induced liver injury” with “Increased liver transaminases” to be consistent with Investigator Brochure  (update as per PACL 
dated 09- Nov-2021) 
• Section 5.5.1: Clarification to the study drug characteristics  (update as per PACL  dated  05-Aug- 
2020)  
• Section  7.2.3: Clarification  on when  ECG  should 
be performed for both treatment arms (update as per PACL dated 05- Aug-2020) 
• Section 11.1: Added a statement on deletion of data in line with the current Pfizer Protocol template Section 11.3: Added a new section on Data Protection  from  the current  Pfizer  Protocol 
template  
• Sections  12.1 and 12.2: Updated  language based 
on the current Pfizer Protocol template 
• Appendix  8: Details  on prior  amendment  to the 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  3  
  
  protocol  are now summarized  in a new Appendix 
8 
This amendment incorporates all revisions to date, including amendments made at the 
request  of country health  authorities  and institutional review  boards (IRBs)/ethics  committees 
(ECs).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  4  
 TABLE OF CONTENTS  
LIST  OF TABLES  ................................................................................................................... 10 
LIST  OF FIGURES  .................................................................................................................. 10 
APPENDICES  .......................................................................................................................... 11 
PROTOCOL  SUMMARY ....................................................................................................... 12 
1. INTRODUCTION  ................................................................................................................ 31 
1.1. Background  .............................................................................................................. 31 
1.2. Mechanism of Action/Indication  ............................................................................. 32 
1.3. Rationale for Conducting This Study ...................................................................... 32 
1.4. Rationale for Study Design, Doses and Control Groups  ......................................... 33 
1.4.1.  Study Design and Control Group  ................................................................ 34 
1.4.2.  Dose  Selection  for ATM -AVI ..................................................................... 35 
1.4.3.  Dose Selection for Metronidazole  ............................................................... 38 
1.4.4.  Dose  Selection  for Meropenem  ................................................................... 38 
1.4.5.  Dose Selection for Colistin  ......................................................................... 38 
1.5. Single Reference Safety  Document  ......................................................................... 38 
1.6. Benefits/Risk  and Ethical  Assessment  ..................................................................... 39 
2. STUDY OBJECTIVES AND ENDPOINTS  ....................................................................... 41 
2.1. Primary  Objective  .................................................................................................... 41 
2.2. Secondary  Objectives  .............................................................................................. 43 
2.3. Safety  Objectives  ..................................................................................................... 43 
2.4.
 Tertiary  Objectives  .................................................................................................. 44 
2.5. Exploratory Objectives  ............................................................................................ 45 
2.6. Other  Objectives  ...................................................................................................... 45 
3. STUDY DESIGN  ................................................................................................................. 45 
4. SUBJECT  ELIGIBILITY  CRITERIA  ................................................................................. 49 
4.1. Inclusion Criteria  ..................................................................................................... 49 
4.1.1.  All Subjects  ................................................................................................. 49 
4.1.2.  Additional Inclusion Criteria  - cIAI Subjects  ............................................. 50 
4.1.3.  Additional Inclusion Criteria  – HAP/VAP  Subjects  ................................... 52 
CCI  
4.2. Exclusion Criteria  .................................................................................................... 53 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  5  
 4.2.1.  All Subjects  ................................................................................................. 53 
4.2.2.  Additional Exclusion Criteria – cIAI Subjects  ........................................... 56 
4.2.3.  Additional Exclusion Criteria  – HAP/VAP  Subjects  .................................. 56 
4.3. Subject Enrolment and Randomization  ................................................................... 56 
4.4. Randomization Criteria ............................................................................................ 57 
4.5. Procedures for Handling Incorrectly Enrolled or Randomized Subjects ................. 57 
4.6. Lifestyle  Requirements  ............................................................................................ 57 
4.6.1.  Contraception  .............................................................................................. 57 
4.7. Sponsor’s Qualified  Medical  Personnel ................................................................... 58 
5. STUDY TREATMENTS  ..................................................................................................... 59 
5.1. Allocation to Treatment  ........................................................................................... 59 
5.2. Methods for Ensuring Blinding  ............................................................................... 60 
5.3. Methods for Unblinding ........................................................................................... 60 
5.4. Subject Compliance  ................................................................................................. 60 
5.5. Investigational Product Supplies  ............................................................................. 61 
5.5.1.  Dosage Forms and Packaging ..................................................................... 61 
5.5.2.  Labelling  ..................................................................................................... 61 
5.5.3.  Preparation  and Dispensing ......................................................................... 62 
5.6. Administration (Dose and Treatment Regimen)  ..................................................... 62 
5.6.1.  ATM -AVI ±MTZ Treatment  Arm .............................................................. 62  
5.6.2.  MER ± COL  Treatment  Arm ....................................................................... 63 
5.6.3.  Optional Aminoglycosides  .......................................................................... 65 
5.6.4.  Optional Gram -positive Antibiotics  ............................................................ 65 
5.6.5.  Changes in Renal  Function during Study Treatment  .................................. 65 
5.7. Investigational Product Storage  ............................................................................... 66 
5.8. Investigational Product Accountability  ................................................................... 66 
5.8.1.  Destruction  of Investigational  Product Supplies  ......................................... 68 
5.9. Post Study Access to Study  Treatment  .................................................................... 68 
5.10. Concomitant Treatment(s)  ..................................................................................... 68 
5.10.1.  Other  Concomitant Treatment  .................................................................. 72 
5.11. Drug -drug Interaction  ............................................................................................ 73 
5.11.1.  Aztreonam -avibactam  ............................................................................... 73 
5.11.2.  Coagulation and Concomitant Use of Anticoagulants  ............................. 74 
5.11.3.  Other  Investigational Products  ................................................................. 74 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  6  
 6. STUDY PROCEDURES ..................................................................................................... 74 
6.1. Screening  and Enrollment  ....................................................................................... 74 
6.1.1.  Visit 1: Eligibility/Screening  Procedures  (Day  -1 to  1) ............................. 74 
6.2. Study Period  ........................................................................................................... 76 
6.2.1.  Visit 2: Baseline Procedures  and Day  1 of Treatment  (Day  1) .................. 76 
6.2.2.  Visit 3 to 15: Ongoing Treatment (Days 2  to 14)  ...................................... 78 
6.2.3.  Post- Treatment  Period  ............................................................................... 79 
6.2.3.1. Visit 16: End  of Treatment  (Within  24 Hours after Last 
Infusion)  ............................................................................................ 79 
6.2.3.2. Visit 17: Test of Cure (Day  28 ± 3 days)  ................................... 80 
6.2.3.3. Visit 18: Late Follow-up (Day 45±3 days)  ............................... 82 
6.3. Discontinuation of Investigational Product  ............................................................. 82 
6.3.1.  Procedures  for Discontinuation of a Subject  from  Investigational  
Product  ............................................................................................................ 83 
6.4. Subject Withdrawal  ................................................................................................ 83 
6.4.1.  Screen  Failures  ........................................................................................... 84 
6.4.2.  Withdrawal  of Consent  .............................................................................. 84 
6.4.3.  Lost to Follow- up ....................................................................................... 84 
7. ASSESSMENTS  ................................................................................................................. 85 
7.1.
 Efficacy  Assessments  ............................................................................................. 85 
7.1.1.  Clinical Response Assessment  ................................................................... 85 
7.1.2.  Microbiological Response .......................................................................... 87 
7.1.2.1. Microbiological Response Assessment  ..................................... 88 
7.2. Safety Assessments  ................................................................................................. 89 
7.2.1.  Laboratory Safety  Assessments  ................................................................. 89 
7.2.2.  Physical  Examination  ................................................................................. 92 
7.2.3.  ECG  ............................................................................................................ 92 
7.2.4.  Vital Signs  .................................................................................................. 93 
7.2.4.1. Pulse and Blood Pressure  ......................................................... 93 
7.2.4.2. Body Temperature  .................................................................... 93 
7.2.5.  Pregnancy  Testing  ...................................................................................... 93 
ATM -AVl 
C3601002 
 Fi nal  Protocol Amendmen t 2, 18 May 2022   
7.2.6.  Other  Safety  Asses sments  ........................................................................... 94 
7.2.6.1. Chest X-ray/ CT Scan  ................................................................ 94 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  7  
 
7.2.6.2. Acute Physiology and Chronic Health  Evaluation  .................... 94 
7.3. Microbiology  ........................................................................................................... 94 
7.4. Pharmacokinetics  ................................................................................................... 95 
7.4.1.  Collection  of Plasma  Samples  for Analy sis of Aztreonam -Avibactam  ...... 95 
7.4.2.  Determination  of Drng  Concentration  ...................................................... 100 
7.4.3.  Storage and Destruction  of Phannacokinetic Samples  ............................. 100 
7.5. Pharmacogenomic s: not applicable  ....................................................................... 100 
7.6. Biological  Samples  ................................................................................................ 100 
7.6.1.  Storage,  Re-use and Destruction  of Biological Samples  ........................... 101 
7.6.2. Labelling and  Shipment of Biological Samples  ........................................ 102 
7.6.3.  Chain  of Custody of Biological Samples  .................................................. 102 
 
8. ADVERSE EVENT  REPORTING  .................................................................................... 104 
8.1. Requirement s ......................................................................................................... 104 
8.1.1. Additional Detail s on Recording Adverse Events  on the CRF ................. 105 
8.1.2. Eliciting  Adverse Event Information  ........................................................ 105 
8.1.3. Withdrawal  from the  Study Due to Adverse Events ( see also the 
Subject  Withdrawal  Section)  .......................................................................... 105 
8.1.4. Time Period  for Collecting  AE/SAE  Infonnation  ..................................... 105 
8.1.4.1. R eporting SAEs  to Pfizer  Safety  ............................................. 106 
8.1.4.2. Recording Non -serious AE s and SAEs  on the CRF ................ 106 
8.1.5. Causality  Assessment  ................................................................................ 106 
8.1.6. Sponsor's Repo1iing Requirement s to Regulato1y Authorities  ................. 107 
8.2. Definition s ............................................................................................................. 107 
8.2.1. Adverse Events  ......................................................................................... 107 
8.2.2. Abnonnal Test Findings ............................................................................ 108 
8.2.3. Definition s of Serious Adverse Events  ..................................................... 108 
8.2.4. Hospitalization  .......................................................................................... 109 
8.3. Severity  Assessment.  ............................................................................................. 110 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  8  
 8.4. Special Situations .................................................................................................. 110 
8.4.1. Protocol- Specified  Serious  Adverse Events  ............................................. 110 
8.4.2. Adverse Events Based  on Signs and Symptoms  ...................................... 110 
8.4.3. Adverse Events Based  on Examinations and Tests .................................. 110 
8.4.4. Exceptions from  Standard  Adverse Events Collection  ............................ 111 
8.4.4.1. Lack  of Effect  ......................................................................... 111 
8.4.4.2. Disease Progression  ................................................................ 111 
8.4.5. Potential Cases  of Drug -Induced Liver  Injury  ......................................... 112 
8.4.6. Exposure to the Investigational Product During Pregnancy or 
Breastfeeding, and Occupational Exposure  .................................................. 113 
8.4.6.1. Exposure During Pregnancy  ................................................... 113 
8.4.6.2. Exposure During Breastfeeding  .............................................. 115 
8.4.6.3. Occupational  Exposure  ........................................................... 115 
8.4.7. Medication  Errors ..................................................................................... 115 
8.4.7.1. Overdose  ................................................................................. 116 
8.5. Management of Laboratory Safety  ....................................................................... 117 
8.5.1. Renal  Function  ......................................................................................... 117 
8.5.2. Monitoring of Liver -related  Laboratory Parameters  ................................ 117 
9. DATA ANALYSIS/STATISTICAL  METHODS  ............................................................ 118 
9.1. Sample Size Determination  .................................................................................. 118 
9.2. Definitions  of Analysis Sets ................................................................................. 118 
9.2.1. Efficacy  Analysis  Set ............................................................................... 118 
9.2.1.1. Intent- To-Treat  (ITT)  Analysis  Set ......................................... 118 
9.2.1.2. Clinically  Evaluable (CE) Analysis Set  .................................. 118 
9.2.1.3. Microbiological Intent- To-Treat  (micro -ITT)  Analysis Set ... 119 
9.2.1.4. M icrobiologically  Evaluable (ME) Analysis Set .................... 119 
9.2.1.5. Modified Intent- To-Treat  Analysis Set ................................... 119 
9.2.1.6. Microbiological Modified Intent- To-Treat (micro -MITT) 
Analysis Set .................................................................................... 119 
9.2.2. Safety  Analysis Set  .................................................................................. 120 
9.2.3. Population Pharmacokinetic (popPK) Analysis Set ................................. 120 
9.2.4. Other  Analysis Sets .................................................................................. 120 
9.2.4.1. All Subjects  Analysis Set  ....................................................... 120 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  9  
 9.3. Outcome Measures  for Analyses  ........................................................................... 120 
9.3.1. Primary  Outcome Variable  ....................................................................... 120 
9.3.2. Secondary  Outcome Variables  .................................................................. 120 
9.3.3. Tertiary  Outcome Variables  ...................................................................... 121 
9.3.4. Exploratory Outcome Variables  ................................................................ 121 
9.3.5. Safety  Variables  ........................................................................................ 122 
9.4. Methods for Statistical Analyses  ........................................................................... 122 
9.4.1. Analysis of the Primary  Variable  .............................................................. 122 
9.4.2. Analysis of the Secondary/Tertiary  Variable(s)  ........................................ 123 
9.4.3. Subgroup Analysis  .................................................................................... 123 
9.4.4. Interim Analysis  ........................................................................................ 124 
9.4.5. Supportive Analyses  ................................................................................. 124 
9.4.6. Exploratory Analysis  ................................................................................. 124 
9.4.7. Analysis Methods for Safety  Variables  ..................................................... 124 
9.5. Data Monitoring Committee  .................................................................................. 125 
9.6. Independent Clinical Hepatologist Review  of Potential Hy’s  Law Cases  ............ 125 
9.7. Independent Adjudication Committee  ................................................................... 125 
10. QUALITY CONTROL  AND QUALITY ASSURANCE  ............................................... 126 
11. DATA HANDLING AND  RECORD  KEEPING  ............................................................ 126 
11.1. Case Report Forms/Electronic  Data Record  ........................................................ 126 
11.2. Record  Retention  ................................................................................................. 127 
11.3. Data Protection  .................................................................................................... 127 
12. ETHICS  ............................................................................................................................ 128 
12.1. Regulatory and Ethical Considerations  ................................................................ 128 
12.1.1. Reporting of Safety  Issues and Serious Breaches  of the Protocol or 
ICH GC P  ........................................................................................................ 129 
12.2. Subject  Information  and Consent  ........................................................................ 129 
12.3. Reporting of Safety  Issues and  Serious Breaches  of the Protocol or ICH  
GCP  .......................................................................................................................... 130 
13. DEFINITION  OF END OF  TRIAL  ................................................................................. 130 
13.1. End of Trial  in a Member  State  ........................................................................... 130 
13.2. End of Trial  in All Other  Participating  Countries  ................................................ 131 
14. SPONSOR  DISCONTINUATION  CRITERIA  ............................................................... 131 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  10  
 15. PUBLICATION OF STUDY RESULTS  ........................................................................ 131 
15.1. Communication of Results by Pfizer  ................................................................... 131 
15.2. Publications by Investigators  ............................................................................... 132 
16. REFERENCES  ................................................................................................................. 134 
 
LIST OF TABLES  
Table 1. Schedule of Activities  .......................................................................................... 25 
Table 2. Identity  of Investigational Product  ....................................................................... 61 
Table 3. ATM -AVI Doses  in Relationship  to CrCL  .......................................................... 62 
Table 4. MER  Doses  in Relationship  to CrCL  ................................................................... 63 
Table 5. COL  Doses in  Relationship to  CrCL  .................................................................... 64 
Table 6. Allowed  Concomitant Medications  ....................................................................... 69 
Table 7. Restricted  Concomitant Medications  .................................................................... 71 
Table 8. Prohibited Concomitant Medications  .................................................................... 71 
Table 9. Definition  of Clinical Response Categories  at the EOT  and TOC visits  .............. 86 
Table 10. Definition of Microbiological Response Categories at the EOT and TOC 
Visits,  for Each  Pathogen Identified  at Initial/Pre  Study (Study Qualifying)  
Culture  ................................................................................................................... 87 
Table 11. Definition  of Emergent  Infection  Categories  ........................................................ 89 
Table 12. Laboratory Safety  Variables  ................................................................................. 91 
Table 13. Pharmacokinetic ATM -AVI Sample  Collection  Time  Points ............................... 97 
Table 14. Volume of Blood to  Be Drawn  from  Each  Subject  ............................................. 101 
 
 
LIST  OF FIGURES  
Figure 1 Study Outline  ............................................................................................................ 47 
Figure 2 S tudy Treatment  ................................................................................................... 48 
Figure 3 ATM -AVI Pharmacokinetic  Sample  Collection  Time -Points for Subjects  
with CrCL  >30mL/min (Q6h Maintenance Dose)  ............................................... 98 
Figure 4 ATM -AVI Pharmacokinetic  Sample  Collection  Time -Points for Subjects  
with CrCL  >15 to ≤30 mL/min  (Q8h  Maintenance  Dose)  .................................... 99 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  11  
 APPENDICES  
Appendix 1. Abbreviations  .................................................................................................... 140 
Appendix 2. International Airline Transportation Association (IATA) 6.2 Guidance 
Document  ........................................................................................................... 145 
Appendix 3. Calculation  of Estimated  Creatinine  Clearance  ................................................ 146 
Appendix 4. Actions Required  in Cases of  Increases  in Liver Biochemistry  and 
Evaluation of Hy’s  Law  ..................................................................................... 147 
Appendix 5. Acute Physiology and Chronic Health  Evaluation - APACHE  II Score  .......... 153 
Appendix 6. Microbiological Assessments  ........................................................................... 159 
Appendix 7. Colistin  Conversion Table  ................................................................................ 163 
Appendix 8. Summary  of Changes from  Original Protocol through Amendment  ................ 164 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  12  
  
PROTOCOL  SUMMARY  
Background and Rationale  
The prevalence of multidrug resistant (MDR) bacteria is increasing worldwide. This has 
become a significant public health threat as there are fewer, or even sometimes no, effective antimicrobial agents  available for infections caused  by MDR  bacteria.  In particular,  ongoing 
surveillance studies have demonstrated an increasing frequency of antibiotic resistance among MDR Gram- negative bacteria.  Of particular concern is the spread of metallo  
β-lactamase (MBL) producing isolates, which are often MDR.  The combination product 
aztreonam -avibactam (ATM -AVI) is being developed for intravenous (IV) treatment of 
serious infections caused  by Gram -negative pathogens producing MBL  in addition  to other 
β-lactamases.  
Study  sites and number  of subjects  planned  
The study is planned to be performed  in approximately 170 sites in up to 30 countries in the 
Americas, Africa, Europe, and Asia, in regions with emerging and/or elevated incidence of carbapenem resistance, including resistance caused by MBLs.  
Up to approximately 425 subjects  with a diagnosis of complicated  intra-abdominal infections 
or hospital-acquired pneumonia/ventilator-associated pneumonia will be randomized in this study, including approximately 283 randomized in the aztreonam- avibactam±metronidazole 
treatment arm and approximately 142 in the meropenem ± colistin treatment arm.  
Objectives  and Endpoints 
Objectives  
Based on differing regulatory requirements for European Medicines Agency and US Food and Drug  Administration,  the following objectives  and outcome measures  may differ for the 
United States and non United States countries analyses as noted below. 
 
Primary  Objective:  Primary Endpoint:  
To evaluate the efficacy  of 
aztreonam -avibactam  ±metronidazole and 
meropenem ± colistin at Test of Cure visit 
for the treatment  of serious  infections due 
to Gram -negative bacteria, including 
those due to 
metallo -β-lactamase-producing multidrug 
resistant pathogens. Proportion of subjects with clinical cure at 
Test of Cure visit in the Intent- To-Treat and 
Clinically  Evaluable analysis  sets (Note:  For 
non-United States countries, the Intent- To-Treat  and Clinically  Evaluable are 
considered  co-primary  analysis  sets. For the 
US, the Intent- To-Treat is considered the 
primary analysis set, while Clinically Evaluable is secondary).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  13  
  
Secondary  Objectives:  Secondary Endpoint(s):  
To evaluate efficacy  of 
aztreonam -avibactam  ±metronidazole and 
meropenem ± colistin at the Test of Cure 
visit in the microbiological 
Intent- To-Treat  and Microbiologically 
Evaluable analysis sets.  Proportion of subjects with clinical  cure at the 
Test of Cure visit in the microbiological Intent- To-Treat and Microbiologically 
Evaluable analysis sets.  
To evaluate the efficacy  of 
aztreonam -avibactam  ±metronidazole and 
meropenem ± colistin at the Test of Cure 
visit in key sub populations. • Proportion of subjects  with clinical  cure at 
the Test of Cure visit by infection type in 
the Intent- To-Treat and Clinically 
Evaluable analysis sets.  
• Proportion of subjects  with clinical  cure at 
the Test of Cure visit for subjects with 
metallo -β-lactamase-positive pathogens in 
the microbiological Intent- To-Treat and 
Microbiologically  Evaluable analysis  sets. 
To assess the per-subject  microbiological 
response to aztreonam -avibactam  
±metronidazole and meropenem  ±colistin 
at the Test of Cure visit.  Proportion of subjects  with a favorable  
per-subject  microbiological response at the 
Test of Cure visit in the microbiological 
Intent- To-Treat and Microbiologically 
Evaluable analysis sets.  
To assess 28- day all-cause mortality.  Proportion of subjects who died on or before 
28 days from randomization in the Intent- To-Treat  and microbiological 
Intent- To-Treat analysis sets.  
To evaluate the pharmacokinetics of aztreonam  and avibactam  in subjects  with 
serious infections and to characterize the relationship between exposure and clinical and microbiological response for 
aztreonam -avibactam ± metronidazole 
utilization (listings to be provided in the 
Clinical Study Report, analysis to be reported outside of the Clinical Study Report).  • Pharmacokinetics of aztreonam and avibactam  in subjects in the population 
pharmacokinetic analysis set.  
• Pharmacokinetic/pharmacodynamic relationship  between  exposure and clinical 
and microbiological response for 
aztreonam -avibactam ± metronidazole in 
the population pharmacokinetic analysis 
set. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  14  
  
Safety Objective:  Safety Endpoint:  
To evaluate the safety  and tolerability 
profile of aztreonam -avibactam  
±metronidazole and meropenem  
±colistin . Safety  and tolerability  as assessed  by adverse 
events, physical examination, vital signs, 
electrocardiograms, and laboratory assessments in the safety analysis set.  
 
 
Tertiary  Objectives:  Tertiary Endpoint(s):  
To evaluate the efficacy  of 
aztreonam -avibactam±metronidazole  and 
meropenem ± colistin at the End of 
Treatment visit.  Proportion of subjects with clinical  cure at the 
End of Treatment visit in  the Intent- To-Treat, 
microbiological Intent -To-Treat, Clinically 
Evaluable and Microbiologically Evaluable 
analysis sets.  
To evaluate the efficacy  of 
aztreonam -avibactam  ±metronidazole and 
meropenem ± colistin at the End of 
Treatment visit in key sub populations. • Proportion of subjects  with clinical  cure at 
the End of Treatment visit by infection 
type in the Intent- To-Treat and Clinically 
Evaluable analysis sets.  
• Proportion of subjects  with clinical  cure at 
the End of Treatment visit for subjects 
with metallo -β-lactamase -positive 
pathogens in the microbiological 
Intent- To-Treat  and Microbiologically 
Evaluable analysis sets.  
To evaluate the efficacy  of 
aztreonam -avibactam  ±metronidazole and 
meropenem  ±colistin  at End of Treatment 
and Test of Cure visits by pathogen 
resistance types.  Proportion of subjects with clinical  cure at End 
of Treatment and Test of Cure visits by Pathogen resistance type  
(eg, aztreonam -non-susceptible, 
extended -spectrum  β-lactamase-positive, 
carbapenamase-positive, etc) in the microbiological Intent -To-Treat and  
Microbiologically  Evaluable analysis  sets. 
To assess the per-subject  microbiological 
response to aztreonam -avibactam  
±metronidazole and meropenem  ±colistin 
at End of Treatment visit.  Proportion of subjects  with a favorable  
per-subject  microbiological response at the 
End of Treatment in the microbiological Intent- To-Treat and Microbiologically 
Evaluable analysis sets.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  15  
  
Tertiary  Objectives:  Tertiary Endpoint(s):  
To assess the microbiological response 
by pathogen and by pathogen resistance 
type to aztreonam avibactam  
±metronidazole and meropenem  ±colistin 
at End of Treatment and Test of Cure 
visits.  • Proportion of subjects with a favorable 
per-pathogen microbiological response at 
the End of Treatment and Test of Cure 
visits in the microbiological  
Intent- To-Treat  and Microbiologically 
Evaluable analysis sets.  
• Proportion of subjects with a favorable 
per-subject  microbiological response by 
pathogen resistance type 
(eg, aztreonam -non-susceptible, 
extended -spectrum  β-lactamase-positive, 
carbapenamase- positive,  
metallo -β-lactamase positive) at the End of 
Treatment and Test of Cure visits in the microbiological Intent -To-Treat and 
Microbiologically Evaluable analysis sets. 
• Proportion of subjects with a favorable 
per-pathogen microbiological response by 
pathogen resistance type 
(eg, aztreonam -non-susceptible, 
extended -spectrum  β-lactamase-positive, 
carbapenamase- positive,  
metallo -β-lactamase-positive) at the End of 
Treatment and Test of Cure visits in the microbiological Intent -To-Treat and 
Microbiologically Evaluable analysis sets. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  16  
  
Exploratory Objectives:  Exploratory Endpoint(s):  
To evaluate efficacy  of 
aztreonam -avibactam  ±metronidazole and 
meropenem ± colistin using objective 
clinical measures.  Composite endpoint including symptom- based 
objective clinical measures, to be defined in 
the Statistical Analysis Plan (Intent- To-Treat 
and clinically evaluable analysis sets).  
To assess 14- day all-cause mortality.  Proportion of subjects who died on or before 
14 days from randomization in the Intent- To-Treat  analysis  set. 
To evaluate  health  resource utilization 
(listings to be provided in the Clinical Study Report, analysis to be reported outside of the Clinical Study Report). • Length of hospital stay, including any 
readmissions up to Test of Cure  (days).  
• Length of study treatment (days).  
• Length of intensive care unit  stay (days).  
• Transferred  to the intensive care unit 
(Yes/No).  
• Mechanical  ventilation  (Yes/No)  for 
hospital -acquired. 
pneumonia/ventilator -associated 
pneumonia subjects. 
• Length of mechanical  ventilation  (days) 
for hospital-acquired. pneumonia/ventilator -associated 
pneumonia subjects. 
• Subsequent unplanned surgical 
intervention after treatment success  versus 
failure (up to the Test of Cure visit) for 
complicated intra -abdominal infection 
subjects.  
Supportive  Analyses  
Additional descriptive analyses  of the primary  endpoint (clinical  cure rate) will be performed 
for the effect of protocol-allowed additional antibiotics (eg, Gram- positive antibiotics, 
aminoglycosides).  
An additional descriptive analysis will be performed for clinical cure at Test of Cure using 
the modified  Intent- To-Treat  population which  comprises  subjects  who were  randomized and 
received any amount of intravenous study drug. 
Additional descriptive analyses will also be performed for the secondary and tertiary outcomes of clinical cure rate and microbiological favourable response rate at End of Treatment  and Test of Cure  using the microbiological modified  Intent- To-Treat  which  is a 
subset of the microbiological Intent- To-Treat comprising those subjects  who  received any 
amount of intravenous study drug. 
ATM -AVl 
C3601002 
 Final  Protocol Amendmen t 2, 18 May 2022   
PFIZER  CONFIDENTIAL  
Page  17  
  
 
Study Design  
This is a Phase 3 prospective , randomized , multicenter,  open -label , central  assessor- blind ed, 
parallel group , comparative study to detennine the efficacy , safety, and tolerability of 
azti·eo nam-avibactam ±meti ·onidazole  versus meropenem  ±colistin in the ti·eatinent of 
hospitalized adults with  comp licated inti·a -abdominal  infection or nosocomial pneumonia 
includin g hospital-acquired pneumonia  and ventilator-associated pneumonia , in regions  with 
endemic  or emerging carbapenem r esistance, and where metallo -j3-lactamase- produ cing 
multidrng resistant pathogens are suspected . 
The study will consist  of a Screening visit (Visit  1), a Baseline visit  (Visit 2) on Day 1 of the 
study  ti·eatinent , ongoing ti·eatinent visits (Visits 3 to 15) from  Day 2 to Day 14, an End of 
Treatinent visit (Visit 16) within 24 hours after the last  infusion, a Test of Cure v isit 
(Visit  17) on Day 28 (±3 days)  and a Late Follow-Up visit (Visit 18) on Day 45 (±3 days).  
Subjects wi ll be randomized in a 2:1 ratio to the azti·eonam-avibactam±meti·onidazole 
ti·eatinent ann or the meropenem±colistin h'eatment  aim. Rand omization will be sti·atified 
based on infe ctious disease  type (comp licated  inti·a -abdominal infection  and 
hospital -acquired pneumonia/ventilator -associated  pneumonia).  For complicated  
inti-a-abdominal infection , subjects wi ll also be sti·at ified by Acute Physiology and Chroni c 
Health Evaluation score ( 10 and >10) (Appendix 5).  For hospital-acquired 
pneumonia /ventilator -assoc iated pneumonia,  subjects will also be sti·at ified by mechanical 
ventilation status (YIN).  
For subjects randomized  to azti·eonam -avibactam±meh'o nidazole, spai·se blood  sampl es will 
be collected for population phannacokinetic assessments and 
phannacokinetic /phannacodynamic relations hips will be evaluated in  subjects  where plasma 
samples and microb iologica l respo nse data have been collected.  
Each  subject is expected to complete the study, includin g the Late Follow-Up visit. 
Paiiicipants in  the study must be  inpatients  at the study  site institutio n to receive study 
medication.  
Target  Subject Population  
Adult hospitalized  subjects with a confome d diagnosis  of comp licated  inti-a-abdominal 
infection or hospital acq uired pneumonia /ventilator assoc iated pneumonia related to 
Gram -negative pathogens including , but not limited to , those infected with multidrng  

ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  18  
 resistant  strains,  and requiring administration  of intravenous antibacterial  treatment  will be 
enrolled in this study. 
The study will randomize up to approximately 425 subjects  (at least 300 subjects  with 
complicated intra -abdominal infection anticipated).  The number of complicated 
intra-abdominal infection  subjects  with a perforated  appendix or appendiceal  abscess  will be 
limited to approximately 40% of the study population with complicated intra-abdominal 
infections.  
Study Treatments 
Duration of Treatment  
The recommended minimal duration of treatment in this study is 5 days for complicated 
intra-abdominal infections and 7 days for hospital acquired  pneumonia/ventilator associated 
pneumonia. The maximal duration of treatment is 14 days. 
Investigational Product,  Dosage Form  and Strength  
 
Investigational product Dosage form  and strength 
Test product  
Aztreonam -Avibactam  Aztreonam  for injection,  lyophilised powder  
for solution for infusion 2 g 
Avibactam  lyophilisate  for concentrate for 
infusion 600 mg 
Comparators  
Meropenem  Meropenem  1 g powder for solution for 
infusion  
Colistin  Colistin  2 million  international units powder 
for solution for infusion 
Co-administered  drug  
Metronidazole  Metronidazole 500 mg/100 ml solution for 
infusion  
 
Note: Aztreonam  and avibactam  will be provided as separate  vials  for reconstitution  and mixed  together  in a 
saline bag for co -administration at the appropriate concentration for intravenous infusion.  
Note: Comparators  and co-administered  drug are supplied  centrally  via the sponsor.  In some  instances,  locally 
obtained commercial supplies will be utilized in accordance with local regulations.  
Note: Aztreonam,  Meropenem, Colistin  and Metronidazole  are commercial  products  over-labeled  with the study 
clinical label.  
 
All investigational products will be administered  by intravenous infusion. Aztreonam  and 
avibactam will be supplied as vials for reconstitution.  The investigational 
aztreonam -avibactam  will be prepared  for co-administration  in saline  using standard  aseptic 
intravenous infusion technique (see investigational product (IP) manual). 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  19  
 Aztreonam -avibactam±metronidazole treatment  arm:  
Subjects  will be given a loading dose and then an extended  loading dose before  commencing 
on a maintenance dose (The loading dose and extended loading dose are only given once on 
Day 1 at the start of study treatment).  All doses (loading, extended loading and 
maintenance), and the dosing frequency of the maintenance dose are dependent on renal function as per the table below and also Section 5.6.1. 
 
Creatinine 
Clearance (mL/min)*  Loading dose of aztreonam - 
avibactam (by intravenous 
infusion 
over 
30 minutes)  Extended loading dose of 
aztreonam - 
avibactam 
immediately 
following  the 
loading dose (by 
intravenous 
infusion 
over 
3 hours)  Time interval between end of extended  
loading dose and start  of first 
maintenance 
dose Maintenance 
dose of aztreonam - 
avibactam (by intravenous 
infusion over 
3 hours)  Frequency  
of 
aztreonam - 
avibactam maintenance dose 
>50 500 mg 
aztreonam 
plus 167 mg 
avibactam  1500 mg 
aztreonam plus 500 mg 
avibactam  3 hours  1500 mg 
aztreonam plus 500 mg 
avibactam  Every  
6 hours 
>30 to 50 500 mg 
aztreonam 
plus 167 mg 
avibactam  1500 mg 
aztreonam plus 500 mg 
avibactam  3 hours  750 mg 
aztreonam plus 250 mg 
avibactam  Every  
6 hours 
>15 to 30 675 mg 
aztreonam plus 225 mg 
avibactam  675 mg 
aztreonam plus 225 mg 
avibactam  5 hours  675 mg 
aztreonam plus 225 mg 
avibactam  Every  
8 hours 
*Estimated  creatinine  clearance using Cockcroft -Gault formula  rounded to the nearest  whole  number  (see 
Appendix 3).  
 
Creatinine  clearance should be monitored daily  through the local  laboratory from  Day  1 to 
Day 4 (and Day 3 or 5 by the central laboratory, if PK samples are to be collected on 
Days 3 or 5) and then as clinically indicated. In the case that renal impairment recovers or 
deteriorates  during the treatment  period, the dose of aztreonam -avibactam  should be adjusted 
by the investigator to meet the applicable dose regimen, based on the latest creatinine 
clearance value.  If subsequent to randomization and while still on intravenous study 
treatment, a subject’s estimated creatinine clearance falls below the threshold for study 
inclusion (ie, estimated creatinine clearance ≤ 15 mL/min) and there is a requirement to start 
renal  replacement  therapy,  the Investigator should discontinue aztreonam -avibactam  therapy. 
In addition to aztreonam -avibactam,  subjects  with complicated  intra-abdominal infection  in 
this treatment arm will also receive intravenous metronidazole 500 mg every 8 hours (by 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  20  
 intravenous infusion over 60 minutes), starting after the extended loading dose of 
aztreonam -avibactam  has completed  and maintained  until the end of the intravenous study 
treatment  period. The Summary  of Product Characteristics  (Baxter  Healthcare Ltd) does not 
indicate a dose reduction for metronidazole in subjects with renal impairment. 
Subjects with hospital-acquired pneumonia/ventilator-associated pneumonia and proven or suspected co -infection with Pseudomonas aeruginosa may  receive adjunctive therapy  with 
an IV aminoglycoside (eg, amikacin, gentamicin or tobramycin, based upon local practice and epidemiology) at the Investigator's discretion. The need  for adjunctive aminoglycoside 
therapy should be re- evaluated once culture and susceptibility  results are available and the 
aminoglycoside should be discontinued if not needed. 
Meropenem  ±Colistin  Treatment  Arm:  
Subjects  will initially  be given meropenem  1000 mg every  8 hours (given as an intravenous 
infusion over 30 minutes).  If a meropenem -resistant  pathogen is strongly suspected,  a dose 
of meropenem 2000 mg every 8 hours can be used (given as an intravenous infusion over 3 hours). Colistin (colistimethate sodium) can also be initiated, at the Investigator’s 
discretion. Colistin  will be dosed based  on guidance described  by the European Medicines 
Agency (see Clinical Study Protocol Section 5.6.2).  
If a meropenem -resistant Gram -negative pathogen is subsequently isolated, colistin 
(colistimethate sodium) can be added (if not already started), and/or the dose of meropenem can be increased  to 2000 mg every  8 hours (given as  an intravenous infusion over 3 hours),  if 
this dose was not already used initially. 
If a meropenem -susceptible Gram -negative pathogen is subsequently isolated and colistin 
(colistimethate  sodium) had been  initially  started,  the colistin  (colistimethate  sodium) should 
be discontinued and the dose of meropenem adjusted to the labeled dose regimen (1 g every 
8 hours intravenously over 30 min, if a meropenem dose of 2000 mg every 8 hours was initially started).  
Meropenem  ±colistin  doses will need  to be adjusted for subjects with renal  impairment.  The 
dose of meropenem will need to be further adjusted once the susceptibility of the baseline Gram -negative pathogen(s) to meropenem is known. 
Subjects with hospital-acquired pneumonia/ventilator-associated pneumonia and proven or suspected co -infection with Pseudomonas aeruginosa may receive adjunctive therapy  with 
an intravenous aminoglycoside (eg, amikacin, gentamicin or tobramycin, based upon local practice and epidemiology) at the Investigator's discretion at any time during the treatment period. For subjects  receiving  colistin  (colistimethate  sodium), adjunctive aminoglycosides 
therapy should not be used concurrently; treatment with colistin (colistimethate sodium) should be discontinued prior to initiating aminoglycoside therapy. The need for adjunctive aminoglycoside therapy should be re- evaluated once culture and susceptibility results are 
available and the aminoglycoside should be discontinued if Pseudomonas aeruginosa is not 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  21  
 isolated  or is no longer suspected,  or susceptibility  results  indicate  a carbapenem -susceptible 
strain.  
If Pseudomonas aeruginosa is isolated  and is non-susceptible to meropenem, an intravenous 
aminoglycoside may be added to meropenem if not originally commenced. Colistin should 
be discontinued if meropenem and aminoglycoside are being used together. 
Statistical  Methods  
The study will randomize up to approximately 425 subjects in a 2:1 randomization ratio 
(approximately 283 subjects randomized to the aztreonam- avibactam ± metronidazole 
treatment  arm and approximately  142 subjects  to the meropenem  ±colistin  treatment  arm).  
As no formal  hypothesis testing  will be performed  for this study, no power calculation  was 
carried out to assess the number of subjects required for each treatment arm.  The planned 
sample size is considered sufficient to estimate the overall clinical cure rates in each arm. 
The smaller numbers of subjects in these groups will be reflected in the precision of the estimate of clinical cure rate.  
Definition  
of analysis  sets 
The all subjects  analysis  set will compromise all enrolled subjects  for the study and will be 
used for reporting of disposition. 
The Intent- To-Treat  analysis  set will include all randomized subjects  regardless  of receipt  of 
study drug. Subjects in the Intent- To-Treat analysis set will be analyzed according to the 
treatment they are randomized to.  The Intent -To-Treat analysis set will be used to evaluate 
the primary, secondary and tertiary objectives. The safety  analysis  set will be used for reporting  safety  data and  will include all subjects  who 
received any amount of intravenous study treatment.  Subjects in the safety analysis sets will 
be analyzed according to the treatment they receive.  
The Clinically  Evaluable analysis  set is defined  as all subjects who:  
• Meet  the definition  of the Intent- To-Treat  analyses.  
• Meet  disease criteria  for diagnosis of complicated  intra-abdominal infection  or 
hospital-acquired pneumonia/ventilator-associated pneumonia. 
• Received at least 48 hours of study treatment (aztreonam- avibactam±metronidazole or 
meropenem±colistin)  or received  <48 hours of study treatment  before  discontinuing study 
drug due to an adverse event. 
• Did not receive concomitant antibiotic treatment with potential activity against any 
baseline pathogens between  the time of first dose of study treatment  and the time of Test 
of Cure.  This does not include those subjects who have received protocol- allowed  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  22  
 antibiotics  or have failed  study treatment  and require  additional antibiotics  to treat their 
infection.  
• Had no important protocol deviations that may affect  the assessment  of efficacy  (to be 
defined in the Statistical Analysis Plan).  
• Did not have a clinical  outcome of indeterminate  at Test of Cure.  
• Did not have monomicrobial infections due to non-eligible pathogens (eg, any 
Acinetobacter  spp., Pseudomonas aeruginosa) and did not have only Gram -positive 
pathogens.  
Subjects  in the Clinically  Evaluable analysis  set will be analyzed  according to the treatment 
they are randomized to. The Clinically Evaluable analysis set will be used to evaluate 
selected primary, secondary and tertiary objectives. 
The microbiological Intent -To-Treat  analysis  set is a subset of the Intent- To-Treat analysis 
set and includes all subjects who have at least 1 Gram -negative pathogen in an adequate 
initial/prestudy culture.  Subjects with monomicrobial infections due to any Acinetobacter 
spp., and those subjects with only Gram-positive pathogens will be excluded from the 
microbiological Intent- To-Treat  analysis  set. The microbiological Intent- To-Treat  analysis 
set will be used to evaluate selected secondary and tertiary objectives.  
The Microbiologically Evaluable analysis set includes all subjects included in both microbiological Intent- To-Treat  and Clinically  Evaluable analysis  sets, with at least 
1 Gram -negative pathogen. The Microbiologically  Evaluable analysis  set will be used to 
evaluate selected secondary and tertiary objectives.  
Sensitivity analyses will be performed using the modified Intent- To-Treat and 
microbiological modified Intent- To-Treat.  The modified Intent- To-Treat and 
microbiological modified Intent- To-Treat are subsets of the Intent -To-Treat and 
microbiological Intent- To-Treat  respectively  and include all randomized subjects  who 
receive any amount of intravenous study drug. 
The population pharmacokinetic analysis  set includes all  subjects  who  have at least 1 plasma 
concentration  data assessment  available for aztreonam -avibactam±metronidazole and  will be 
used to report all pharmacokinetic data. 
Methods for statistical analysis  
All data will be presented by  treatment arm.  Descriptive statistics (number, mean, standard 
deviation, median,  minimum,  and maximum)  will be provided for continuous variables,  and 
counts and percentages will be presented for categorical variables.  
No formal  hypothesis testing  will be performed  for this study; any comparisons between 
treatment arms will only be assessed as evidence of an effect, no formal statistical 
comparisons will be made.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  23  
 Methodology for dealing with  missing data  will be  specified in  the Statistical Analysis Plan.  
The primary descriptive efficacy analysis (for non- United States countries) will be the 
estimate of the clinical cure rate and 95% confidence interval in each treatment arm 
(aztreonam -avibactam±metronidazole and meropenem±colistin) in the Intent -To-Treat and 
Clinically  Evaluable co -primary  analysis  sets. The estimate  of the clinical  cure rate and 95% 
confidence interval in each treatment arm in the Intent- To-Treat analysis set will be the 
primary analysis for the United States.  Single arm confidence intervals will be computed 
using Jeffrey’s method ( Brown et al 2001; Cai 2005).  The number and percentage of 
subjects who had a clinical response of clinical cure, clinical failure, and indeterminate in each treatment arm will be tabulated for the Intent -To-Treat and Clinically Evaluable 
analysis sets at the Test of Cure visit.  
The primary  analysis  will be conducted using the clinical response assessment  determined  by 
a blinded independent adjudication committee. The Investigator’s assessment of clinical 
response will also be summarized for the Intent -To-Treat and Clinically Evaluable analysis 
sets at the Test of Cure visit.  In case of any discrepancy between the Investigator’s and 
adjudication committee’s clinical response assessment, the adjudication committee’s assessment will prevail for the analysis.  
Difference in clinical cure rate between treatment arms at Test of Cure visit 
(aztreonam -avibactam  ±metronidazole minus meropenem  ±colistin)  and corresponding 
two-sided 95% confidence interval will be calculated for the Intent- To-Treat and Clinically 
Evaluable analysis sets.  The two -sided 95% confidence interval for the observed difference 
in the cure rates (aztreonam -avibactam ± metronidazole group minus meropenem ± colistin 
group) will be computed using the method proposed for unstratified  designs by Miettinen  and 
Nurminen and an additional supporting descriptive analysis will be conducted using the 
stratified Miettinen and Nurminen method ( Miettinen and Nurminen 1985 ), if each stratum 
has at least 3 subjects per each treatment group.  
Clinical response summaries  will be presented  for the overall  population, and also split by 
infection type (complicated intra-abdominal infection or hospital- acquired pneumonia/ 
ventilator -associated pneumonia), and by resistance group (eg, extended- spectrum  
β-lactamase  status,  carbapenemase status  and metallo -β-lactamase status)  as 
secondary/tertiary descriptive analysis. 
Secondary  and tertiary  efficacy  outcome measures will be presented  using the same methods 
as the primary  outcome measures.  For descriptive  secondary and tertiary  outcome measures, 
number and percentage in each treatment arm will be tabulated.  
The final pharmacokinetic data will be pooled with data from other studies to conduct a 
population pharmacokinetic analysis  (using Nonlinear Mixed  Effects  Modelling). Using 
these parameter estimates (mean pharmacokinetic parameters including inter individual variance estimates), Monte-Carlo simulation will be undertaken and potential pharmacokinetic/pharmacodynamic relationships will be explored. Aztreonam and 
avibactam  plasma  concentrations versus time will be depicted  graphically in the Clinical 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  24  
 Study Report (CSR). Full details of the pharmacokinetic and 
pharmacokinetic/pharmacodynamic analysis  will be given in the Pharmacokinetic  Modeling 
Analysis Plan. These results will be reported separately.  
For exploratory efficacy  variables,  the proportion of subjects  who died on or before  14 days 
after randomization will be presented by treatment arm.  Further details on the analysis 
methods for response endpoint utilising objective measures of clinical response will be detailed in the Statistical Analysis Plan.  
Regarding safety variables, adverse events will be summarized by means of counts summaries by Medical Dictionary for Regulatory Activities System Organ Class and preferred term separately for the study periods (treatment period [from first dose to End of Treatment] [treatment emergent adverse events], from End of Treatment to Late Follow -Up, 
and for the full study period [from  first dose to Late Follow- Up]).  All adverse events  will be 
listed (including prior to first dose). Deaths, adverse events leading to discontinuation, and serious adverse events will be summarized.  
Laboratory data for hematology and clinical chemistry will be summarized. The frequency  
of changes with respect to normal ranges between baseline and each post- treatment time  
point will be tabulated.  Frequencies  of clinically  noteworthy values  (defined  in the Statistical 
Analysis Plan) occurring during the clinical study will also be given. Shifts from normal to 
abnormal between baseline and each post- baseline time point will be evaluated for all 
laboratory parameters. 
The incidence of markedly abnormal values  and changes  from  baseline in the 
electrocardiogram parameters will be summarized by treatment arm.  
Subgroup analyses, which may include subject characteristics, disease severity, prior 
antibiotic  use, infection  type and pathogen resistance type, may be performed.  More  details 
on the subgroup analyses will be provided in the Statistical Analysis Plan. Additional descriptive analyses of the primary endpoint (clinical cure rate) will be performed for the effect of protocol-allowed additional antibiotics (eg, Gram- positive antibiotics, 
aminoglycosides).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  25  
  
SCHEDULE  OF ACTIVITIES  
The schedule of activities table provides an overview of the protocol visits and procedures. Please refer to Section 6 (Study 
Procedures)  and Section  7 (Assessments)  of the protocol for detailed  information  on each procedure and assessment  required for 
compliance with the protocol. 
The investigator may schedule visits  (unplanned visits)  in addition to those listed  on the schedule of activities  table,  in order to 
conduct evaluations or assessments required to protect the well-being of the subject. 
 
Table 1.  Schedule of Activities  
 
Visit  Name  Eligibility/ 
Screeninga Treatment  period  EOT  TOC  LFU  
 Visit 1 Visit 2 Visits  3 to 15 Visit 16 Visit 17 Visit 18 
Procedures  and Assessments  Days  –1 
to 1 Day 1 
(Baselineb) Days  2 to 14 Within 
24 hours 
after  last 
infusion  Day 28 
±3 days  Day 45 
±3 days  
Informed  consent  X      
Inclusion  and exclusion  criteria  X X     
Demographics  X      
Medical  history  X      
APACHE  II score  (see Appendix 5)c X      
Prior and concomitant medications 
(including  prior  antibiotic  treatment)  X X Daily  X X X 
Complete  physical  examination  X   X X  
Assess  infection -related  signs  and 
symptoms  X X Daily  X X  
Perform  focused  physical  examination  X X Daily  X X Xd 
Vital  sign measurementse X X Daily  X X  
12-lead digital triplicate ECG   X Day 3    
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  26  
  
Table 1.  Schedule of Activities  
 
Visit  Name  Eligibility/ 
Screeninga Treatment  period  EOT  TOC  LFU  
 Visit 1 Visit 2 Visits  3 to 15 Visit 16 Visit 17 Visit 18 
Procedures  and Assessments  Days  –1 
to 1 Day 1 
(Baselineb) Days  2 to 14 Within 
24 hours 
after  last 
infusion  Day 28 
±3 days  Day 45 
±3 days  
Chest  X-ray or computed  tomography 
scan (for HAP/VAP subjects only) Xf As 
clinically 
indicated  As clinically 
indicated  As clinically 
indicated  As 
clinically 
indicated   
Collection  of imaging  and surgical 
report (for cIAI subjects only) X As 
clinically 
indicated  As clinically 
indicated  As clinically 
indicated  As 
clinically 
indicated   
Document  whether  subject  is ventilated 
(for HAP/VAP subjects only)  X X Daily  X X  
Serious  and non-serious  adverse  event 
monitoring  X X Daily  X X X 
Culture  of abdominal  site infection  (for 
cIAI subjects only)g At surgical 
interventio 
n At surgical 
interventio 
n As clinically 
indicated  As clinically 
indicated  As 
clinically 
indicated   
Respiratory specimen for Gram - 
stain/culture  (for HAP/VAP  subjects 
only)  Xh Xi As clinically 
indicated  Xj X  
Blood  culturesk Xk As 
clinically 
indicatedk As clinically 
indicated  As clinically 
indicated  As 
clinically 
indicated   
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  27  
  
Table 1.  Schedule of Activities  
 
Visit  Name  Eligibility/ 
Screeninga Treatment  period  EOT  TOC  LFU  
 Visit 1 Visit 2 Visits  3 to 15 Visit 16 Visit 17 Visit 18 
Procedures  and Assessments  Days  –1 
to 1 Day 1 
(Baselineb) Days  2 to 14 Within 
24 hours 
after  last 
infusion  Day 28 
±3 days  Day 45 
±3 days  
Safety  laboratories  (chemistry, 
hematology, urinalysis)l X X Central lab 
samples:  Every  
3 days, starting  on 
Day 4; Local lab 
serum creatinine: 
Daily from Day 2 
to Day 4, and as 
clinically  
indicated  X X  
Collection  of arterial  blood  gases  Xm As 
clinically 
indicated  As clinically 
indicated  As clinically 
indicated    
Blood  for PK analysisn  Xo Day 4p    
Estimate CrCLq X X Daily from 
Day 2 to 
Day 4 and as 
clinically 
indicated  As clinically 
indicated  As 
clinically 
indicated   
Serum  or urine  β-hCG  for women  of 
childbearing potentialr X      
Contraception  checks X X Daily  X X  
Randomization   X     
Administer  study  treatment   X Daily     
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  28  
  
Table 1.  Schedule of Activities  
 
Visit  Name  Eligibility/ 
Screeninga Treatment  period  EOT  TOC  LFU  
 Visit 1 Visit 2 Visits  3 to 15 Visit 16 Visit 17 Visit 18 
Procedures  and Assessments  Days  –1 
to 1 Day 1 
(Baselineb) Days  2 to 14 Within 
24 hours 
after  last 
infusion  Day 28 
±3 days  Day 45 
±3 days  
Clinical response assessment     X X  
Mortality assessment   X Daily  X X  
Abbreviations: ABG=arterial blood gas; ALP=alkaline phosphatase; ALT=alanine aminotransferase; APACHE=Acute Physiology and Chronic Health 
Evaluation; AST=aspartate aminotransferase; ATM -AVI=aztreonam -avibactam; BAL=bronchoalveolar lavage; β -hCG= β-human chorionic gonadotropin; 
cIAI=complicated  intra-abdominal  infections; CrCL=creatinine clearance;  ECG=electrocardiogram;  EOT=end  of treatment;  HAP=hospital -acquired  pneumonia; 
INR=international normalized ratio; LFU=late follow -up; MTZ=metronidazole; PSB=protected -specimen brush; PK=pharmacokinetics; TBili=total bilirubin; 
TOC=test of cure; ULN=upper limit of normal; VAP=ventilator -acquired pneumonia.  
a. Study treatment  should be started  as soon as possible  (within  24 hours)  after a subject’s  eligibility  has been  confirmed  and the subject  has been  randomized. 
Consequently, Day −1 and Day 1 may be the same calendar day, ie, all procedures scheduled for Day -1 and Day 1 could happen on the same day.  
b. All procedures at Visit 2 are to be done before first dose of study therapy except for PK sampling.  The repeat safety lab samples (including local lab for 
eligibility  criteria  confirmation)  and clinically  relevant  cultures  are only required  if Visit 1 and Visit 2 are separated  by surgery  OR are >12 hours  apart  (see 
Section 6.2.1).  Administration of the first dose of IV study therapy marks the beginning of study treatment Day 1.  
c. Calculate  APACHE  using most  recent  local  laboratory results  available  within  the previous  24 hours  prior  to screening. Arterial blood gases  are required  for 
ventilated and recommended for non- ventilated HAP/VAP subjects, and for cIAI subjects as clinically indicated.  
Use of temperature obtained  rectally  in determining  the APACHE  II score  is preferred  but not mandatory.  See Appendix 5 . If an arterial  blood gas is not 
clinically indicated, the APACHE score will be calculated using serum bicarbonate instead of arterial pH and assuming normal oxygenation  
(Variable  score  = 0). 
d. If the subject  has been  discharged  from  hospital  and is unable  to return  the physical  examination  will not be conducted  at the LFU  visit since  the visit will be 
conducted by telephone.  
e. Vital signs should be measured and documented at least once daily, preferably at a similar time each day.  However, if any significant excursions occur 
during the study day, those measurements should also be captured.  Body temperature will be measured using an automated thermometer.  The subject’s 
body temperature will be evaluated at least twice a day (suggested at least 8 hours apart) and the actual time of body temper ature collection will be recorded. 
Fever  will be defined  as a body  temperature ≥38°C.  For each individual  subject,  the method  of temperature measurement  ideally  should be consistent  for the 
duration of the study.  At the TOC visit only a single body temperature measurement is required.  The actual time of body temperature collection will be 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  29  
  
recorded.  For subjects  with HAP/VAP,  respiratory  rate (breath  per minute)  and peripheral  O2 saturation  will be collected  at Visit 1, at Visit  2, daily  while 
the subject is receiving IV study treatment, at EOT and TOC visits.  
f. Performing  a chest  X-ray or CT scan (if not available  within  48 hours  prior  to randomization)  in subjects  with HAP/VAP.  
g. Specimens  must  be obtained for culture  at initial qualifying surgical  procedure  (performed  within  24 hours  before  or after randomization).  If additional 
surgical procedures are performed, additional abdominal site specimens should be obtained for microbiological culture (see Appendix 6).  
h. Cultures  from  respiratory  specimens  obtained  within  48 hours  prior  to randomization  may be used,  but subjects  ventilated  subsequently,  regardless  of 
whether they meet the criteria for VAP, must have a specimen obtained while ventilated.  
i. Repeat of culture of respiratory specimens are not required, unless a Screening sample was obtained from a non -ventilated subject and the subject is 
subsequently ventilated  (or the subject  had a bronchoscopy).  In this case, an appropriate  respiratory  specimen  should be obtained via BAL,  miniBAL,  PSB 
sample or endotracheal aspirate at the Baseline visit (prior to the first dose of study treatment) (see Appendix 6 ). 
j. If treatment  is discontinued early,  an attempt to obtain  an appropriate  respiratory  specimen  for culture  should be made,  ideally  after stopping the study 
treatment and before the new treatment is administered.  
k. All subjects must have had 2 sets of blood cultures obtained prior to randomization.  Repeat samples for blood cultures are not required at Screening if 
available within 48 hours prior to randomization.  Blood should be taken prior to the first dose of study treatment if not available within 48 hours prior to 
randomization.  When obtaining samples for blood culture, blood should be collected from 2 sites (see Appendix 6).  All subjects require 2 sets of blood 
cultures  (1 anaerobic and 1 aerobic bottle  from  each site, ie, 4 bottles  in total).  For subjects  who are bacteremic at any time during the study,  repeat  blood 
cultures should be performed at least every 3 days, until clearance of bacteremia is documented.  Blood cultures should also be obtained as clinically 
indicated.  See Section 7.3 and Appendix 6 for details of sample collection.  
l. At Screening, the following assessments will be performed in the local laboratory for eligibility determination: serum creatinine (including calculation of 
CrCL), AST, ALT, ALP, TBili, and hematology as listed in Section 4.2.1. In addition, safety laboratory samples must be sent to the central reference 
laboratory for testing.  During  treatment  period,  if ALT  or AST  are >3 x ULN and the subject  has not met the liver discontinuation criteria  (Section  8.5.2 ), 
the frequency of liver laboratory testing collection, and INR, should be increased to daily monitoring (using local laboratory data and recorded as unscheduled visits) until the liver function tests recover to <3 x ULN.  
m. For HAP/VAP  subjects  – obtaining arterial  blood sample  for ABG  (required  for ventilated  subjects,  recommended  for non-ventilated  subjects);  for cIAI 
subjects - obtaining arterial blood sample for ABG as clinically indicated.  
n. PK sampling  is only relevant  for subjects  randomized  to ATM -AVI ±MTZ.  
o. 3 samples  should  be taken  on Day 1 - see Table  13 and Figure  3 and Figure  4 for detailed  guidance  on schedule. 
p. 3 samples  have  to be taken  on Day 4±1 day - see Table  13 and Figure  3 and Figure  4 for detailed  guidance  on schedule. 
q. Subjects must be frequently and closely monitored for rapidly changing CrCL through local laboratory measurement of serum cre atinine.  In case that renal 
function recovers  or deteriorates  during the treatment period,  the dose of study treatment  should be adjusted  by the Investigator  to meet  the appropriate  dose 
regimen, based on the latest CrCL value and in line with Section 5.6.5. In addition, to coincide with PK sample collection for patients randomized to the 
ATM -AVI treatment  arm, CrCL will  be estimated  using central  laboratory measurement  of serum  creatinine.  PK samples  should be collected  on Day 4, but 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  30  
  
can be collected  on Days  3 or 5. CrCL  will therefore  also be estimated  on Days  3 or 5 if PK blood samples  are collected  on Days  3 or 5. In this case, a 
blood sample for estimation of serum creatinine will also be collected on Days 3 or 5 and sent to the central laboratory.  (See Appendix 3) 
r. Serum  or urine  β-hCG  for pregnancy test will performed  in local  laboratory for eligibility  determination.  
s. The contraception check  is an opportunity to confirm  that contraception  is used consistently  and correctly  for the duration  of the study and for at least 7 days 
after the last infusion of investigational product.  Also, for studies enrolling adult subjects, it is the opportunity to assess changing potential to father/bear 
children and allows for altering contraception if new disease contraindicates a selected method of contraception or if nonchildbearing status is achieved.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  31  
 1. INTRODUCTION  
1.1. Background  
The prevalence of multidrug resistant (MDR) bacteria is increasing worldwide. This has 
become a significant public health threat as there are fewer, or even sometimes no, effective antimicrobial agents available for infections caused by MDR bacteria ( Lucasti et al. 2013; 
Magiorakos et al. 2012).  In particular, ongoing surveillance studies have demonstrated an 
increasing frequency of antibiotic resistance among MDR Gram -negative bacteria.  New 
antibiotics or combinations of existing antibiotics with resistance enzyme inhibitors are urgently needed  to provide treatment  options for patients  with infections known or suspected 
to be caused by MDR Gram-negative pathogens ( IMI; IMI 2015).  
One of the most common resistance mechanisms in Gram-negative pathogens is the production of extended -spectrum  β-lactamase  (ESBL)  (Lucasti  et al. 2013 ). Infections due to 
ESBL- producing organisms present a major therapeutic dilemma especially as isolates are 
also increasingly expressing resistance to other first line agents such as fluoroquinolones or aminoglycosides, leaving few available options for treatment. ESBL are found in a significant percentage of Enterobacteriaceae (including Escherichia coli , Klebsiella 
pneumoniae , Enterobacter spp., Citrobacter spp., Proteus spp., Morganella morganii , 
Serratia marcescens , and Shigella dysenteriae ). They can also be found in Pseudomonas 
aeruginosa although they do not contribute significantly to resistance in this organism. 
Carbapenems  are the preferred  treatment  option for serious infections due to such MDR 
Gram -negative pathogens but carbapenemases have steadily accumulated in the 
Enterobacteriaceae with the epidemiology of carbapenem -resistant  Enterobacteriaceae 
characterized by large heterogeneity in genotypes (with >20 reported resistance gene 
families, such as New Delhi Metallo -β-lactamase (NDM), Klebsiella pneumonia 
carbapenemase (KPC), Verona Integron encoded metallo -β-lactamase (VIM), and 
Oxacillinase (OXA) -48 (Nordmann and Poirel 2013).  The expression of 
metallo -β-lactamases  (MBLs) such as VIM  and NDM -1, in addition to other resistance 
mechanisms, is of increasing concern as the treatment options are extremely limited.  
A particular threat is posed by a family of MBLs known as NDM. NDM -1-producing 
pathogens have already been reported in a number of countries outside of the regions where the first producing strains  were identified  in 2009 (India, Pakistan,  Sweden,  United  Kingdom 
[UK]), including Australia, Singapore, Taiwan, and the United States (US). The recent 
emergence of NDM -1 has caused particular concern in the international infection 
community, as the genetic element encoding NDM-1 is able to rapidly spread amongst bacteria in both community and hospital settings ( Johnson and Woodford 2013; Moellering 
2010).  
The spread of resistance leading to multi -drug resistant pathogens due to the ESBL 
cefotaximase -M (CTX -M) may  provide a useful model for the spread  of NDM -1 as  the 
bla
NDM -1 gene is found on the same promiscuous ST131 clone as CTX -M. In particular, 
organisms that produce NDM- 1 have spread geographically and are now seen in  
community -acquired  infections, similar  to the spread  of CTX -M, which  has reached  endemic  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  32  
 levels  in much  of Asia,  Europe, and South America.  These pathogens have become endemic 
in the Indian subcontinent, where they have been detected in the environment ( Walsh et al.  
2011).  
1.2. Mechanism of Action/Indication  
With more than 30 years of use worldwide, aztreonam (ATM) is an established injectable 
antibiotic indicated for the treatment of various infections caused by Gram- negative bacteria 
including but not limited to pneumonia and complicated intra abdominal infections (cIAIs) (see Summary of Product Characteristics [SmPC] of ATM and ATM prescribing information). It has a unique monocyclic β-lactam  nucleus that makes  it structurally  different 
from other β -lactam antibiotics (including penicillins and cephalosporins), as well as several 
chemical side groups that interfere with degradation by MBLs. Activity against MBL  
(Class  B) producing pathogens is possible, although potential inactivation  by Class  A, C, or 
D β-lactamases remains problematic.  
Avibactam (AVI)  is a novel, non β-lactam,  β-lactamase inhibitor of a broad spectrum  of 
enzymes, including Ambler Class A ESBLs, Class A KPC, and Class C (ampicillinase Class  C [AmpC]) enzymes,  and some Class  D enzymes,  notably OXA-48, a problematic  
carbapenemase in  the European Union (EU) and  Middle East.  The inhibition of β-lactamase 
by AVI occurs through formation of a covalent bond between AVI and the enzyme. Alone, AVI has no meaningful antibacterial  activity; rather,  its beneficial  effect  in combination with 
ATM occurs by rendering inactive those enzymes that inactivate ATM. 
Together, ATM  and AVI have the potential to address  the unmet need  for safe and  effective 
agents to combat MBLs and other problematic β -lactamases, such as ESBLs and KPCs, 
which may be co -expressed with MBLs and contribute to a MDR phenotype. 
1.3. Rationale for Conducting This Study  
The combination product referred to as ATM- AVI in this Clinical Study Protocol (CSP) is 
being developed for the treatment  of serious infections caused  by Gram -negative bacteria for 
which there are limited or no treatment options.  These include infections caused by 
MBL -producing pathogens that can also co-produce ESBLs,  KPC  and/or AmpC  
β-lactamases.  Relevant to the clinical development of the study treatment is the fact that 
ATM -AVI has shown excellent activity in pre- clinical studies against a broad range of 
Gram -negative pathogens thereby  restoring  ATM  activity  against  ATM -resistant  pathogens, 
including several of the most problematic MDR pathogens, but excluding A. baumannii as 
listed above (see Investigator’s Brochure (IB) for further details). 
To date, 92 healthy volunteers have been dosed with the investigational product (IP) 
(ie, ATM -AVI,  placebo  or ATM/AVI  separately),  in a single Phase 1 study (Please see 
Section 1.4 for further details).  Additional details can be found in the ATM- AVI IB.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  33  
 A prospective, open-label, multicenter Phase 2a study to determine the pharmacokinetics 
(PK), safety and tolerability of ATM -AVI for the treatment of cIAI in hospitalized adults, 
and to provide dose confirmation for Phase 3 clinical  studies has completed  enrolment and 
the CSR is pending. The PK/pharmacodynamic (PD) data generated will contribute to a 
robust package of data, supported by prior experience with ATM and AVI, and will be validated by qualitative data for the combination from the ATM-AVI Phase 3 program. 
This ATM -AVI Phase 3 study is part of the Work Package  2B (WP2B)  in the Innovative 
Medicines Initiative (IMI) supported COMBACTE- CARE project.  IMI is a joint 
undertaking between the EU and the pharmaceutical industry association European 
Federation of Pharmaceutical Industries and Associations (EFPIA) (see IMI). 
COMBACTE -CARE  (Combatting  Bacterial  Resistance in Europe – Carbapenem- resistence) 
is a consortium of 19 academic and 3 pharmaceutical partners focusing on carbapenem resistance in Europe.  The study is registered in the EudraCT database with the number 
2017- 002742 -68. 
1.4. Rationale for  Study  Design,  Doses  and Control Groups  
In patients  with hospital- acquired  pneumonia/ventilator- associated  pneumonia (HAP/VAP) 
and cIAIs, Gram-negative pathogens, including those producing ESBLs and AmpC 
β-lactamases,  are important causative pathogens.  
Most intra -abdominal infections are polymicrobial and caused by organisms residing in the 
gastrointestinal tract, including aerobes and facultative and obligate anaerobes. In patients 
with cIAI, MTZ will be added to ATM-AVI to provide coverage for anaerobic organisms 
such as the Bacteroides fragilis group. The spectrum of activity of ATM-AVI when combined with MTZ is well suited to treatment of pathogens commonly responsible for cIAIs.  In patients with HAP/VAP, anaerobic organisms are not common causative 
pathogens; therefore  ATM -AVI is considered to provide efficient  coverage for the pathogens 
causing HAP/VAP.  
Meropenem (MER) has been selected as the comparator because of its established efficacy 
against resistant Gram -negative pathogens isolated in cIAI and HAP/VAP, for which is it 
approved and widely used in these indications due to the spectrum of activity including 
efficacy against ESBL - and AmpC- producing Enterbacteriaceae causing cIAI and 
HAP/VAP ( MERREM
, 2016; MERONEM SmPC, 2017).  It is amongst the treatment 
options recommended  as a first-line agent  for the treatment  of serious bacterial  infections due 
to MDR Gram -negative pathogens ( Kalil et al. 2016 ). 
The option to add concomitant therapy with colistin (COL) (colistimethate sodium) is based on current standard of care for proven or suspected carbapenem- resistant Enterobacteriaceae 
(CRE)  (Nation  et al. 2015).  Both COL  and tigecycline  are frequently used in the treatment  of 
CRE infections based on demonstrated activity against CRE, yet both agents are associated with significant tolerability and safety concerns.  Optional COL was chosen for use in the 
comparator arm because it shows more consistent in vitro activity against MBL pathogens than tigecycline ( Morill et al. 2015; Narayabab et al. 2016 ; Tängden et al. 2015).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  34  
 The decision to select MER ± COL rather than COL monotherapy as the starting treatment 
regimen was based on current standard of care for serious infections due to Gram -negative 
bacteria,  including MBL -producing MDR  pathogens ( IDSA  2016, Hopkins 2015-2016 and 
Solomkin et al. 2010).  Since only a relatively small proportion of sites are likely to have a 
high prevalence of  MBLs,  many  investigators may  be reluctant  to initiate  a patient  on COL 
unless they suspect the involvement of an MBL pathogen in the patient’s infection. 
Mandating COL  therapy  for all patients  could expose patients  who have only a 
MER -susceptible Gram -negative pathogen to unnecessary risks. Considering the safety 
concerns  that are associated  with COL,  compared  with the better -tolerated  standard  of care 
agents for Gram -negative pathogens, such as high dose MER, the use of COL will be 
optional and at the investigator’s discretion ( Jaruratanasirikul et al. 2005, Keel et al. 2011 , 
and Li et al. 2006).  
1.4.1. Study  Design  and Control Group  
This is a Phase 3 prospective, randomized, open- label, central assessor -blinded, parallel 
group, multicenter comparative study to determine the efficacy, safety and tolerability of 
aztreonam -avibactam ± metronidazole (ATM -AVI ±MTZ) versus meropenem ± colistin 
(MER  ±COL)  in the treatment  of serious infections  due to Gram -negative bacteria,  including 
MBL -producing MDR pathogens for which there are limited or no treatment options. 
The comparative, 2 -arm study design is sufficient to provide descriptive estimates of 
efficacy, safety and tolerability for ATM- AVI and comparator in the treatment of patients 
with cIAI or HAP/VAP.  The study is open-label due to the complicated dosing regimens of 
the investigational product. The Investigators, site personnel, and patients  will not be blinded 
in this open-label study. The independent adjudication committee (central assessor) will be 
blinded with the aim of unbiased adjudication of the primary objective measure. The 
2:1 ratio  for randomization (to  ATM -AVI ±MTZ versus MER  ±COL,  respectively)  is chosen 
in order to enrich the safety and efficacy  data for patients treated with ATM -AVI ±MTZ and 
increase the number of potential MBL -producing Gram-negative pathogens in that group. 
Due to the excessive fluid burden that would be expected in the case of a double-blinded study, for patients with different infection types  (cIAI  or HAP/VAP)  and for a range of renal 
functions, it was not considered feasible to use placebo infusions to create a double-blinded study. Volume overload is associated with the development of serious medical complications and increased mortality; a recent study in 3147 patients in the Sepsis Occurrence in Acutely Ill Patients (SOAP) study in 24 European countries found that a 1 L positive fluid balance per 24 hours was associated with an approximate 20% increase in mortality  risk (Payen  et al. 2008).  Instead,  a study design with a blinded central  adjudication 
committee is considered to be most appropriate for the proposed ATM- AVI ± MTZ study in 
order to reduce risk to patients and reduce the risk for bias. 
Clinical efficacy  for the study population will be estimated  using a clinical  response endpoint 
applicable to all patients.  Secondary endpoints include microbiological response in 
microbiological analysis sets, and 28 day mortality. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  35  
 The duration of study drug treatment (5 to 14 days for cIAI and 7 to 14 days for HAP/VAP) 
takes into account the current US Food and Drug Administration (FDA) recommendations for the development of drugs for treatment of cIAI ( FDA 2015 ). The study is approximately 
45 days in duration. It will consist of a Screening visit (Visit 1), a Baseline visit (Visit 2) on 
Day 1 of the study treatment,  ongoing treatment  visits  (Visits  3 to 15) from Day 2 to Day 14, 
an End of Treatment (EOT) visit (Visit 16) within 24 hours after the last infusion, a Test of 
Cure  (TOC) visit (Visit 17) on Day 28 (±3 days) and a Late Follow Up (LFU) visit (Visit 18) 
on Day 45 ( ±3 days). 
The study is planned to be performed  in approximately 170 sites in up to 30 countries in the 
Americas, Africa, Europe, and Asia, in regions with emerging and/or elevated incidence of 
carbapenem resistance, including resistance caused by MBLs.The chosen study design as described below takes into account the joint scientific advice received from the European Medicines Agency (EMA) and the FDA in October 2012 and April 2015 and further scientific advice from the FDA in December 2016 alongside the current regulatory guidelines, ie, the EMA “Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections” ( EMA 2011 ), EMA “Addendum to the guideline on the 
evaluation of medicinal products indicated for treatment of bacterial infections”  
(EMA  2013),  the US FDA  Guidance for Industry “Antibacterial  Therapies  for Patients  With 
an Unmet Medical Need for the Treatment of Serious Bacterial Diseases” ( FDA 2017), the 
US FDA Guidance for Industry “Complicated Intra-Abdominal Infections: Developing Drugs for Treatment” ( FDA 2015), and the US FDA Guidance for Industry 
“Hospital -Acquired  Bacterial  Pneumonia and Ventilator -Associated  Bacterial  Pneumonia: 
Developing Drugs for Treatment” ( FDA 2014 ). 
1.4.2. Dose  Selection  for ATM -AVI 
The intention for ATM- AVI is that it will be active against clinically isolated Gram- negative 
bacteria for which there are limited or no treatment options.  The ATM -AVI doses for this 
Phase 3 study have been selected based on pre- clinical and clinical data on ATM -AVI, using 
PK data for ATM, AVI and ATM-AVI and including covariate information collected in healthy volunteers and patients to construct a robust population PK model. Furthermore, AVI PK and safety  data together with PK/PD  modelling  results  obtained during development 
of the new ceftazidime -avibactam (CAZ -AVI) combination product Avycaz
 in the US 
(Zavicefta in Europe) have been taken into account ( FDA prescribing information: 
AVYCAZ 2017 , European Commission: Product information Zavicefta 2016).  
Patients  will be monitored frequently  and closely  for rapidly changing creatinine  clearance 
(CrCL), and the Investigator will adjust the study drug dose promptly if needed. (See 
Appendix 3) 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  36  
 Dose  selection  (ATM -AVI)  for patients  with normal renal  function or mild renal  impairment 
(CrCL >50 mL/min)  
For patients  with serious bacterial  infections where  there are limited  or no treatment  options, 
it is recommended for β -lactams to rapidly achieve target attainment and steady state 
concentrations while prolonging time above the minimum inhibitory concentration (MIC) 
with extended  infusion time and shorter dosing intervals.  The rationale  for the selected  dose 
regimen is based on the objective of obtaining optimal exposure to achieve a >90% probability of target attainment (PTA) against PK/PD targets for both ATM and AVI which have been identified from non- clinical data.  The PK/PD targets are:  
• Maintain  unbound ATM  concentrations above an  MIC  for 60% of the dosing interval.  
• Maintain  unbound AVI concentrations above a threshold concentration  (C
T) of 
2.5 mg/L  for 50% of the dosing interval.  
The dose has been  selected to  achieve >90% PTA  at an ATM -AVI MIC  of 8 mg/L.  
Population PK models have been constructed using the following data: ATM PK data from the literature, ATM and AVI PK data from the Phase 1 study (C3601005) of the ATM- AVI 
development program, and AVI PK data from the Zavicefta development program (AVI in combination with ceftazidime [CAZ]) which included a substantial amount of PK data in patients.  Most recently, the PK model was updated using PK and covariate data from 
patients with cIAI in the Phase 2a study. The PK models were used in Monte Carlo simulations  of 5000 patients  to select  a dosing regimen  which  achieved  a >90%  joint PTA  for 
ATM and AVI based on PK/PD targets: 
In Cohort 1 of the Phase 2a study in patients with cIAI (and CrCL >50 mL/min) the dosing 
regimen was selected based on the Phase 1 safety data and PK/PD modeling above, ie, a loading dose (500 mg ATM plus 137 mg AVI  by IV infusion) over a 30 minute period, was 
immediately  followed by a maintenance infusion of 1500 mg ATM  plus 410 mg AVI over a 
3 hour period [q6h]). Patients also receive 500 mg MTZ infused over 1 hour every 8 hours (q8h), starting after the first ATM -AVI maintenance infusion.  
The safety and PK data from 10 patients in Cohort 1 (who completed all safety and PK assessments) was reviewed by a Scientific Advisory Committee (SAC).  Based on 
assessment of the safety and PK data in Cohort 1, Cohort 2 was subsequently initiated using 
a higher AVI dose (a loading dose of 500 mg ATM plus 167 mg AVI by IV infusion over a 30 minute period, immediately followed by a dose of 1500 mg ATM plus 500 mg AVI by IV infusion over a 3 hour period q6h [maintenance infusion]). Following the review of PK and safety  data from  10 patients  in Cohort 2 by the SAC,  the higher AVI dose was continued 
in Cohort 3. The higher AVI dose was selected as it provides a higher PTA for AVI using the PK/PD targets as described above compared to the lower AVI dose. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  37  
 In this Phase 3 study, the dosing regimen is the same as that administered in Cohorts 2 and 3 
of the Phase 2a study. The loading dose for patients  with normal renal  function or mild renal 
impairment (CrCL  >50 mL/min)  is 500 mg  ATM  plus 167 mg  AVI infused over a 30 minute 
period, immediately followed by an extending loading dose of 1500 mg ATM plus 500 mg AVI over a three hour period. Three hours after the extended loading dose is completed, a maintenance dose of 1500 mg ATM and 500 mg AVI is infused over 3 hours and administered (q6h). The targeted total daily dose on Day 1 is 6500 mg ATM/2167 mg AVI. From Day 2 onwards, this will be 6000 mg ATM/2000 mg AVI. 
Dose  s
election  (ATM -AVI)  for patients  with moderate renal  impairment (CrCL  >30 mL/min  
to ≤50 mL/min) and severe renal impairment (CrCL >15 mL/min to ≤ 30 mL/min) 
As both ATM and AVI are eliminated primarily as unchanged substances by the kidney, 
dosing regimens  for patients  with moderate to severe renal  impairment (CrCL  >15 mL/min  to 
≤50 mL/min) require adjustment.  Doses are based on PK modeling and simulation.  
The r eview  and approval of data from  the Phase  2a Cohort 1 by the SAC  also led to the 
approval that Cohort 2 could recruit patients with moderate renal impairment ( CrCL  
>30 mL/min to ≤ 50 mL/min ). The population PK models for both ATM and AVI included 
data from patients with renal impairment which allowed the use of modeling and simulation for dose selection in Phase 2a and 3. The dose selection for patients with moderate renal impairment was based on the following criteria: matching the predicted ATM steady state 
area under the curve between time zero and 24 hours after dose (AUC
(0-24,ss)) in patients with 
moderate renal impairment, to the predicted AUC (0-24,ss)  in patients with normal renal 
function (CrCL >80 mL/min) receiving ATM 1500 mg/AVI 500 mg; maintaining the same dosing ratio between ATM and AVI; and maintaining >90% PTA. Furthermore, since the dosing ratio between ATM and AVI is fixed, and given the differential impact of renal impairment on the clearance of ATM and AVI, it was accepted that matching an area under the plasma  concentration  versus time curve (AUC)  target  for ATM  would result in exceeding 
the exposure targets for AVI in patients with normal renal function, but should not appreciably exceed the exposure in patients with mild renal impairment with the standard dose. As patients can have fluctuating renal function, in order to ensure sufficient exposure on the first day of dosing, the loading and first maintenance dose for patients with moderate renal impairment (CrCL >30 to 50 mL/min) will be the same as for patients with normal renal function. Thus in this Phase 3 study, the dose for patients with moderate renal impairment is a loading dose of 500 mg ATM plus 167 mg AVI by IV infusion over a 30 minute period, immediately  
 followed by an extended  loading dose of 1500 mg ATM  plus 
500 mg  AVI by IV infusion over a 3 hour period, and then  following a 3 hour gap, a reduced 
maintenance doses of 750 mg ATM plus 250 mg AVI by infusion over a 3 hour period q6h. 
In this Phase  3 study, the dose for patients  with  severe renal  impairment (CrCL  >15 mL/min 
to ≤30 mL/min) has been selected on a similar basis using modeling and simulation and is a 
loading dose of 675 mg ATM plus 225 mg AVI by IV infusion over a 30 minute period, 
immediately  followed by an extended  loading dose of 675 mg ATM  plus 225 mg AVI by IV 
infusion over a 3 hour period, then following a 5 hour gap, maintenance dose of 675 mg ATM plus 225 mg AVI by IV infusion over 3 hours q8h. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  38  
 1.4.3. Dose Selection for Metronidazole  
MTZ will be co -administered with ATM -AVI in patients with cIAI for the entire duration of 
study drug treatment (5 to 14 days) to provide coverage for anaerobic pathogens. The dose 
to be administered  (500 mg MTZ IV over 1 hour q8h starting  after the extended loading dose 
[second dose] of ATM-AVI) was chosen based on the current Guidelines of the Infectious Diseases Society of America for management of cIAI ( Solomkin et al. 2010).  This dose 
selection for MTZ is also in line with nationally approved SmPCs in Europe ( Baxter 
Healthcare Ltd. ) which do not indicate a need for dose adjustments in renal impairment. 
1.4.4. Dose  Selection  for Meropenem  
The dose of MER selected for this study (1 g IV q8h over 30 minutes) is consistent with the 
currently labeled recommendations for adult patients with cIAI ( MERONEM
 SmPC 2017, 
MERREM 2016) and HAP/VAP ( MERONEM SmPC 2017).  The protocol allows for the 
option to use an increased  dose of MER  (2 g IV  q8h) in the case of proven or suspected  CRE. 
Prolonged infusion (over 3 hours) may be used if this is the standard of care or in the case of 
proven or suspected  CRE.  The use of increased  dose MER  and prolonged infusion time  is an 
evolving standard of care for patients with presumed MDR Gram-negative infections, based on extensive PK/PD analyses indicating improved target attainment for certain high- MIC 
pathogens otherwise classified as MER -resistant, including MBL- and KPC-producing 
strains ( Jaruratanasirikul et al. 2011; Roberts et al. 2009; Tsala et al. 2016 ). Doses are to be 
adjusted for patients with renal impairment based on frequent monitoring of CrCL. 
1.4.5. Dose  Selection  for Colistin  
The COL  dosing regimen  specified  by the  study protocol is  consistent with  recent  guidance 
issued by EMA ( EMA 2014a  and EMA  2014b),  which  indicates that COL should be dosed 
and monitored as follows: a loading dose of 9 million international units (IU) over 30 to 
60 minutes, followed by 9 million IU daily in 2 or 3 divided doses as a slow IV infusion. Doses are to be adjusted for patients with renal impairment based on frequent monitoring of CrCL.  Recent clinical studies indicate this dose regimen to be generally well tolerated and 
efficacious  in the treatment of patients  with serious blood stream  infections and patients  with 
ventilator -associated bacterial pneumonia ( Dalfino et al. 2012; Dewan and Shoukat 2014).  
1.5. Single  Reference Safety  Document  
Additional information  for ATM -AVI may  be found in  the single reference  safety  document 
(SRSD), which for this study is the ATM- AVI Investigator Brochure (IB).  
The SRSD  for co- administered  drug MTZ is  MTZ  United  Kingdom (UK) SmPCs  (Baxter 
Healthcare Ltd .) and Metronidazole, CHINA ; Metronidazole, USA . The SRSD for 
comparator Meropenem is United Kingdom (UK) MERONEM
 SmPC 2017, and for 
comparator  Colistin  is Colomycin United  Kingdom (UK)  SmPC  2016 and Colistimethate 
sodium, USA . 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  39  
 1.6. Benefits/Risk  and Ethical  Assessment  
Patients enrolled into this clinical study will have cIAIs requiring surgical intervention 
(including open laparotomy,  percutaneous  drainage of an abscess  and laparoscopic surgery) 
or nosocomial pneumonia (NP) including HAP and VAP that are of sufficient severity to require hospitalization and treatment with IV antibiotics.  
The potential benefit to patients participating in this study is that they will receive effective antibiotic treatment for their infection.  ATM -AVI is covering Gram -negative pathogens in 
cIAI and HAP/VAP patients, and other suspected pathogens are covered by the administration of allowed concomitant antibiotics while MTZ will be covering anaerobic pathogens in cIAI, see details in Section 5.10. Microbiology data reported for ATM- AVI to 
date shows it has potent in vitro activity against Enterobacteriaceae, including activity against MDR isolates that carry  MBLs (see  IB for further details).  In addition, AVI has been 
shown to restore the effectiveness of ceftazidime in clinical studies in patients with cIAI and HAP/VAP (see IB of ATM -AVI), and restoration of activity of aztreonam is also expected 
when combined with AVI. Thus ATM -AVI warrants further study in difficult to treat, 
serious infections where MDR Enterobacteriaceae may occur.  The potential benefit of the 
study, in general, is the identification of a novel antibiotic combination product that is an effective treatment for a representative serious bacterial infection, in the face of the changing pattern  and increasing  frequency of antibiotic  resistance which  results  in limited  or no current 
treatment options (see Section 1.1).  It is possible that ATM -AVI will not prove to be as 
effective as the comparator regimens which represent current standard of care for a cIAI and/or NP. In order to mitigate this risk, the study patients will be closely monitored and managed with appropriate therapies as determined by the Investigator who is providing treatment, based on the clinical response of the patient. In addition, protocol- allowed 
specified concomitant antibiotics to cover non-susceptible pathogens, are permitted according to local microbiological results (see Section 5.10).  
ATM -AVI is not approved for marketing  in any country. However,  ATM  has been  marketed 
for over 30 years and has an established safety profile. Extensive data in over 2000 patients from  the CAZ -AVI program indicates  that AVI does not alter the established  safety  profile  of 
its β-lactam  partner  in the combination, thus the same could be reasonably  expected  for ATM 
in combination with AVI. 
All adverse drug reactions  (ADRs)  expected  for the ATM  monoproduct are considered  ADRs 
for ATM -AVI, and to date no unique risks have been identified for the combination of 
ATM -AVI compared  with ATM  alone.  
ATM  solution for injection  (Azactam ) was  first approved by the US FDA  in 1986 and is 
indicated for intra-abdominal infections. The most frequent ADR for ATM comprise 
gastrointestinal disorders (diarrhea, nausea, vomiting: common according to Council for International Organizations of Medical Science (CIOMS) Working Group III standard categories; see IB).  Further relevant ADRs are Clostridium difficile colitis, anaphylactic 
reactions  and ventricular  extrasystoles  (uncommon). For further information  regarding the 
risks attributable to ATM see IB and SmPC ( ER Squibb & Sons Limited 2014).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  40  
 Human experience with AVI includes studies of all phases in which AVI was administered 
either  as a single agent  or in combination with other  antibiotics  (CAZ  or ceftaroline).  As part 
of the CAZ-AVI development program and in a Phase I study for the ATM- AVI 
development, the safety and PK of AVI have been investigated in more than 10 clinical pharmacology studies after IV administration of AVI alone or in combination with ceftaroline, CAZ or ATM. CAZ -AVI was approved by the FDA on 
25 February 2015 (Trademark: Avycaz) and by the EMA on 28 April 2016 (Trademark: Zavicefta).  No ADRs are currently expected for the AVI monoproduct. More than 
2000 patients across the indications of cIAI, complicated urinary tract infections, and HAP/VAP  have been  exposured to CAZ -AVI and no significant differences  in the safety 
profile for CAZ -AVI were found compared to ceftazidime (CAZ) only. 
To date on the ATM -AVI clinical  development program, data are available  from  1 completed 
Phase I study in healthy volunteers (Study C3601005), and an ongoing Phase 2a study in patients with cIAI (Study C3601001). In completed Study C3601005, the most common adverse  events  (AEs)  reported  in the ATM -AVI treatment  arms  were headache,  liver function 
test abnormal, diarrhoea and infusion/cannula site pain/reaction, which are expected events for the ATM monoproduct ( ER Squibb & Sons Limited 2014).  
Increases in transaminase levels are expected for ATM -AVI on the basis of the ATM 
labelling and are listed in Section 4.8 (“Undesirable effects”) of the UK ATM SmPC where they are considered to be “usually reversing during therapy and without overt signs or symptoms of hepatobiliary dysfunction” ( ER Squibb & Sons Limited 2014).  Although data 
are limited at this stage of development, the transaminase elevations observed in the completed  ATM -AVI Study C3601005 and preliminary  unvalidated data from  ongoing Study 
C3601001 show a similar pattern to that expected with ATM monotherapy, ie, generally asymptomatic, mild and reversible.  Preliminary post-hoc exposure- response analyses for 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevations in study C3601005 suggest that AVI does not contribute to the expected effect of ATM on AST and ALT (in -house data).  Increased liver transaminases are considered an important potential 
risk for ATM -AVI (see IB for further details).  Liver related AEs and increases in serum 
transaminases will continue to be kept under close surveillance in ATM- AVI clinical studies 
and managed appropriately, including the use of individual patient liver specific withdrawal criteria in line with guidance from the Regulatory Agencies. 
Data from  the Phase I study did not show evidence of a drug-drug interaction  (DDI) between 
ATM and AVI after single doses. Based on current knowledge, also the potential for DDIs 
between  ATM -AVI and other drugs is low. Both ATM  and AVI show linear  (approximately 
dose proportional) PK, undergo limited metabolism and are eliminated primarily as unchanged substances by the kidney. In addition, neither shows significant inhibition or induction of cytochrome P450 (CYP) enzymes in vitro and/or in vivo. Both ATM and AVI 
have low binding to human plasma proteins (ATM: approximately 43% [ Colomycin
 SmPC 
2016; Crandon and Nicolau 2013; Vinks et al. 2007]; AVI: 5.7% to 8.2% [ FDA prescribing 
information: AVYCAZ 2017]).  Furthermore, data from the Phase I study suggest that there 
is no clinically relevant influence of sex or age on the PK of AVI ( Tarral and Merdjan ). As 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  41  
 only renal  function influences PK of ATM  and AVI,  reduced  doses in the regimens for 
moderate and severe renal impairment patients were included in this study. 
In addition to the identified and potential risks for ATM- AVI described above, there are also 
general study related risks that encompass puncture of a vein and/or placement of indwelling 
catheters  for blood sampling, which  may cause pain and occasionally  results  in thrombosis or 
thrombophlebitis and/or peripheral nerve damage (numbness). The total volume of blood to be drawn from each patient is expected to range – depending on clinical response – from  
107 to 154 mL; 18 mL thereof will be used for PK analysis (see Table 14 ). The results of 
safety laboratory sampling (clinical chemistry, hematology) will be made available to the investigators. Similarly,  the results  of specimen  cultures obtained for study purposes will be 
made available to the investigators without delay and may yield clinically important additional information. Discomfort may be caused by any further study procedure such as study-related examinations, microbiological sampling, and recording of electrocardiograms (ECGs).  These procedures however are not considered as risks for the patients that would 
affect the benefit -risk assessment.  
In summary, the known and potential risks  of receiving  ATM -AVI are expected  to be similar 
to those seen with ATM. To date, no unique risks have been identified for the AVI component or the combination of ATM and AVI. Thus, the benefit/risk of ATM- AVI 
remains acceptable in this population of patients with life -threatening serious infections 
caused by Gram -negative pathogens producing MBLs and other β -lactamases implicated in 
the development of MDR for whom only limited alternative treatment options are available. The potential risks and discomforts to the individual patients in this study are well balanced by providing best practice medical monitoring and clinical care for each patient. Under the conditions of the study as described  in the present  protocol, the investigators and the sponsor 
consider the benefit/risk relation to be positive (ie, medically and ethically justified).  
Detailed  information on identified  and important risks  for ATM -AVI is located  in the 
ATM -AVI IB.  
2. STUDY OBJECTIVES  AND ENDPOINTS  
2.1. Primary  Objective  
Based  on differing  regulatory requirements  for EMA  and FDA,  the following  objectives  and 
outcome measures may differ for the US and non-US countries analyses as noted below. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  42  
  
Primary  Objective:  Primary Endpoint:  
To evaluate the efficacy  of 
ATM -AVI ±MTZ and MER ± COL  at the 
Test of Cure  (TOC) visit for the treatment 
of serious infections due to 
Gram -negative bacteria, including those 
due to  MBL -producing MDR  pathogens.  Proportion of subjects with clinical cure at the 
TOC visit in the Intent- To-Treat (ITT) and 
Clinically  Evaluable (CE) analysis sets (Note: 
non-US countries, the ITT and CE are considered co -primary analysis sets.  For the 
US, the ITT is considered  the primary  analysis 
set, while CE is secondary).  
This protocol will use an independent adjudication committee (central blinded assessor) to determine  whether  certain  investigator- reported  events meet  the definition  of disease- related 
efficacy endpoints, using predefined endpoint criteria (see Section 9.7).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  43  
 2.2. Secondary  Objectives  
 
Secondary  Objectives:  Secondary  Endpoint(s):  
To evaluate  efficacy  of ATM -AVI ±MTZ 
and MER ± COL at the TOC visit in the 
microbiological ITT (micro -ITT) and 
Microbiologically Evaluable (ME) 
analysis sets.  Proportion of subjects with clinical  cure at the 
TOC visit in the micro -ITT and ME analysis 
sets. 
To evaluate the efficacy  of 
ATM -AVI ±MTZ and MER  ±COL  at the 
TOC visit in key sub populations. • Proportion of subjects  with  clinical  cure  at 
the TOC visit by  infection type in the ITT 
and CE analysis sets.  
• Proportion of subjects  with  clinical  cure at 
the TOC visit for subjects with  
MBL -positive pathogens in  the micro -ITT 
and ME analysis sets.  
To assess the per-subject microbiological 
response to ATM- AVI ± MTZ and  
MER ± COL  at the TOC  visit.  Proportion of subjects  with a favorable  
per-subject microbiological response at the 
TOC  visit in the micro -ITT and ME analysis 
sets. 
To assess 28- day all-cause mortality.  Proportion of subjects who died on or before 
28 days from randomization in the ITT and 
micro -ITT analysis sets.  
To evaluate the pharmacokinetics (PK) of 
ATM and AVI in subjects with serious 
infections and to characterize the relationship between exposure and clinical and microbiological response for 
ATM -AVI ± MTZ utilization (listings to 
be provided in the Clinical Study Report 
(CSR), analysis to be reported outside of the CSR.  • PK of ATM  and AVI in subjects  in the 
popPK analysis set. 
• PK/ Pharmacodynamic (PD) relationship 
between exposure and clinical and 
microbiological response for 
ATM -AVI ±MTZ in the popPK analysis 
set. 
2.3. Safety  Objectives  
 
Safety  Objective:  Safety Endpoint:  
To evaluate the safety  and tolerability 
profile of ATM -AVI ± MTZ and 
MER ± COL.  Safety  and tolerability  as assessed  by adverse 
events (AEs), physical examination, vital 
signs, electrocardiograms (ECGs), and laboratory assessments in the safety analysis set. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  44  
 2.4. Tertiary  Objectives  
 
Tertiary  Objective:  Tertiary Endpoint(s):  
To evaluate the efficacy  of 
ATM -AVI ±MTZ and MER  ±COL  at the 
End of Treatment (EOT) visit.  Proportion of subjects with clinical  cure at the 
EOT visit in the ITT, micro -ITT, CE and ME 
analysis sets.  
To evaluate the efficacy  of 
ATM -AVI ±MTZ and MER  ±COL  at the 
EOT visit in key sub populations. • Proportion of subjects  with  clinical  cure  at 
the EOT visit by  infection type in the ITT 
and CE analysis sets.  
• Proportion of subjects  with  clinical  cure  at 
the EOT visit for subjects with  
MBL -positive pathogens in  the micro -ITT 
and ME analysis sets.  
To evaluate the efficacy  of 
ATM -AVI ±MTZ  and MER  ±COL  at 
EOT and TOC visits by pathogen 
resistance type.  Proportion of subjects with clinical cure at EOT  and TOC  visit by pathogen resistance 
type (eg, ATM-non-susceptible, ESBL-positive, carbapenamase-positive, etc) in the micro -ITT and ME analysis sets.  
To assess the per-subject microbiological 
response to ATM- AVI ± MTZ and  
MER  ±COL  at the EOT  visit.  Proportion of subjects  with a favorable  
per-subject microbiological response at the 
EOT  in the the micro - ITT and ME analysis 
sets. 
To assess the microbiological response by pathogen and by pathogen resistance 
type to aztreonam  
avibactam ± metronidazole and 
meropenem  ±colistin  at the EOT  and 
TOC visits.  • Proportion of subjects with a favorable per-pathogen microbiological response at 
the EOT  and TOC  visits  in the micro -ITT 
and ME analysis sets.  
• Proportion of subjects with a favorable per-subject  microbiological response by 
pathogen resistance type 
(eg, ATM -non- susceptible,  ESBL-positive, 
carbapenamase-positive, MBL - positive) at 
the EOT and TOC visits in the micro -ITT 
and ME analysis sets.  
• Proportion of subjects with a favorable 
per-pathogen microbiological response by 
pathogen resistance type 
(eg, ATM -non- susceptible,  ESBL-positive, 
carbapenamase- positive, MBL -positive) at 
the EOT and TOC visits in the micro -ITT 
and ME analysis sets.  
ATM -AVl 
C360 1002 
PFIZER  CONFIDENTIAL  
Page 45  
 
 Final  Protocol Amendmen t 2, 18 May 2022   
 
2.5. Exploratory Objectives  
 
Exploratory Objectives:  Exploratory Endpoint(s):  
To evaluate  efficacy  of ATM -AVI ±MTZ 
and MER ±COL u sing objec tive clinical 
measures. Composite endpoint  includin g symptom-based 
objective clinica l measures, to be defined in 
the Statistical Anal ysis Plan (SAP) (ITT and 
CE analysis sets).  
To assess  14-day all-cause  m01ia lity. Prop ortion of subjects who died on or before 
14 days fr om rand omization in th e ITT 
analysis set. 
To evaluate  health resource  utilizatio n 
(listings to be provided in t he CSR, 
analysis to be repo1ied outside of  the 
CSR) . • Length  of hospital stay,  includin g any 
readmissions up to TOC (days). 
• Length  of study treatment  (days) . 
• Length  of intensive care unit (ICU) stay 
(days). 
• Tran sfened to the ICU (Yes/No) . 
• Mechanical  ventilation  (Yes/No)  for 
HAPN AP subjects. 
•  Length  of mechanical  ventilatio n (days) 
for HAP N AP subjects. 
• Subsequent unplanned s urgical 
interven tion after  treatment  success vs 
failure (up to the TOC  visit) for cIAI 
subjec ts. 
 
3. STUDY DESIGN  
This is a Ph ase 3,  prospective , randomized , multice nter, open-label , central assessor- blind ed 
(see Sectio n 9.7), parallel group, comparati ve stud y to detennine the efficacy , safety, and 
tolerability  of ATM -AVI ±MTZ vers us MER ±COL in the  treatm ent of hospitalized a dults 
with cIAI  or NP (includin g HAP  and VAP) in regions  with endemic  or emerging carbapenem 
resistance , and where MBL -producing MDR pathogens are suspected. 
The study outline  is provided in Figure  1, the study  treatment  is provided in Figure 2. 
ATM -AV1 
C3601002 
PFIZER  CONFIDENTIAL  
Page  46  
 Final  Protocol  Amendment  2, 18 May 2022  
Adult hospitalized  subjects with a confirmed  diagnosis of complicated  intra-abdominal 
infection or hospital acquired pneumonia/ventilator associated pneumonia related to 
Gram -negative pathogens including, but not limited to, those infected with multidrug 
resistant  strains,  and requiring  administration  of intravenous antibacterial  treatment  will be 
enrolled in this study. 
The study will randomize up to approximately 425 subjects (at least 300 subjects with cIAI 
anticipated) in regions with emerging and/or elevated incidence of carbapenem resistance, including MBL -producing pathogens. The number of subjects  with a perforated  appendix or 
appendiceal  abscess  will be limited  to approximately 40% of the study population with cIAI. 
It is estimated that approximately  8-10% of subjects will be identified with MBL -producing 
Gram -negative pathogens. 
The study will consist of a Screening visit (Visit 1), a Baseline visit (Visit 2) on Day  1 of the 
study treatment,  ongoing treatment  visits  (Visits  3 to 15) from  Day 2 to Day  14, an EOT  visit 
(Visit 16) within 24 hours after the last infusion, a TOC visit (Visit 17) on Day 28 ( ±3 days) 
and a LFU visit (Visit 18) on Day 45 ( ±3 days). 
After obtaining written informed consent and confirming eligibility, subjects will be 
randomized in a 2:1 ratio to the ATM- AVI ± MTZ treatment arm or the MER ± COL 
treatment arm according to a central randomization schedule (approximately 283 subjects to 
ATM -AVI ±MTZ and approximately  142 subjects  to MER  ±COL  per group). Please refer to 
Section 5.6, for more details with regard to treatment arms, dosage and mode of 
administration and duration of treatment. Subjects will be stratified at randomization based 
on infectious disease type (cIAI and HAP/VAP).  For cIAI, subjects will also be stratified by 
Acute Physiology and Chronic Health Evaluation (APACHE) II score ( ≤10 and >10) (see 
Appendix 5).  For HAP/VAP,  subjects  will also  be stratified  by mechanical  ventilation  status 
(Y/N).  
The recommended  minimal duration of treatment  is 5 days for cIAI and 7 days for 
HAP/VAP.  The maximal duration of treatment is 14 days. 
For subjects  randomized  to ATM -AVI ±MTZ,  sparse  blood samples  will be collected  for PK 
assessments by  population pharmacokinetic (popPK) analysis, and PK/PD relationships will 
be evaluated  in subjects  where plasma samples  and microbiological response data have been 
collected.  
Each  subject  is expected  to complete  the study, including the LFU  visit.  Subjects  will 
receive their study treatment by study center personnel while in the hospital. 
ATM -AVl 
C3601002  
 Final  Protocol  Amendmen t 2, 18 May  2022   
Figure  1 Study Outline  
PFIZER  CONFIDENTIAL  
Page  47  
  
 
Abbrevia tions:  ATM -AVI=aztreonam -avibactam ; ATM -AVI ±MTZ =ATM -AVI ±metronidazo le; cIAI =comp licated intra -abdominal  infections; COL =colistin 
(colistimethate  sodium); DoT =duration of treatmen t; EOT =end of t reatment; HAPN  AP=hospital -acquired pneumonia/ventilator -associa ted pneumonia ; 
IU=intemational uni ts; IV=intravenous (ly); LFU =late follow -up; MER =meropenem; MER ±COL =MER±colistin ; MTZ = metronidazole: TOC=test of cure.  
Note:  Administration  of the first dose  of IV study therapy  marks  the beginning  of study treatment  Day 1. 

ATM -AVl 
C3601002  
 Final  Protocol  Amendmen t 2, 18 May 2022   
Figure  2 Study Treatment  
PFIZER  CONFIDENTIAL  
Page 48  
 
 
 
ATM -AVI 
ATM -AVI± MTZ  anu 
 
ATM -AVI 
 
 
  
 
  
D  = mandato1y  
 
= ootional  
Gram -positive cover 
(vancomycin  or linezolid) 
 
Pseudomonas cover 
IV aminoglycos ide 
Gram -positive cover 
(vancomycin  or linezolid) 
 IV aminoglycos ide 
Gram -positive cover 
(vancomycin , linezolid , or 
daptomycin)  
 
 
 
  
 
  
 
                 
 
      
 
Abbre viations:  ATM -AVI=aztreonam -avibactam ; cIAI =complicated  intra -abdomina l infections ; COL =colistin (colistime thate sodium) ; 
HAP N AP=hospi tal-acquired pneumoni a/ ventilator -associat ed pneumonia ; IV=intravenou s(ly); MER =meropenem ; MER±COL =meropenem±colistin ; 
MTZ =metronidazole.  
 
For details of study  treatment see Section  5.6, and for details of allowed  concomi tant medication  see Section  5.10.  ATM -AVI± MTZ  anu 
MTZ  Gram -positive cover 
(vancomycin , linezolid , or 
daptomycin)  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  49  
 4. SUBJECT  ELIGIBILITY  CRITERIA  
This study can fulfill its objectives only if appropriate subjects are enrolled. The following 
eligibility criteria are designed to select subjects for whom participation in the study is considered  appropriate.  All relevant  medical  and nonmedical conditions should be taken  into 
consideration when deciding whether a particular subject is suitable for this protocol. 
Subject  eligibility  should be reviewed  and documented by an appropriate member  of the 
investigator’s study team before subjects are included in the study. The target  population is hospitalized  subjects  with a diagnosis of cIAI or HAP/VAP.  
For subjects with cIAI, a presumed diagnosis is necessary for enrolment. The diagnosis of 
cIAI will be based  on the subject’s  clinical  syndrome or will be supported by intra-operative 
findings, including intra-operative culture of specimens. Operative intervention must be required and includes open laparotomy, laparoscopic surgery, and percutaneous drainage of an abscess.  All subjects will undergo a preliminary evaluation for eligibility within the  
24-hour period prior to initiation of IV study treatment. The exact clinical diagnoses and 
brief descriptions that define the population of subjects with cIAI eligible for this study are given in Sections  4.1.1 and 4.1.2 and for subjects  with HAP/VAP  in Sections  4.1.1 and 4.1.3. 
For subjects  with HAP/VAP,  an established  diagnosis of NP is required, as detailed  in 
Section 4.1.3. 
The inclusion and exclusion  criteria  will be assessed  by a site Investigator before  enrolment 
of the subject to the study. Clinically indicated antibiotic treatment must not be delayed 
because subject is being considered for clinical study participation. Each  subject should meet  all of the inclusion criteria  and none of the exclusion criteria  for 
this study. Under no circumstances can there be exceptions to this rule. 4.1. Inclusion  Criteria  
Subjects  must meet  all of the following inclusion criteria  to be eligible  for enrollment into the 
study:  
4.1.1. All Subjects  
1. Subject  must be ≥ 18 years of age. 
2. Evidence of a personally  signed and dated informed consent document indicating that the 
subject  or a legally  acceptable representative has been  informed  of all pertinent  aspects  of 
the study. If a subject is unable to consent for themselves at Screening, the subject’s 
legally acceptable representative may provide written consent, in accordance with the country- specific regulations.  Those subjects who are unconscious or considered by the 
Investigator clinically unable to consent at Screening and who are entered into the study by the consent of a legally acceptable representative should provide their own written 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  50  
 informed  consent for continuing to participate  in the study as soon as possible on 
recovery, as applicable in accordance with local regulations. 
3. Subjects must have a confirmed diagnosis of HAP/VAP, or presumed diagnosis of cIAI 
requiring administration  of IV antibacterial  treatment (see additional Inclusion Criteria  on 
cIAI and HAP/VAP for minimum disease criteria).  
4. Female subjects of nonchildbearing potential must meet  at least 1 of the following 
criteria:  
a. Achieved  postmenopausal status,  defined  as follows: cessation  of regular menses  for 
at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed with a serum follicle -stimulating hormone (FSH) 
level confirming the postmenopausal state; 
b. Have undergone a documented hysterectomy  and/or bilateral oophorectomy;  
c. Have medically  confirmed ovarian failure.  
Note:  All other female subjects  (including female subjects  with tubal ligations)  are 
considered to be of childbearing potential. 
5. Female  subject  of childbearing  potential must have a negative serum  or urine pregnancy 
test, with sensitivity of at least 25 mIU/mL.  
6. Subject  must be willing  and able to comply with scheduled  visits,  treatment  plan, 
laboratory tests, and other study procedures. 
4.1.2. Additional  Inclusion  Criteria  - cIAI  Subjects  
1. Diagnosis of cIAI as: 
EITHER:  
Intra -operative/postoperative enrolment with visual confirmation (presence of pus 
within the abdominal cavity) of an intra-abdominal infection associated with peritonitis.  Surgical  intervention includes open laparotomy, percutaneous  drainage of 
an abscess, or laparoscopic surgery. Specimens from the surgical intervention must be sent for culture. Subjects who undergo a surgical procedure with complete fascial closure are appropriate for  the study. The skin incision  may  be left  open for purposes 
of wound management as long as complete fascial closure is accomplished. The 
subject has at least 1 of the following diagnosed during the surgical intervention: 
a. Cholecystitis  with gangrenous rupture or perforation or progression of the 
infection beyond the gallbladder wall; 
b. Diverticular  disease  with perforation or abscess;  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  51  
 c. Appendiceal perforation or peri-appendiceal  abscess;  
d. Acute gastric  or duodenal perforations, only if operated  on >24 hours after 
diagnosis;  
e. Traumatic  perforation of the intestines,  only if operated  on >12 hours after 
diagnosis;  
f. Other  secondary peritonitis  (not primary/  spontaneous bacterial  peritonitis 
associated with cirrhosis or chronic ascites);  
g. Intra -abdominal abscess  (including of the liver and spleen  provided that there is 
extension beyond the organ with evidence of intra-peritoneal involvement). 
OR 
Pre-operative enrollment where the following clinical criteria are met with 
confirmation  of infection  by surgical  intervention within  24 hours (before  or after)  of 
randomization:  
h. Requirement  for surgical intervention, defined  per protocol as open laparotomy, 
percutaneous drainage of an abscess, or laparoscopic surgery; 
i. Evidence of systemic  inflammatory  response, with  at least  one of the following:  
• Documented  fever  (defined  as body temperature ≥38°C) or hypothermia (with 
a rectal core body temperature ≤ 35°C);  
• Elevated  white  blood cells (WBC)  (>12000 cells/μL);  
• Systolic  blood pressure  (SBP)  <90 mmHg  or mean  arterial  pressure (MAP)  
<70 mmHg,  or a SBP decrease  of >40 mmHg;  
• Increased  heart  rate ( >90  beats  per minute  [bpm]) and respiratory  rate 
(>20 breaths/min);  
• Hypoxemia (defined  as oxygen [O2] saturation  <95%  by pulse oximetry);  
• Altered  mental  status.  
j. Physical  findings consistent with intra-abdominal infection, such as: 
• A bdominal pain and/or tenderness, with or without rebound;  
• Localized  or diffuse abdominal wall rigidity;  
• Abdominal mass.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  52  
 k. Supportive radiologic imaging  findings of intra-abdominal infection  such as 
perforated intraperitoneal abscess detected on computed tomography scan, 
magnetic resonance image, or ultrasound. 
l. Specimens  from  the surgical  intervention  will be sent for culture for isolation  of 
both aerobic and anaerobic bacteria.  
2. Subject  must have had  or will have a surgical  intervention within  24 hours (before  or 
after)  of randomization. A specimen  from an  abdominal source must be obtained for 
culture during surgical  intervention. Surgical  intervention includes open laparotomy, 
percutaneous drainage of an abscess, or laparoscopic surgery. Isolates taken from 
surgical wound exudates must not be used. 
4.1.3. Additional  Inclusion  Criteria  – HAP/VAP  Subjects  
1. Onset  of symptoms >48 hours after admission  or <7 days after discharge from  an 
inpatient care facility (for which the duration of admission was >3 days). 
2. New  or worsening infiltrate  on chest  X-ray (or computerized  tomography [CT]  scan) 
obtained within 48 hours prior to randomization. 
3. At least 1 of the following:  
• Documented  fever  (temperature ≥38°C)  or hypothermia (rectal/core temperature  
≤35°C);  
• WBC ≥ 10,000 cells/mm3, leukopenia with total WBC ≤ 4500 cells/mm3, or 
>15% immature  neutrophils (bands) noted on peripheral  blood smear.  
4. At least 2 of the following:  
• A new cough (or worsening of cough at baseline);  
• Production of purulent sputum or purulent endotracheal  secretions;  
• Auscultatory finding consistent  with pneumonia/pulmonary consolidation (eg, rales, 
rhonchi, bronchial breath sounds, dullness on percussion, egophony);  
• Dyspnea, tachypnea,  or hypoxemia (O2 saturation  <90% or partial  pressure of 
O2 [pO 2]<60 mmHg while breathing room air);  
• N eed for acute changes in the ventilator support status/system to enhance 
oxygenation, as determined by worsening oxygenation (arterial blood gas [ABG] or 
pO2 in arterial  blood [PaO 2]/fraction  of inspired O 2 [FiO 2]) or needed  changes  in the 
amount of positive end-expiratory pressure.  
ATM -AVl 
C360 1002 
PFIZER  CONFIDENTIAL  
Page  53  
 
 Final  Protocol  Amendmen t 2, 18 May 2022   
 
5.  Subjects must  have  a respirato1y specimen obtained for Gram - stain and culture  after  the 
onset of signs and symptoms for HAPN  AP and 48h prior to randomiz ation.  This 
include s culture of either expectorated sputum  or a specimen of respirato1y secretio ns 
obtained by endotracheal aspiration in intub ated sub jects, or by bronchoscopy w ith 
bronchoalveolar  lavage  (BAL),  mini -BAL or protected -specimen  brnsh  (PSB) samp ling. 
See Appe ndix 6  for details  on appropri ate specimen  collection  for ventilate d and 
non-ventilated  subje cts. 
 
 
4.2. Exclusion Criteria  
Subjects with any of the following  characteristics/ cond itions will not be included  in the 
study:  
4.2.1. All Subjects  
1. Subject has an APACHE  II score >30. 
2.  At Scree ning the subject is found to have/or strongly  suspected to have an infection 
caused by a Gram -negative  species  not expecte d to respond to either  ATM -AVI and/or 
MER (eg, Acinetobacter baumannii) , or an infection caused by  only Gram -positive 
species . The subject is allowed to paiiicipate in  the study if the Investigator co nsiders 
that the  species is a colonizer which does  not waiTa nt specific treatment. 
3. Subject has received  more  than one day (>24 hours) of any systemic  antibiotic  within 
48 hours  prior to  randomization. This is inclu sive of  all doses  of any systemic antibiotic 
initiated in  this time period (but  not count ing ove rlappin g periods of antibiotics),  eg, a 
subject who receives 4  doses  of an 8 hourly regime n with the last dose  given  just before 
randomizat ion is calculated as 32 hours of prior antibiotic.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  54  
 The exception  to this is a subject  who is a failure  of prior systemic  antibiotic  treatment  as 
evident by either  documented worsening of objective signs and symptoms of infection  or 
lack of improvement in at least one objective sign or symptom of infection despite a 
minimum of 48 hours antibiotic treatment.  
For cIAI subjects, who received less than one day (<24 hours) of any systemic antibiotic within 48 hours prior to randomization, one dose of antibiotic may be received postoperatively within  6 hours of the surgical  procedure (defined  as 6 hours from  the time 
of skin closure or, if skin closure is not performed, 6 hours from the time the wound dressing is applied). 
4. Subject has a history of serious allergy such as anaphylaxis, angioedema and bronchospasm, hypersensitivity  or any serious reactions  to any systemic  antibacterial 
which is allowed per protocol including ATM, carbapenem, monobactam or other 
β-lactam  antibiotics,  AVI,  colistimethate  or polymixin B, nitroimidazoles  or MTZ, 
vancomycin, linezolid, daptomycin, aminoglycosides (eg, amikacin, gentamicin, 
tobramycin), or any of the excipients of the respective (investigational) medicinal products to be administered during the study. 
5. Subject  is unlikely  to respond to up to 14 days of study treatment.  
6. Clinical judgment by the Investigator that the subject has a high likelihood of dying within  the specified  study treatment  period despite delivery  of adequate antibiotics  for 
treatment of the index infection. 
7. Subject  has a concurrent  infection  that may interfere  with the evaluation  of response to 
the study antibiotics. 
8. Subject  has known Clostridium  difficile  associated  diarrhea.  
9. Subject  has a need  for effective concomitant systemic  antibacterials  in addition to those 
allowed per protocol, and/or systemic antifungals, and/or any prohibited medication (eg, probenecid) (see Section 5.10).  
10. Subjects  receiving  hemodialysis or peritoneal  dialysis.  
11. Subject  has an estimated  CrCL  ≤15 mL/min  by Cockcroft -Gault  formula  (Cockcroft and 
Gault 1976) or expected to require peritoneal dialysis, hemodialysis or hemofiltration during the study. 
12. Subject  has acute hepatitis  or acute hepatic failure,  cirrhosis  or chronic hepatic failure 
(any Child-Pugh class). 
13. Presence of hepatic disease as indicated by ALT or AST >3 x upper limit of normal (ULN) at Screening.  However, subjects with AST and/or ALT up to 5 x ULN are 
eligible  if these elevations  are acute and  are documented  as being directly  related  to the 
infectious process being treated.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  55  
 14. Subject has a total bilirubin (TBili) >2 x ULN, unless isolated hyperbilirubinemia is 
directly  related  to the acute infection  or due to known Gilbert’s  disease.  This must be 
documented.  
15. Alkaline  phosphatase (ALP) >3 x ULN.  However,  subjects  with values  >3 x ULN and 
<5 x ULN are eligible  if this value is acute and  directly  related  to the infectious process 
being treated.  This must be documented. 
16. Subject  has a perinephric infection.  
17. Subject  has an absolute neutrophil count <500/mm3. 
18. Subject  has previously been treated with the ATM -AVI.  
19. Subject  has been  previously enrolled  in this study. 
20. Pregnant female subjects; breastfeeding  female subjects;  fertile  male subjects and female 
subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study treatment and for at least 7 days after the last infusion of investigational product (see Section 4.6.1).  
21. Subject is participating in or has participated in other investigational interventional 
studies (drug) within the last 30 days (or 5 times the half-life of the previously 
administered  investigational compound, whichever is longer) prior to screening  and/or 
during study participation. 
22. Subject has other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may  increase the risk associated with study  participation or investigational product 
administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study (eg, in HAP/VAP subjects with pulmonary disease such as lung cancer, active tuberculosis, cystic  fibrosis,  granulomatous disease,  fungal pulmonary disease  or recent 
pulmonary embolism). 
23. Subject  is unlikely to comply with protocol, eg, uncooperative attitude  and unlikelihood 
of completing the study. 
24. Subject  has past or current  history of epilepsy  or seizure disorders excluding febrile 
seizures of childhood. 
25. Investigator site staff members directly involved in the conduct of the study and their family  members,  site staff members  otherwise supervised  by the investigator, or subjects 
who are Pfizer employees, including their family members, directly involved in the conduct of the study. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  56  
 4.2.2. Additional  Exclusion Criteria  – cIAI  Subjects  
1. Subject was diagnosed with traumatic bowel perforation undergoing surgery within 
12 hours; perforation of gastroduodenal ulcers  undergoing surgery  within  ≤24 hours. 
Other intra -abdominal processes in which the primary etiology is not likely to be 
infectious.  
2. Subject  has infections limited  to the hollow viscous, such as simple  cholecystitis, 
gangrenous cholecystitis without rupture, and simple appendicitis, or has acute 
suppurative cholangitis, infected necrotizing pancreatitis, or pancreatic abscess. 
3. Subject  has abdominal wall abscess  or small-bowel obstruction without perforation or 
ischemic bowel without perforation. 
4. Subject  has a prior liver,  pancreas,  or small-bowel transplant.  
5. Subject whose surgery will include staged abdominal repair, or “open abdomen” technique, or marsupialization.  This criterion  is intended  to exclude subjects  in whom 
the abdomen is left open, particularly those for whom re-operation is planned. 
4.2.3. Additional  Exclusion Criteria  – HAP/VAP  Subjects  
1. APACHE  II score <10.  
2. HAP/VAP subject has a known or high likelihood (based on any available microbiological results  at the time of enrollment)  of monomicrobial infection  with a 
Gram -positive organism. 
3. Subjects  with lung abscess,  pleural  empyema,  or post-obstructive pneumonia.  
4. Subject  is a recipient  of a lung or heart transplant.  
5. Subjects  with myasthenia gravis.  
For procedures  for withdrawal  of incorrectly  enrolled  subjects  see Section  4.5. 
4.3. Subject  Enrolment  and Randomization  
Investigator(s) should keep  a record,  the subject  screening  log, of subjects who entered 
pre-study screening. 
The Investigator will: 
1. Obtain  signed informed  consent from  the potential subject  or their legally  acceptable 
representative before any study specific procedures are performed. The subject is 
considered enrolled when the ICF is signed and the enrolment call is done in the interactive response technology (IRT) system. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  57  
 2. IRT system  will assign  the subject  with a unique enrolment number ie, subject  identifier 
(ID) at the screening visit (sites will have to enter the subject ID into the IRT system to 
retrieve subject data).  
3. Determine  subject eligibility.  See Section  4.1 and 4.2. 
4. At Baseline,  the Investigator will confirm  that all eligibility  criteria  still are fulfilled  and 
will then perform the randomization transaction in the IRT system.  
5. At randomization the IRT system  will assign  eligible  subjects  a unique randomization 
code and IP kit number(s). 
If a subject  withdraws  from  participation  in the study, then his/her enrollment/randomization 
code cannot be reused. 
Randomization codes  will be assigned  strictly  sequentially  as subjects  become eligible  for 
randomization.  
4.4. Randomization Criteria  
All subjects  being enrolled and fulfilling  all eligibility  criteria  will be randomized  in a 
2:1 ratio to receive 1 of the 2 IV dosing regimens  of either  the ATM -AVI ±MTZ treatment 
arm (ie, test product) or the MER±COL treatment arm (ie, comparator).  
4.5. Procedures  for Handling  Incorrectly  Enrolled  or Randomized  Subjects  
Subjects who fail to meet the eligibility criteria should not, under any circumstances, be 
randomized  or receive study medication.  There can be no exceptions to this rule. Subjects 
who are enrolled, but subsequently found not to meet all the eligibility  criteria must not be 
randomized or initiated on treatment, and must be withdrawn from the study. 
Where a subject does not meet all the eligibility criteria but is randomized in error, or 
incorrectly started on treatment, the Investigator should inform the Medical Monitor immediately, and a discussion should occur between the Medical Monitor and the Investigator regarding whether  to continue or discontinue the subject  from  treatment.  The 
Medical Monitor must ensure all decisions are appropriately documented. 
4.6. Lifestyle  Requirements  
4.6.1. Contraception  
All fertile  male  subjects and female subjects who are of childbearing potential who are, in the 
opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) 
must agree to use a highly effective method of contraception consistently and correctly for the duration of the active treatment period and for at least 7 days after the last dose of investigational product. The investigator or his or her designee, in consultation with the subject, will confirm that the subject has selected an appropriate method of contraception for the individual subject and his or her partner from the permitted list of contraception methods (see below) and will confirm that the subject has been instructed in its consistent and correct 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  58  
 use. At time points indicated in the Schedule of Activities , the investigator or designee will 
inform  the subject  of the need  to use highly effective contraception consistently  and correctly 
and document the conversation and the subject’s affirmation in the subject’s chart (subject 
needs to affirm their consistent and correct use of at least 1 of the selected methods of contraception). In addition, the investigator or designee will instruct the subject to call immediately  if the selected  contraception method is  discontinued or if pregnancy  is known or 
suspected in the subject or the partner. 
Highly effective methods of contraception are those that, alone or in combination, result in a 
failure  rate of less than 1% per year  when  used consistently  and correctly  (ie, perfect  use) and 
include the following: 
1. Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal) provided the subject or male  subject’s  female partner  plans to remain  on the same treatment  throughout the entire 
study and has been using that hormonal contraceptive for an adequate period of time to ensure effectiveness.  
2. Correctly  placed  copper-containing intrauterine  device (IUD).  
3. Male condom used WITH a separate spermicide product (ie, foam, gel, film, cream, or suppository). For countries where  spermicide  is not available or condom plus spermicide 
is not accepted as highly effective contraception, this option is not appropriate. 
4. Male sterilization with absence of sperm in the postvasectomy  ejaculate.  
5. Bilateral  tubal ligation/bilateral salpingectomy or bilateral  tubal occlusive procedure 
(provided that occlusion has been confirmed in accordance with the device’s label). 
NOTE: Sexual abstinence, defined as completely and persistently refraining from all heterosexual  intercourse (including during the entire  period of risk associated  with the study 
treatments) may obviate the need for contraception ONLY if this is the preferred and usual lifestyle of the subject, or as necessitated by the clinical status of the subject during the period of hospitalization, eg, unconscious/ventilated. 
All sexually  active male subjects must agree to prevent potential transfer to and exposure of 
partner(s) to drug through ejaculate by using a condom consistently  and correctly,  beginning 
with the first dose of investigational product and continuing for at least 7 days after the last 
dose of investigational product. 
4.7. Sponsor’s  Qualified  Medical  Personnel  
The contact information for the sponsor's appropriately qualified medical personnel for the 
study is documented in the study contact  list located  in the supporting study documentation. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  59  
 To facilitate access to appropriately qualified medical personnel on study -related medical 
questions or problems, subjects are provided with a contact card. The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
contact information for the investigator site, and contact details for a contact center in the event that the investigator site staff cannot be reached to provide advice on a medical question or problem originating from another healthcare professional not involved in the subject’s participation in the study. The contact number can also be used by investigator staff if they are seeking  advice on medical  questions or problems; however, it should be used 
only in the event that the established communication pathways between the investigator site and the study team are not available.  It is therefore intended to augment, but not replace, the 
established communication pathways between the investigator site and the study team for advice on medical questions or problems that may arise during the study. The contact 
number is not intended for use by the subject directly, and if a subject calls that number, he or she will be directed back to the investigator site. 
5. STUDY TREATMENTS  
For the purposes of this study, and per International Conference on Harmonisation (ICH) 
guidelines, investigational product is defined as a pharmaceutical form of an active ingredient or placebo being tested or used as a reference/comparator in a clinical trial, including a product with a marketing  authorization when  used or assembled  (formulated  or 
packaged) in a way different from the approved form, or when used for an unapproved indication, or when  used to gain further  information  about an  approved use (ICH E6  1.33). 
For this study, the investigational products are test product Aztreonam- Avibactam (ATM -AVI),  co-administered  drug Metronidazole (MTZ),  and comparators Meropenem 
(MER) and Colistin (COL).  
5.1. Allocation to Treatment  
All subjects being enrolled and fulfilling all eligibility  criteria will be randomized.  
Randomization will be performed  using an IRT system.  Specific information concerning the 
use of the IRT system will be provided in a separate user manual. 
Block  randomization using an IRT  system  will be used to randomize subjects  in a 2:1 ratio to 
receive 1 of the 2 IV dosing regimens of either the ATM- AVI ± MTZ treatment arm (ie, test 
product) or the MER ± COL treatment arm (ie, comparator).  The randomization scheme for 
this study will be generated using the Sponsor randomization system. Randomization will be stratified  as follows:  
• Infectious  disease type (cIAI  versus HAP/VAP)  
• For cIAI subjects,  they will be further stratified  by APACHE  II score  category 
(≤10 versus >10) (see Appendix 5);  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  60  
 • For HAP/VAP  subjects,  they will be further stratified  by mechanical 
ventilation status (yes versus no). 
The IP (ATM -AVI ±MTZ  or MER  ±COL)  should, if possible, be administered  as soon as 
possible after the IP kit number is assigned. 
5.2. Methods for Ensuring Blinding  
This is an open-label study. The Investigators, site personnel, and subjects will not be 
blinded in this open- label  study; however, reasonable attempts  by investigators and site 
personnel should be made to minimize bias wherever possible. 
Clinical response outcome recorded at scheduled visits will be assessed by an independent 
adjudication committee (central assessor) in a blinded fashion with the aim of unbiased adjudication of the primary  objective measure.  Data  will be provided relating  to the subject’s 
clinical response (eg, death status, disease progression, AEs, surgical procedures) without disclosing treatment arm.  Details on the central independent adjudication committee will be 
provided in a separate charter.  
No interim analysis is planned, and no analysis of data according to treatment arm assignment will be made prior to database lock, except  for the interim E- DMC  reviews  (See 
Section 9.5).  
Programming and statistical personnel separate from the Sponsor study team will be responsible for producing the data outputs and will help limit access  by the study team  to 
individual subject and group treatment assignment until database lock has occurred. 
5.3. Methods for Unblinding  
Only  the independent adjudication committee  members  will be blinded during the study. 
They will not require unblinding. 5.4. Subject Compliance  
The administration  of all study drugs (including IPs) should be recorded  in the appropriate 
sections of the CRF. Qualified study center personnel will administer  the IV  study treatment  and assure treatment 
compliance.  At a minimum the dose, date,  and exact  start  and stop time  of administration  of 
the IV study treatment will be recorded in the appropriate sections of the CRF and checked 
by the monitor at monitoring visits.  The deviation from  study treatment  will be reported  and 
documented.  
Subject compliance with dosing administration will be verified by accounting doses administered.  The subject dosing compliance should be within the range of 80% and 120% 
of expected  doses during treatment  period. Subject noncompliance cases  should be discussed 
with medical monitors.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  61  
 5.5. Investigational Product Supplies  
5.5.1. Dosage Forms  and Packaging 
The identity  of the IP is provided in  Table 2. 
 
Table 2.  Identity  of Investigational Product  
 
Investigational product  Dosage form  and strength  
 
Test product  
Aztreonam -Avibactam  Aztreonam  2 g powder for concentrate for 
solution for infusion 
Avibactam  600 mg powder for concentrate 
for solution for infusion 
Comparators  
Meropenem  Meropenem  1 g powder for solution for 
infusion  
Colistin  Colistin 2 million IU powder for solution 
for infusion. Colistimethate sodium equivalent to 150 mg colistin  base activity 
per vial.  
Co-administered  drug  
Metronidazole  Metronidazole 500 mg/100 mL solution for 
infusion  
Note: Aztreonam  and avibactam  will be provided as separate vials  for reconstitution  and mixed  together  in a 
saline bag for co -administration at the appropriate concentration for intravenous infusion.  
Note: Comparators  and co-administered  drug are supplied  centrally  via the sponsor.  In some  instances,  locally 
obtained commercial supplies will be utilized in accordance with local regulations.  
Note: Aztreonam, Meropenem, Colistin  and Metronidazole are commercial  products  over-labeled  with the study 
clinical label.  
 
Central  supply or locally  obtained commercial  supplies of these drugs will be used in 
accordance with local regulations.  
All IPs  will be administered  by IV infusion. Aztreonam  and AVI will be supplied as vials  for 
reconstitution. The IP ATM -AVI will be prepared for co- administration in saline using 
standard aseptic IV infusion technique (see IP Manual). 
5.5.2. Labelling  
Labels  will be prepared  in accordance with Good Manufacturing Practice (GMP)  and local 
regulatory guidelines. The labels will fulfil GMP Annex 13 requirements for labelling 
(European Commission GMP Guideline 2010).  Label text will be translated into local 
language.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  62  
 Labels  will be provided as  either a single panel label  or as  multi-language booklet labels.  
5.5.3. Preparation  and Dispensing  
See the IP manual and package insert for instructions on how to prepare the investigational 
product for administration.  Investigational product should be prepared  and dispensed by an 
appropriately qualified and experienced member of the study staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as allowed by local, state, and institutional guidance. 
5.6. Administration  (Dose  and Treatment  Regimen)  
The recommended  minimal duration of treatment  with IV study treatment  is 5 days for cIAI 
and 7 days for HAP/VAP. The maximal duration of treatment is 14 days. 
5.6.1. ATM -AVI ±MTZ  Treatment  Arm  
ATM -AVI:  Subjects  will be given a loading dose and then an extended  loading dose before 
commencing on a maintenance dose. All doses (loading, extended loading and 
maintenance), and the dosing frequency of the maintenance dose are dependent on renal function according to Table 3 below. 
 
Table 3.  ATM -AVI Doses in  Relationship to CrCL  
 
CrCL  
(mL/min)*  Loading  dose 
of ATM -AVI 
(by IV 
infusion over 
30 minutes)  Extended 
loading dose 
of ATM -AVI 
immediately 
following  the 
loading dose (by IV 
infusion over 
3 hours)  Time  interval 
between end of extended loading dose 
and start of 
first 
maintenance 
dose Maintenance 
dose of  
ATM -AVI 
(by IV infusion over 
3 hours)  Frequency of 
ATM -AVI 
maintenance 
dose 
>50 500 mg ATM  
plus 167 mg 
AVI 1500 mg ATM  
plus 500 mg 
AVI 3 hours  1500 mg ATM plus 
500 mg AVI q6h 
>30 to 50 500 mg ATM  
plus 167 mg 
AVI 1500 mg ATM  
plus 500 mg 
AVI 3 hours  750 mg ATM  
plus 250 mg 
AVI q6h 
>15 to 30 675 mg ATM  
plus 225 mg 
AVI 675 mg ATM  
plus 225 mg 
AVI 5 hours  675 mg ATM  
plus 225 mg 
AVI q8h 
Abbreviations:  ATM -AVI=  aztreonam -avibactam;  CrCL=creatinine  clearance;  IV=intravenous(ly); 
q6h=every 6 hours; q8h=every 8 hours.  
*Estimated  creatinine  clearance using Cockcroft -Gault formula  rounded to the nearest  whole  number  (see 
Appendix 3).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  63  
 MTZ:  Subjects  with cIAI  will also  receive MTZ 500 mg IV q8h (by IV infusion over 
60 minutes). The first dose of MTZ will be started immediately after the extended loading 
dose of ATM-AVI has completed and treatment will be continued until the end of the 
treatment period.  The SmPC ( Baxter Healthcare Ltd. ) does not indicate a dose reduction for 
MTZ in subjects  with renal  impairment.  However,  a dose reduction may be necessary  in end 
stage renal disease (ESRD) subjects (see Section 5.6.5).  
5.6.2. MER  ±COL  Treatment  Arm  
Subjects will initially  be given IV MER 1000 mg q8 h (with or without COL). However, if 
an MER -resistant pathogen is strongly suspected, COL (ie, colistimethate sodium) can also 
be initiated, and/or a dose of MER 2000 mg q8h can be used (given as an IV infusion over 3 hours), at the Investigator’s discretion  (Jaruratanasirikul  et al. 2005; Keel  et al. 2011; Li  et 
al. 2006).  
If a MER -resistant  Gram -negative pathogen is  subsequently isolated,  COL  can be added  (if 
not already started), and/or the dose of MER can be increased to 2000 mg q8h (given as an 
IV infusion over 3 hours, if this dose was not already used initially). 
If a MER -susceptible Gram -negative pathogen is subsequently isolated and COL had been 
initially  started,  the COL  should be discontinued and the dose of MER  adjusted  to the labeled 
dose regimen (1 g q8h IV over 30 minutes) (if a MER dose of 2000 mg q8h was initially 
started) (Table 4).  
Meropenem  (MER) ( MERONEM
 SmPC ): 
• First day of dosing (or until the MER  susceptibility  of the baseline Gram -negative 
pathogen(s) is known):  
 
Table 4.   MER Doses  in Relationship  to CrCL  
 
CrCl (mL/min)*  Baseline  Gram -negative pathogen 
not initially suspected to be  
MER -resistant  
Dose  of MER  (by IV infusion 
over 30 minutes) Baseline Gram -negative 
pathogen strongly suspected 
to be MER -resistant **  
Dose  of MER  (by IV infusion 
over 180 minutes) 
>50 1000  mg q8h 2000 mg  q8h 
>25 to 50 1000  mg q12h  2000  mg q12h  
>15 to 25 500 mg q12h  1000  mg q12h  
Abbreviations:  CrCL=creatinine clearance;  IV=intravenous(ly);  MER=meropenem;  q8h=every 8 hours; 
q12h=every 12 hours.  
*Estimated  creatinine  clearance using Cockcroft -Gault formula  rounded to the nearest  whole  number  (see 
Appendix 3).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  64  
  
** Note  the infusion time over 180 minutes  recommended  for the higher  doses  of meropenem  is based  on usual 
clinical practice for subjects with infections due to resistant pathogens ( Jaruratanasirikul et al. 2005; Keel 
et al. 2011 ; Li et al. 2006 ). 
 
Meropenem ± colistin doses will need to be adjusted for subjects with renal impairment 
(Section  5.6.5).  The dose of MER  will need  to be further adjusted  once the susceptibility  of 
the baseline Gram -negative pathogen(s) to MER is known (see notes above). 
Colistin  (COL) (colistimethate  sodium):  
This is optional study therapy that can be added to MER, at the Investigator’s discretion. 
Doses  of COL  are expressed  as colistimethate  sodium in IU, as described  by EMA  2014a and 
EMA 2014b. For colistimethate sodium (IU and mg) and COL base activity (CBA) mg conversion table see Appendix 7 and Table 5. 
Polymyxin B may  be used as an alternative  to COL  where COL  is not available or readily 
accessible.  Polymyxin B will be sourced locally and administered per local label. 
 
Table 5.  COL  Doses  in Relationship  to CrCL  
 
CrCl  (mL/min)*  Loading dose of Time  interval  Maintenance  dose 
 colistin  between end of of COL  
 (colistimethate  loading dose and  
 sodium)  (First  dose)  start  of maintenance   
 for subjects  dose  
 ≥60 kg**    
 (by IV infusion over  (by IV infusion  
 30 to 60  minutes)   over  30 to 
   60 minutes)  
>50 9 million IU  12 hours  9 million  IU daily 
in 2 or 3 divided 
doses  
>30 to 50 9 million IU  24 hours  6 million  IU daily 
in 2 divided doses  
>20 to 30 9 million IU  24 hours  5 million  IU daily 
in 2 divided doses  
>15 to 20 9 million IU  24 hours  4 million IU daily in 2 divided doses. 
Abbreviations:  COL=colistin  (colistimethate  sodium);  CrCL=creatinine clearance;  IU=international units; 
IV=intravenous(ly).  
*Estimated  creatinine  clearance using Cockcroft -Gault formula  rounded to the nearest  whole  number  (see 
Appendix 3).  
**Dose  of colistin  should be reduced  to 6 million  IU for subjects  below  60 kg. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  65  
 5.6.3. Optional Aminoglycosides  
Subjects with HAP/VAP and proven or suspected co- infection with Pseudomonas 
aeruginosa may receive an optional IV aminoglycoside (eg, amikacin, gentamicin or 
tobramycin, based upon local practice and epidemiology) at the Investigators discretion to allow coverage for suspected or proven Pseudomonas aeruginosa infection. For subjects receiving  colistin  (colistimethate  sodium), adjunctive aminoglycosides therapy should not be 
used concurrently; treatment with colistin (colistimethate sodium) should be discontinued prior to initiating aminoglycoside therapy. The need for adjunctive aminoglycoside therapy should be re- evaluated once culture and susceptibility results are available and the 
aminoglycoside should be discontinued if Pseudomonas aeruginosa is not isolated or is no longer suspected, or susceptibility results indicate a carbapenem susceptible strain. 
If Pseudomonas aeruginosa is isolated  and is non-susceptible to meropenem,  an intravenous 
aminoglycoside may be added to meropenem if not originally commenced. Colistin should 
be discontinued if meropenem and aminoglycoside are being used together. 
The need  for continued dosing with an aminoglycoside should be reviewed  at least after 
72 hours to mitigate potential nephrotoxic effect. 5.6.4. Optional Gram -positive Antibiotics  
Subjects with HAP/VAP may receive optional vancomycin or linezolid and subjects with 
cIAI may receive optional vancomycin, linezolid or daptomycin at the investigators discretion to provide antibiotic cover for a Gram- positive infection.  The need for an 
adjunctive Gram -positive antibiotic should be re-evaluated once culture and susceptibility 
results  are available and the Gram -positive agent  should be discontinued if a Gram -positive 
species is not isolated or is no longer suspected. 
5.6.5. Changes in Renal  Function during  Study  Treatment  
In some subjects, the CrCL estimated from serum creatinine can rapidly recover (or 
deteriorate), especially early in the course of treatment for the infection.  There is potential 
for accumulation of MTZ metabolites in ESRDsubjects, and therefore enhanced monitoring for MTZ associated AEs is recommended, and a dose reduction may be necessary.  Renal 
function should therefore be closely monitored throughout the treatment period (as clinically indicated)  and the dose of study treatment  adjusted by the Investigator according to the CrCL 
value calculated by the Cockcroft -Gault formula ( Appendix 3).  
Creatinine  clearance should be monitored daily  through the local  laboratory from  Day  1 to 
Day 4 (and Day 3 or 5 by the central laboratory, if PK samples are to be collected on Days  3 or 5) and then as clinically  indicated.  If subsequent to randomization and while  still 
on IV study treatment, a subject’s estimated CrCL falls below the threshold for study 
inclusion (ie, estimated CrCL ≤ 15 mL/min) and/or there is a requirement to start renal 
replacement therapy, the Investigator should discontinue ATM- AVI or MER ± COL 
investigational therapies.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  66  
 5.7. Investigational Product Storage  
The investigator or an approved representative, eg, pharmacist, will ensure that all 
investigational products including any comparator and/or marketed products are stored in a secured  area with controlled access  under required  storage conditions and in accordance with 
applicable regulatory requirements.  
Investigational products should be stored  in their original containers  and in accordance with 
the labels.  
See the IP manual  for storage conditions of the product once reconstituted  for ATM -AVI.  
Any storage conditions stated  in the SRSD  will be superseded  by the storage conditions 
stated on the product label. 
Site systems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily minimum and maximum temperatures for all site storage locations (as applicable, including frozen, refrigerated, and/or room-temperature products). This should be captured from the time of investigational product receipt throughout the study. Even for continuous-monitoring systems, a log or site procedure that ensures active evaluation for excursions should be available. The intent is to ensure that the minimum and maximum 
temperature is checked  each  business day to confirm  that no excursion occurred  since the last 
evaluation  and to provide the site with the capability  to store  or view  the minimum/maximum 
temperature for all non -working days upon return to normal operations. The operation of the 
temperature monitoring device and storage unit (for example, refrigerator), as applicable, should be regularly inspected to ensure they are maintained in working order. 
Any excursions from  the product label  storage conditions should be reported  to Pfizer  upon 
discovery. The site should actively pursue options for returning the product to the storage 
conditions described in the labeling, as soon as possible. Deviations from the storage requirements, including any actions taken, must be documented and reported to Pfizer. 
Once an excursion is identified, the investigational product must be quarantined and not used 
until Pfizer  provides permission  to use the investigational product. It will not be considered  a 
protocol deviation if Pfizer approves the use of the investigational product after the temperature excursion.  Use of the investigational product prior to Pfizer approval will be 
considered a protocol deviation. Specific details regarding information the site should report for each excursion will be provided to the site. 
5.8. Investigational Product  Accountability  
The investigator site must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies. All investigational products will be 
accounted for using a drug accountability form/record. 
The study treatment  provided for this study will be used only as directed  in the study 
protocol.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  67  
 The study personnel at the investigational site will account  for all drugs supplied, purchased, 
dispensed and returned for appropriate destruction. Certificates of delivery, destruction and 
return must be signed. 
Study site personnel will account  for all study drugs received  at the site, unused study drugs 
and for appropriate destruction. Certificates of delivery, destruction and return should be 
signed.  
IV study treatment will be dispensed to the Investigator or medically  qualified personnel by 
the study center pharmacist.  IV study treatment will only be prepared/administered to 
subjects by qualified pharmacy personnel/medically qualified personnel who have been appropriately trained to prepare/administer IV study treatment.  Written authorization of 
study personnel to administer  IP must be documented  on the Delegation  of Authority Log in 
one of 2 ways: 
• All study staff trained  and authorized  by the Investigator  to prepare/administer  IV 
study treatment are listed on the Delegation of Authority Log, 
OR 
• The nurse manager(s)/supervisor(s) and study pharmacists authorized by the Investigator are listed  on the Delegation  of Authority Log as the person(s) responsible 
for ensuring that the nursing/pharmacy staff are appropriately trained on IV study treatment preparation/administration prior to preparing/administering it, and for maintaining current and complete training documentation at all times.  
Written documentation of training of IV study treatment administration and pharmacy study center personnel will be kept current throughout the study, and ongoing training will be provided by study center personnel as assigned by the Investigator on the Delegation of Authority Log. It is the Investigator’s responsibility  to ensure that all documentation remains 
current and complete throughout the study. The Investigator will document how he or she will ensure staff are adequately trained before they perform the infusion, and he or she will ensure that there is a system in place that will guarantee supervision of the study treatment administration process and subject safety (eg, study treatment will only be administered to subjects  under supervision of an Investigator). Source documentation should clearly  indicate 
who administered the infusion. Records of IV study treatment usage should include the identification of the subject to whom the IV study treatment was administered, the quantity and date of administration, and a record of unused IV study treatment. The 
Investigator/pharmacist is responsible for maintaining accurate IV study treatment accountability records throughout the study on the relevant forms provided by Pfizer. Each 
administration of IV study treatment will be documented in the CRF.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  68  
 It is the Investigator’s responsibility  to establish  a system  for handling study  treatments, 
including IPs, to ensure that: 
• Deliveries  of such products are correctly  received  by a responsible person (eg, 
pharmacist).  
• Deliveries  are recorded.  
• IV study treatment is handled  and stored safely  and properly.  
• IV study treatment  provided for this study is used only as directed  in the study 
protocol.  
• Study center personnel account for all study drugs received at the study center, 
dispensed for the subject,  and returned  to the pharmacy.  Any discrepancies  should be 
documented, investigated, and appropriately resolved. 
• The monitor performs complete IV study treatment accountability during each monitoring visit,  including verifying documentation of receipt,  dispensing, return, and 
destruction of IV study treatment  and consistency  of this documentation with physical 
inventory.  
5.8.1. Destruction  of Investigational Product  Supplies  
The sponsor or designee will provide guidance on the destruction of unused investigational product (eg, at the site).  If destruction is authorized to take place at  the investigator site, the 
investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any special instructions provided by Pfizer, and all destruction must be adequately documented. 
5.9. Post Study Access to Study Treatment  
At the end of the study, the sponsor will not continue to supply study drug to subjects or 
Investigators unless the sponsor chooses to extend  the study. The Investigator should ensure 
that the subject receives appropriate standard of care to treat the condition under study. 
5.10. Concomitant Treatment(s)  
All prescription and over the counter medications being taken by the subject for the 2 weeks 
prior to the first dose of study medication (considered prior treatment) and from the first dose of study medication through the LFU visit (considered concomitant treatments) must be documented on the appropriate pages of the CRF. Systemic antibiotics should be documented for the entire duration of the study (from 2 weeks prior to the first dose of study medication  through the LFU  visit).  Application  of topical  antibacterial  and antifungal agents, 
and peritoneal lavage for cIAI subjects, also need to be recorded in the CRF. All actions 
related to the administration of concomitant antibiotics should be documented in the CRF. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  69  
 Concomitant medications  which  are allowed  per protocol, restricted  and prohibited  are 
detailed in Table 6, Table 7 , and Table 8 , respectively:  
 
Table 6.  Allowed  Concomitant Medications  
 
Allowed 
Procedure/Medicatio n/Class of drug: Subjects with cIAI:  Subjects  with  HAP/VAP:  
MTZ Subjects  in the ATM -AVI±MTZ 
arm will all receive MTZ as part 
of study therapy (see Section  5.6.1).  N/A 
Vancomycin, linezolid 
or daptomycin If a Gram -positive pathogen is 
suspected then vancomycin, linezolid  or daptomycin may be 
added to the study regimen according  to the usual practice of 
the Investigator. If a 
Gram -positive pathogen is not 
isolated,  then the Gram -positive 
agent should be stopped, at the Investigator’s discretion, and subjects should continue in the study.  If a Gram -positive pathogen 
is suspected then vancomycin or linezolid may be added to the study regimen according to the usual practice of the Investigator. If a 
Gram -positive pathogen is 
not isolated, then the Gram -positive agent should 
be stopped, at the Investigator’s discretion, and subjects should continue in the study. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  70  
  
Table 6.  Allowed  Concomitant Medications  
 
Allowed 
Procedure/Medicatio n/Class of drug: Subjects with cIAI:  Subjects  with  HAP/VAP:  
IV aminoglycoside 
(eg, amikacin, gentamicin or tobramycin based upon local  practice 
and epidemiology)  N/A In the ATM -AVI ±MTZ arm, 
an IV aminoglycoside may be 
added if Pseudomonas aeruginosa is suspected. 
In the MER  ±COL  arm; 
if Pseudomonas aeruginosa is 
suspected, an IV 
aminoglycoside may be added to MER. In this case COL should not be commenced.  
If Pseudomonas aeruginosa is isolated and is susceptible to MER, the Investigator may stop COL (if this had been started) and an IV aminoglycoside may be added to the subject’s regimen.  COL and an IV 
aminoglycoside should not be 
used together. 
The need for continued 
dosing with an aminoglycoside should be reviewed after 72 hours to mitigate  potential nephrotoxic 
effects.  
Peritoneal  lavage with 
saline or other non-antibacterial -cont 
aining solution Permitted (note that antibiotic peritoneal  lavage is not allowed).  N/A 
Topical antibacterial and antifungals (or any oral antibiotic  that 
has very poor absorption systemically, eg, oral vancomycin)  Permitted except that they may not be applied  to the surgical  site. Permitted  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  71  
  
Abbreviations: ATM -AVI ±MTZ =aztreonam -avibactam±metronidazole; cIAI=complicated intra- abdominal 
infection; COL=colistin  (colistimethate  sodium);  HAP/VAP=hospital -acquired  pneumonia/ventilator -associated 
pneumonia; IV=intravenous (ly); MER=meropenem; MER ± COL=meropenem±colistin; MTZ=metronidazole; 
N/A=not applicable.  
 
Table 7.  Restricted  Concomitant Medications  
 
Restricted 
Procedure/Medication  
/Class  of drug:  Subjects with cIAI:  Subjects  with  HAP/VAP  
Systemic  antibiotics  Concomitant systemic antibiotics are not allowed (except those 
specified as allowed per the protocol), unless the subject is 
considered  to have failed  study treatment  and requires  additional 
antibiotics to treat their infection.  
OR 
The subject develops a new infection at a remote site and the Investigator considers addition  of non-study antibiotics  essential 
for the safety and well -being of the subject.  
Systemic  antifungals  Antifungal  treatment  to treat the 
cIAI should be avoided unless clinically indicated.  Antifungal  treatment  to treat 
the HAP/VAP should be avoided unless clinically 
indicated.  
Abbreviations:  cIAI=complicated  intra-abdominal  infection; HAP/VAP=hospital- acquired  pneumonia/ 
ventilator -associated pneumonia.  
 
Table 8.  Prohibited  Concomitant Medications  
 
Prohibited Procedure/Medication  
/Class of drug:  Subjects with cIAI:  Subjects  with  HAP/VAP  
Probenecid  To be avoided  from  informed  consent  to end of IV study 
treatment  
Antibiotic  peritoneal 
lavage  Not permitted (note that peritoneal  lavage with saline  or 
other  
non-antibacterial -containing 
solution is allowed). N/A 
Inhaled  antibiotics  N/A Should be avoided from  the 
start to the end of IV study treatment for subjects in either treatment arm.  
Abbreviations:  ATM -AVI±MTZ  =aztreonam -avibactam±metronidazole;  cIAI=complicated  intra-abdominal 
infection; HAP/VAP=hospital -acquired pneumonia/ventilator -associated pneumonia; IV=intravenous(ly); 
N/A=not applicable.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  72  
 Both ATM ( Mattie 1994) and AVI (see IB) are predominantly eliminated by the kidney, 
partly by active tubular excretion. In vitro studies have shown probenecid and furosemide 
interfere with  the active tubular excretion,  resulting  in increased  plasma  concentrations of the 
study drugs, however, these increases  are considered to be clinically  insignificant ( ER Squibb 
& Sons Limited 2014).  Concomitant administration of probenecid should be avoided during 
IV study treatment.  Furosemide should be used with caution in the setting of potentially 
nephrotoxic drugs, eg, aminoglycosides and COL. Based on current knowledge, further relevant DDIs with regard to ATM -AVI administration in this study are not to be expected 
(see Section 5.11.1).  
The use of other systemic antimicrobials not specified by this protocol is not permitted during the study. However, if a new infection develops at a remote site (ie, outside of the 
abdomen for cIAI subjects or outside of the lung for HAP/VAP subjects) between the date and time of the first dose of study treatment  and the LFU  visit,  and the Investigator considers 
addition of non- study antibiotics essential to the safety and well-being of the subject, 
additional antibiotics may be added. If possible, the Investigator should first discuss this with the Medical Monitor and attempt to choose antibiotics (guided by local microbiology and sensitivity testing) that will not have antibacterial activity against the subject’s baseline pathogens to avoid confounding the assessment of the effect of study therapy. 
It is anticipated that in instances of suspected clinical failure, alternative or additional 
antibiotic treatment to treat the index infection (cIAI or HAP/VAP) may be required, and 
where rescue antibiotic treatment is provided the subject should be assessed as a clinical failure.  An appropriate antibiotic  should be selected,  taking into account  results  of sensitivity 
testing.  If possible, the Investigator should first discuss this with the Medical Monitor. 
Information on contraindications, special warnings and precautions and interactions with other medicinal  products and other forms  of interaction  for protocol- allowed  antibiotics  are 
available in the respective SmPCs  for these products and Investigators are recommended  to 
refer to these for further prescribing information.  For ATM -AVI DDI see Section 5.11.1. 
Other  medication,  which  is considered  necessary  for the patient’s  safety  and well-being, may 
be given at the discretion of the investigator and recorded in the appropriate sections of the CRF.  If analgesic medications are needed for pain, the use of analgesic medication without 
antipyretic properties is preferred. Should a subject require a biologic immunosuppressive agent or chemotherapy treatment after enrollment, the Investigator should contact the Medical Monitor before initiating treatment.  Continued subject study participation will be 
determined based upon assessment of the safety risk to the subject if he or she were to 
continue on study treatment. Subjects who have already completed the IV study treatment 
should remain in the study until LFU assessment as they are not actively on study treatment but being followed up for outcomes. 
5.10.1. Other Concomitant Treatment  
Concomitant medication  other than that described  above, which  is considered  necessary  for 
the subject’s safety and well -being, may be given at the discretion of the Investigator and 
recorded in the appropriate sections of the CRF. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  73  
 5.11. Drug -drug  Interaction  
5.11.1. Aztreonam -avibactam  
Drug -drug interactions  with AVI are unlikely. The binding of AVI to human plasma  proteins 
is very  low and concentration-independent. AVI had negligible or no direct inhibitory effect 
on CYP isoenzymes in vitro; the negligible inhibition observed was at high concentration of 
AVI that exceed any clinically relevant exposure.  AVI showed no potential for in vitro 
induction of CYP1A2, 2B6, 2C9 and 3A4 isoenzymes in human hepatocytes. Against 
CYP2E1, AVI  showed a slight induction potential at very high concentrations (1326 µ g/mL) 
that exceed any clinically relevant exposure.  Neither AVI nor ATM is an inhibitor of any 
major renal or hepatic transporters in the clinically relevant exposure range.  In vitro, AVI is 
a potential substrate of human organic anion transporter (OAT)1 and OAT3 renal 
transporters and ATM dose-dependently inhibited the OAT1-mediated uptake of AVI, with 
maximum inhibition of 78% at 1000 µ M. However, considering the in vitro half maximal 
inhibitory concentration (IC50) values (~ 700 µM for OAT1 and > 1000 µM for OAT2) 
relative to the maximum likely clinical plasma concentrations (187 µM) suggests that any 
interaction would probably be minimal. 
The lack of an interaction between ATM and AVI was confirmed clinically.  The PK and 
statistical comparison results  indicated  no DDI between  ATM  (2000 mg) and AVI (600 mg) 
when each drug was administered alone or in combination as a single 1-hour IV infusion in 
healthy young subjects. In addition, following 10 days multiple dosing of the combination, PK parameters at steady state for both ATM and AVI were comparable to Day 1.  
Concomitant administration  of probenecid or furosemide and ATM  cause clinically 
insignificant increases in the serum levels of ATM.  
Due to the induction of β lactamases,  certain  antibiotics  (eg, cefoxitin, imipenem)  have  been 
found to cause antagonism with many  β-lactams,  including ATM,  for certain  Gram -negative 
aerobes, such as Enterobacter species and Pseudomonas species.  
Prolongation of prothrombin time has been reported rarely in subjects receiving ATM. In 
addition, numerous cases of increased activity of oral anticoagulants have been reported in 
subjects  receiving  antibiotics,  including β-lactams.  Severe infection  or inflammation,  and the 
age and general condition of the subject appear to be risk factors.  
Single-dose PK studies have not shown any significant interaction  between  ATM  and 
gentamicin, cephradine, clindamycin or MTZ. 
Unlike broad spectrum antibiotics, ATM produces no effects on the normal anaerobic 
intestinal flora.  No disulfiram- like reactions  with alcohol ingestion have been  reported. 
PFIZER  CONFIDENTIAL  
Page  74  
 
ATM -AVl 
C360 1002 
 Fi nal  Protocol  Amendmen t 2, 18 May 2022   
 
5.11.2. Coagulation  and Concomitant Use of Anticoagulants  
Appropri ate monitoring (acco rding to applicable medical guideline s and institutional 
standard of care) should be unde1iaken  when anticoagulants  are prescribed  conc01nitantly 
with antibiotics.  Adjustments in the dose of oral anticoagulants may  be necessaiy to 
maintain the desired level of anticoagulation.  
5.11.3. Other  Investigational  Products  
fufo1mation on DDi s with other medicinal products  and other fo1ms  of intera ction for 
protocol  allowed  antibiotics are available in the respective SmPCs  for these products and 
fuvestigators ai ·e recomme nded to refer to these  for fmiher prescribing info1mation.  
6. STUDY PROCEDURES  
Study periods are defined  in Figure  1. Details  of the study  plan and timing of procedures are 
provided in Sched ule of Activities ( Table 1). 
Eve1y  effo1i  should be made to collect all the data , blood samples , and cultur es and to 
comple te all assessments required  for each  visit as detai led in the Schedul e of Act ivities 
(Table 1 ) detai ling the procedures and discussed by visit in the following sectio ns. 
6.1. Screening and Enrollment  
Prior to any  study specific procedures , subjects (o r their legally acceptable representative if 
applicable)  must  provide  writte n info1med consent. Enrollment /Scree ning procedures  will be 
perfo1med acco rding to the  Schedul e of Act ivities ( Table 1 ). At Scree ning, subjects w ill be 
assessed  regai·ding eligibi lity criteria. Subjects w ho do not meet all of these  criteria  must  not 
be enrolled in the  study (see Sec tion 4.3). 
 
6.1.1. Visit 1: Eligibility/Screening Procedures  (Day  -1 to 1) 
At Eligibility /Screening (Day  -1 to 1), each potential  subject (or his/her  legally acceptab le 
representative)  will provide written info1med consent prior to staiiing  any study-specific 
procedures.  
Each  subject will undergo Screenin g assessment procedures  less than 24 hours prior  to 
randoinization.  Exceptions  to this  ai·e for respirato1y specime n for culture s and chest 
X- ray/CT scan for HAPN AP subjects w hich are valid  if collected  within 48 hours prior  to 
randoinizat ion and blood  culture s which are valid  if collected wit hin 48 hours prior to 
randoinization  in all subjects. Local laborato1y  test results will be used to qualify  subjects for 
inclu sion.  To this end, the following assessme nts need to be perfo1med in the local 
laborato1y and entered in the CRF:  sernm creat inine (incl uding calc ulation of CrCL),  sennn 
or urine -hCG for pregnancy test, AST, ALT, ALP, TBili, and hematology as li sted in 
Section 4.2. For eligibility assessme nt, CrCL needs  to be calcu lated at the  study site, based  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  75  
 on the creatinine  value determined  at local  laboratory  (see Appendix 3).  In addition, safety 
laboratory samples must be sent to the central reference laboratory for testing (see 
Section 7.2.1).  
Eligibility/Screening  assessments will consist of: 
1. Obtaining informed consent.  
2. Reviewing  of the inclusion and exclusion criteria.  
3. Collecting demographics.  
4. Collecting  medical  history. 
5. Reviewing  and recording prior medications  (including prior antibiotic  treatment).  
6. Performing  complete physical examination  as defined  in Section  7.2.2.  
7. Assessing  infection -related  signs and symptoms. 
8. Performing  focused  physical examination  (see Section  7.2.2).  
9. Measuring  vital signs including blood pressure  (BP),  heart  rate and body temperature 
as defined in Section 7.2.4. For subjects with HAP/VAP, collecting respiratory rate 
(breath per minute) and peripheral O 2 saturation.  
10. Performing  a chest  X-ray or CT scan (if not available  within  48 hours prior to 
randomization) in subjects with HAP/VAP. 
11. Completing  the APACHE  II score ( Appendix 5 ). 
12. Completing  the ventilation  device status  in subjects  with HAP/VAP.  
13. Collecting  imaging  and surgical  report  in subjects  with cIAI.  
14. Collecting  AEs.  
15. Collecting  specimen  of abdominal site infection  and sending to local  laboratory for 
microbiology culture, and sending isolates to central laboratory (for subjects with cIAI only) (see Appendix 6).  
16. Obtaining an appropriate respiratory specimen for Gram- stain and culture (Cultures from respiratory specimens obtained within 48 hours prior to randomization may be used, but subjects ventilated subsequently, regardless of whether they meet the criteria for VAP, must have a specimen obtained while ventilated).  Specimens will 
be sent to local laboratory for microbiological culture and isolates and unstained Gram -stain  slides  (for induced sputum and expectorated  sputums only) will be sent to 
central laboratory (for subjects with HAP/VAP only) (see Appendix 6).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  76  
 17. Obtaining blood samples and sending to local laboratory for microbiological culture, 
and sending isolates  to central  laboratory (see Appendix 6).  Repeat  blood cultures do 
not need to be performed at Screening if available within 48 hours prior to randomization.  
18. Obtaining blood and urine samples  for safety  analysis.  Blood is to be sent to the local 
laboratory (for testing laboratory eligibility criteria as listed in Section 4.2.1) and blood and urine to the central laboratory. 
19. Collection of ABGs (ABGs are required for ventilated and recommended for non-ventilated  HAP/VAP  subjects,  and for cIAI subjects  as clinically  indicated).  
20. Estimating  CrCL  using  the serum  creatinine  results  from  the local  laboratory. See 
Appendix 3 for CrCL calculation. 
21. Obtaining blood or urine  sample  for serum  β-hCG for women  of childbearing 
potential (local laboratory reference laboratory). 
22. Confirming highly effective contraception is being used.  
6.2. Study  Period  
6.2.1. Visit  2: Baseline  Procedures  and Day 1 of Treatment  (Day  1) 
Procedures  for visit 2 will vary depending on the timing  of the visits  1 and 2 relative  to 
surgery. Visit 2 may occur pre- or postoperatively in subjects with cIAI. 
Local  laboratory test results  obtained at  Visit 1 will be used  to qualify  subjects for inclusion 
(see Section  6.1.1).  At Visit  2, safety  lab samples  (including local  lab for eligibility  criteria 
confirmation) and clinically relevant cultures (and further assessments as listed in  
points 3, 11, 13 to 16 of this section) are only required if Visit 1 and Visit 2 are separated by 
surgery  or are more  than 12 hours apart.  If safety  lab samples  and clinically  relevant  cultures 
are required, they should be collected prior to dosing (exception: if Visit 2 occurs pre-operatively, study drug may be administered  before  collecting  abdominal specimen  for 
culture; see below 11).  
Study t
reatment  should be started  as soon as possible (within  24 hours) after a subject’s 
eligibility has been confirmed and the subject has been randomized. Consequently, Day -1 and  Day 1 may  be the same calendar  day, ie, all procedures scheduled  for Day  -1 and 
Day 1 could happen on the same day. All procedures at Visit 2 are to be done before first 
dose of study therapy except for PK sampling. 
The following assessments should be performed  for all  subjects  at Visit  2: 
1. Reviewing  of the inclusion and exclusion  criteria.  
2. Reviewing  and recording prior and concomitant medications  (including prior 
antibiotic treatment).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  77  
 3. Assessing  infection -related  signs and symptoms.  
4. Performing  focused physical examination  (see Section  7.2.2).  
5. Measuring  vital signs including BP, heart  rate and body temperature as defined  in 
Section  7.2.4. For subjects with HAP/VAP,  collecting  respiratory  rate (breath  per 
minute) and peripheral O 2 saturation.  
6. Performing  a 12- lead digital triplicate  ECG.  The subject  should be resting  in a supine 
position for at least 10 minutes prior to the evaluation (see Section 7.2.3).  
7. Performing  a chest  X-ray or CT scan (as clinically  indicated)  in subjects  with 
HAP/VAP.  
8. Completing  the ventilation  device status  in subjects  with HAP/VAP.  
9. Collecting  imaging  and surgical  report  (as clinically  indicated)  in subjects  with cIAI.  
10. Collecting  new AEs and reviewing  ongoing AEs.  
11. Collecting  specimen  of abdominal site infection  (if not already  collected  at Visit 1 
[Note: if Visit 2 occurs pre -operatively, study drug may be administered before 
collecting abdominal specimens; however, they must be collected during the 
surgery]) and sending to local laboratory for microbiology culture, and sending isolates to central laboratory (for subjects with cIAI only) (see Appendix 6 ). 
12. Collecting respiratory specimen for Gram -stain/culture (except where an adequate 
specimen was previously collected within 48 hours prior to randomization) and sending to local laboratory (for subjects with HAP/VAP only) if not collected at Screening.  For subjects who were not ventilated at Screening but were intubated 
subsequently (or subjects who had a bronchoscopy performed): obtaining an appropriate respiratory  specimen  for Gram - stain  and culture.  Specimens  will be sent 
to local laboratory for microbiological culture and isolates and unstained Gram- stain 
slides (for induced sputum and expectorated sputums only) will be sent to central laboratory (for subjects with HAP/VAP only) (see Appendix 6).  
13. Obtaining blood samples as clinically indicated and sending to local laboratory for microbiological culture,  and sending isolates  to central  laboratory  (see Appendix 6).  
14. Obtaining blood and urine samples  for safety  analysis.  Blood is to be sent to local 
laboratory and blood and urine to the central laboratory. 
15. Collection  of ABGs  as clinically  indicated.  
16. Estimating  CrCL  using  the serum  creatinine  results  from  the local  laboratory. See 
Appendix 3 for CrCL calculation. 
17. C
onfirming highly effective contraception is being  used.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  78  
 18. Collecting  mortality  assessment.  
19. Randomization.  
20. Commence dosing according  to the randomization schedule.  
21. Following the initiation  of the IV infusion of study treatment,  blood samples  for PK 
analysis for subjects randomized to ATM-AVI will be obtained as according to 
Table 13 and Figure 3 and Figure 4. 
6.2.2. Visit  3 to 15: Ongoing Treatment  (Days 2 to  14) 
The recommended  minimal duration of  treatment  in this study will be 5 days for cIAI and 
7 days for HAP/VAP.  The maximal duration of treatment  will be 14 days. Subjects,  who 
require continuation of IV study treatment after 5 days (cIAI) or 7 days (HAP/VAP), will 
continue to receive their IV study treatment by study center personnel in the hospital. 
The following assessment  procedures  will be performed  during treatment  with IV study 
treatment:  
1. Daily  reviewing prior and concomitant medications  (including prior and concomitant 
antibiotic treatment).  
2. Daily  assessing  infection -related  signs and symptoms. 
3. Daily  performing  focused physical examination (see Section 7.2.2).  
4. Daily  measuring  vital signs  including BP, heart  rate and body temperature as defined 
in Section 7.2.4. For subjects with HAP/VAP, daily collecting respiratory rate 
(breath per minute) and peripheral O 2 saturation.  
5. Performing  a 12- lead digital triplicate  ECG  on Day 3 immediately  following the end 
of the study drug infusion. The subject should be resting in a supine position for at 
least 10 minutes prior to the evaluation (see Section 7.2.3).  
6. Performing  a chest  X-ray or CT scan (as clinically  indicated)  in subjects  with 
HAP/VAP.  
7. Daily  completing the ventilation device status in subjects with HAP/VAP daily.  
8. Collecting  imaging  and surgical  report  (as clinically  indicated)  in subjects  with cIAI.  
9. D aily  collecting  new AEs and reviewing  ongoing AEs.  
10. Collecting  specimen  as clinically  indicated  of abdominal  site infection  and sending to 
local laboratory for microbiology culture, and sending isolates to central laboratory (for subjects with cIAI only) (see Appendix 6).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  79  
 11. Collecting respiratory specimen for Gram -stain/culture as clinically indicated and 
sending to local laboratory for microbiology culture, and sending isolates and 
unstained Gram -stain  slides  (for induced sputum and expectorated  sputums only) to 
central laboratory (for subjects with HAP/VAP only) (see Appendix 6).  
12. Obtaining blood samples  for subjects  who are bacteremic at least every  3 days until 
clearance  of bacteremia and sending to local  laboratory for microbiological culture, 
and sending isolates to central laboratory (see Appendix 6).  Blood cultures should 
also be obtained as clinically indicated.  
13. Obtaining blood and urine samples every 3 days starting on Day 4 and sending to the central  laboratory for safety  analysis.  Blood samples  are to be sent to local  laboratory 
daily between Days 2 and 4 (and as clinically indicated) for measurement of serum creatinine.  
14. Collection of ABGs as clinically  indicated.  
15. Obtaining blood samples for  PK analysis  on Day  4 (Subjects  randomized  to 
ATM -AVI ±MTZ only) (Day  4 PK samples  can be collected  on Day  4 ±1 day, see 
Table 13 and Figure 3 and Figure 4 for schedule).  
16. Estimating  CrCL  daily  from  Day  2 to Day  4, and as clinically  indicated,  using the 
serum creatinine results from the local laboratory.  See Appendix 3 for CrCL 
calculation.  
17. Confirming daily  that highly effective contraception is being used.  
18. Collecting mortality  assessment daily.  
19. Daily  dosing according to the randomization schedule.  
6.2.3. Post-Treatment  Period  
6.2.3.1. Visit  16: End of  Treatment  (Within  24 Hours after  Last Infusion)  
The following assessment  procedures will be performed  within  24 hours after the completion 
of the last infusion of IV study treatment: 
1. Reviewing  prior and concomitant  medications  (including prior and concomitant 
antibiotic treatment).  
2. Performing  complete  physical  examination  as defined  in Section  7.2.2.  
3. A
ssessing  infection -related  signs and symptoms. 
4. Performing  focused  physical examination  (see Section  7.2.2).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  80  
 5. Measuring  vital signs including BP, heart  rate and body temperature as defined in 
Section  7.2.4. For subjects with HAP/VAP,  collecting  respiratory  rate (breath  per 
minute) and peripheral O 2 saturation.  
6. Performing  a chest  X-ray or CT scan in subjects  with HAP/VAP  as clinically 
indicated.  
7. Completing  the ventilation  device status  in subjects  with HAP/VAP.  
8. Collecting  imaging and surgical report (as  clinically  indicated) in  subjects with cIAI.  
9. Collecting  new AEs and reviewing  ongoing AEs.  
10. Collecting  specimen  as clinically  indicated  of abdominal  site infection  and sending to 
local laboratory for microbiology culture, and sending isolates to central laboratory 
(for subjects with cIAI only) (see Appendix 6).  
11. Collecting  respiratory  specimen  for Gram -stain/culture  if at all possible and sending 
to local laboratory for microbiology culture, and sending isolates and unstained Gram -stain slides (for induced sputum and expectorated sputums only) to central 
laboratory (for subjects with HAP/VAP only) (see Appendix 6).  
12. Obtaining blood samples  for subjects  who are bacteremic as clinically  indicated  until 
clearance of bacteremia and sending to local laboratory for microbiological culture, and sending isolates to central laboratory (see Appendix 6).  
13. Obtaining blood and urine samples for safety analysis and sending to central laboratory. Blood samples  should be sent to the local  laboratory  as clinically 
indicated for measurement of serum creatinine.  
14. Collection of ABGs as clinically  indicated.  
15. Estimating  CrCL  as clinically  indicated,  using the serum  creatinine  results  from  the 
local laboratory. See Appendix 3 for CrCL calculation.  
16. Confirming highly effective contraception is being used.  
17. Assessing  clinical  response.  
18. Collecting mortality  assessment.  
6.2.3.2. Visit  17: Test of Cure (Day 28 ±3 days)  
If it is not possible to perform  the TOC  on study Day 28, then the allowed  visit window is 
Day 25 to 31. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  81  
 The following assessment  procedures  will be performed  at TOC:  
1. Reviewing  prior and concomitant  medications  (including antibiotic  treatment).  
2. Performing  complete  physical  examination  as defined  in Section  7.2.2.  
3. Assessing  infection -related  signs and symptoms. 
4. Performing  focused  physical examination  (see Section  7.2.2).  
5. Measuring  vital signs including BP, heart  rate and body temperature as defined  in 
Section  7.2.4. For subjects with HAP/VAP,  collecting  respiratory  rate (breath  per 
minute) and peripheral O 2 saturation.  
6. Performing  a chest  X-ray or CT scan (as clinically  indicated)  in subjects  with 
HAP/VAP.  
7. Completing  the ventilation  device status  in subjects  with HAP/VAP.  
8. Collecting  imaging  and surgical  report  (as clinically  indicated)  in subjects  with cIAI.  
9. Collecting  new AEs and reviewing  ongoing AEs.  
10. Collecting  specimen  as clinically  indicated  of abdominal  site infection  and sending to 
local laboratory for microbiology culture, and sending isolates to central laboratory 
(for subjects with cIAI only) (see Appendix 6).  
11. Collecting respiratory specimen for Gram -stain/culture if at all possible and sending 
to local  laboratory, and sending isolates  and unstained Gram -stain  slides  (for induced 
sputum and expectorated sputums only) to central laboratory (for subjects with HAP/VAP only) (see Appendix 6).  
12. Obtaining blood samples  for subjects  who are bacteremic as clinically  indicated  until 
clearance of bacteremia and sending to local laboratory for microbiological culture, and sending isolates to central laboratory (see Appendix 6).  
13. Obtaining blood and urine samples for safety analysis and sending to central laboratory. Blood samples  should be sent to the local  laboratory as clinically 
indicated for measurement of serum creatinine.  
14. Estimating  CrCL  as clinically  indicated,  using the serum  creatinine  results  from  the 
local laboratory. See Appendix 3 for CrCL calculation.  
15. C
onfirming highly effective contraception is being used.  
16. Assessing  clinical  response.  
17. Collecting mortality  assessment.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  82  
 6.2.3.3. Visit  18: Late  Follow- up (Day  45±3 days)  
If it is not possible to perform the LFU on study Day 45, then the allowed visit window is 
Day 42 to 48. If the subject  has been  discharged  from  hospital and is unable to return,  the 
LFU visit can be conducted by telephone (with the permitted omission of the physical 
examination).  
The LFU  visit assessment  procedures include:  
1. Performing  focused  physical examination  (see Section  7.2.2).  
2. Collecting  new AEs and reviewing  ongoing AEs.  
3. Reviewing  prior and concomitant  medications  (including prior and concomitant 
antibiotic treatment).  
6.3. Discontinuation of Investigational Product  
Subjects  may be discontinued from  IP in the following situations:  
• Condition under investigation resolved prior to minimum treatment period.  
• Subject  decision. The subject  is at any time free to discontinue treatment,  without 
prejudice to further treatment.  
• Occurrence of an AE or any other condition posing a risk  to a subject  or jeopardizing 
a safe continuation of the study treatment for  the respective subject (as  judged by the 
investigator, and/or the national coordinators, and/or the Medical Monitor and the Study Sponsor). 
• Positive pregnancy test at any  time during the treatment period.  
• In the absence of any alternative explanation for the increase in the following abnormalities,  individual subjects  should be withdrawn  if the following criteria  are 
met (see also Section 8.5.2):  
• ALT  or AST  >8 x ULN;  
• ALT  or AST  >3 x ULN and TBili >2 x ULN or international normalized  ratio 
(INR) > 1.5; 
• ALT or AST >3 × ULN and with appearance of symptoms and signs suggestive of new or progressive liver disease (eg, new or worsening fatigue, 
nausea,  vomiting, right upper quadrant pain or tenderness,  fever,  rash,  and/or 
eosinophilia [eosinophils >2 x ULN]); 
• A s
ubject  meeting  Hy’s  Law  (HL) criteria  (see Section  8.4.5 and Appendix 4 ). 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  83  
 • If CrCL falls ≤ 15 mL/min, or there is a requirement to start renal replacement 
therapy, ATM -AVI should be discontinued. It is at the Investigator’s discretion  to 
either discontinue MER ± COL or whether an immediate dose change or a short 
period of continued observation is required. 
• Treatment  failure  (refer  to Table 9 ). 
• In the opinion of the Investigator, it is not in the best interest of the subject to 
continue the study treatment  or at the request  of the Sponsor or delegates  that the 
subject stops participation in the study. 
• Severe non- compliance with  the CSP.  
6.3.1. Procedures  for Discontinuation of a Subject  from  Investigational Product  
At any time, subjects are free to discontinue IP or withdraw from the study (ie, IP and assessments – see Section  6.4),  without prejudice to further treatment.  A subject  that decides 
to discontinue IP will always be asked about the reason(s) and the presence of any AEs. If 
possible, they will be seen and assessed by  an Investigator(s). AEs will be followed up (See 
Section 8 ). 
The subject  should be scheduled for the EOT  visit within  24 hours after IV study treatment 
discontinuation. For subjects who discontinue study treatment but wish to continue in the study, their follow-up assessments should be collected (EOT, TOC and LFU visits). Data 
from these visits should be captured in the electronic case report form (CRF). 
Adverse events  (AEs) and serious adverse events  (SAEs)  will be followed up as described  in 
Section 8.1.4. If a subject  is withdrawn  from  study, see Section  6.4. 
6.4. Subject Withdrawal  
Subjects may withdraw from the study at any time at their own request, or they may be 
withdrawn  at any time at the discretion  of the investigator or sponsor for safety  (see also the 
Withdrawal From the Study Due to Adverse Events Section 8.1.3) or behavioral reasons,  or 
the inability of the subject to comply with the protocol-required schedule of study visits or 
procedures at a given study site. 
If a subject does not return for a scheduled visit, every effort should be made to contact the 
subject.  All attempts  to contact  the subject and information  received  during contact  attempts 
must be documented in the subject’s medical record. In any circumstance, every effort should be made to document subject outcome, if possible. The investigator should inquire about the reason for withdrawal, request that the subject return for a final visit, if applicable, and follow up with the subject regarding any unresolved AEs. 
If a subject  withdraws  from  participation  in the study, then his/her enrolment/randomization 
code cannot be reused. Withdrawn subjects will not be replaced. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  84  
 6.4.1. Screen  Failures  
Screening failures are subjects who do not fulfil the eligibility criteria for the study, and 
therefore must not be randomized. These subjects should have the reason for study withdrawal  recorded  as ‘Screen  failure’  (the potential subject  who does not meet  one or more 
criteria  required  for participation  in a study, this  reason  for study withdrawal  is only valid  for 
not randomized subjects). 
6.4.2. Withdrawal of Consent  
Subjects who request to discontinue receipt of study treatment will remain in the study and 
must continue to be followed for protocol specified follow-up procedures. The only exception to this is when a subject specifically withdraws consent for any further contact with him or her or persons previously authorized by the subject to provide this information. Subjects should notify the investigator in writing of the decision to withdraw consent from future follow-up, whenever possible. The withdrawal of consent should be explained in detail in the medical records by the investigator, as to whether the withdrawal is only from further receipt  of investigational product or also from  study procedures and/or post treatment 
study follow-up, and entered on the appropriate CRF page. In the event that vital status 
(whether the subject is alive or dead) is being measured, publicly available information should be used to determine vital status only as appropriately directed in accordance with local law.  
If the subject  withdraws  from  the study, and also withdraws  consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be collected.  The sponsor may retain and continue to use any data collected before such 
withdrawal of consent. 
6.4.3. Lost to Follow- up 
All reasonable efforts must be made to locate subjects to determine and report their ongoing 
status.  This includes follow-up with persons authorized by the subject as noted above. Lost 
to follow-up is defined  by the inability  to reach  the subject  after a minimum of 2 documented 
phone calls, faxes, or e- mails as well as lack of response by the subject to 1 registered mail 
letter.  All attempts should be documented in the subject’s medical records. If it is 
determined that the subject has died, the site will use locally permissible methods to obtain the date and cause of death.  If the investigator’s use of a third- party representative to assist 
in the follow-up portion of the study has been included in the subject’s informed consent, then the investigator may use a sponsor- retained third -party representative to assist site staff 
with obtaining the subject’s contact information or other public vital status data necessary to 
complete the follow -up portion of the study. The site staff and representative will consult 
publicly available sources, such as public health registries and databases, in order to obtain 
updated contact  information. If, after  all attempts,  the subject  remains  lost to follow-up, then 
the last -known-alive date as determined by the investigator should be reported and 
documented in the subject’s medical records. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  85  
 7. ASSESSMENTS 
Every effort should be made to ensure that the protocol- required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may be 
circumstances outside of the control of the investigator that may make it unfeasible to 
perform the test.  In these cases the investigator will take all steps necessary to ensure the 
safety  and well-being  of the subject.  When  a protocol- required  test cannot be performed,  the 
investigator will document the reason for this and any corrective and preventive actions that he or she has taken to ensure that normal processes are adhered to as soon as possible. The 
study team will be informed of these incidents in a timely manner.  
For samples being collected and shipped, detailed collection, processing, storage, and shipment instructions and contact  information  will be provided to the investigator site prior 
to initiation of the study. 
The electronic data capture (EDC) system will be used for data collection and query 
handling. The Investigator will ensure that data are recorded  on the CRFs  as specified  in the 
CSP and in accordance with the instructions provided. 
For studies conducted at  US (investigational new drug [IND])  sites and non- US (non- IND) 
sites, data from IND and non-IND study sites will be pooled together for analysis. The Investigator ensures the accuracy, completeness, and timeliness of the data recorded and 
of the provision of answers  to data queries  according  to the Clinical Study Agreement  (CSA). 
The Investigator will sign the completed CRFs. A copy of the completed CRFs will be archived at the study site. 
7.1. Efficacy  Assessments  
7.1.1. Clinical Response  Assessment  
Clinical response will be determined at the EOT and TOC visits as either cure, failure or 
indeterminate.  The clinical response at each visit will be assessed  by the Investigator, and 
subsequently validated by an independent adjudication committee that will be blinded to study treatment (see Section 9.7).  Reason for failure will be indicated according to the 
clinical response definitions as follows ( Table 9 ): 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  86  
  
Table 9.  Definition  of Clinical Response  Categories  at the  EOT  and TOC  visits  
 
Clinical 
response  Definition  
Cure  Baseline signs and symptoms have improved such that after study treatment,  no further antimicrobial treatment  for the index infection 
(ie, cIAI or HAP/VAP) is required.
a 
In addition, none of the failure  criteria  listed below  should be met.  
Additionally  for cIAI  subjects:  
No unplanned drainage or surgical  intervention  is necessary  since the 
initial procedure. 
Failure  Subjects  who meet  any of the following criteria  will be considered  a 
treatment failure: 
Death  (after receiving  at least 48 hours of study treatment).  
Subject who received treatment with further antibiotics for the index 
infectiona.  This includes subjects  prematurely  discontinued from  study 
treatment due to an AE who require further antibiotics for the index infection.  
Additionally  for cIAI  subjects:  
Persisting  or recurrent  infection  within  the abdomen documented by the 
findings at re-intervention either percutaneously or operatively in situation of adequate infection source control at the time of initial surgical procedure. 
Postsurgical wound infections (eg, signs of local  infection  such as 
purulent exudates, erythema, or warmth that requires additional 
antibiotics and/or non-routine wound care). 
Indeterminate  Death  (after  receiving  less than 48 hours of study treatment). 
Subject lost to follow -up. 
Additionally  for cIAI  subjects:  
Inadequate infection  source control at time of initial surgical  procedure.  
Abbreviations:  AE=adverse event;  cIAI=complicated  intra-abdominal  infection;  EOT=end  of treatment; 
HAP=hospital -acquired pneumonia; TOC=test of cure; VAP=ventilator -acquired pneumonia.  
a. Further  antibiotics  for the index infection  should  only be initiated  for ongoing  or worsening signs  and 
symptoms of the infection.  
 
If a subject is assessed  as a clinical  failure  at the EOT  visit,  this assessment  will be carried 
forward to the TOC visit. 
In addition, an exploratory assessment  of clinical  response based  on objective measures  of 
signs and symptoms of infection will be collected. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  87  
 7.1.2. Microbiological Response  
For each pathogen identified  at Baseline,  microbiological outcome at EOT  and TOC  will be 
determined as shown in Table 10. 
 
Table 10. Definition  of Microbiological Response  Categories  at the EOT  and TOC 
Visits, for Each Pathogen Identified at Initial/Pre Study (Study 
Qualifying) Culture  
 
Microbiological response  Definition  
Eradication  Absence of causative pathogen from  an appropriately obtained 
specimena at the site of infection.  
Presumed eradication  Repeat  culture of specimens  were not performed/clinically  indicated  in 
a subject who had a clinical response of cure.  
Persistence  Causative organism is still present from an appropriately obtained specimen  at the site  of infection.  If the causative organism displays  
≥4-fold higher MIC  to study therapy  after  treatment with IV study 
therapy, the response will  also be categorized  as “Persistence with 
increasing MIC”.  
Presumed persistence  Subject  was assessed  as a clinical  failure  and repeat  culture of 
specimens were not performed/clinically indicated.  
Indeterminate microbiological response  Death  (after  receiving  less than 48 hours of study treatment). 
Subject lost to follow -up. 
Additionally  for cIAI  subjects:  
Inadequate infection  source control at  time of initial surgical  procedure.  
Abbreviations: BAL=bronchoalveolar lavage; cIAI=complicated intra -abdominal infection; EOT=end of 
treatment; IV=intravenous(ly);  MIC=minimum  inhibitory  concentration;  PSB=protected -specimen  brush; 
TOC=test of cure. 
a. A definition of an appropriately obtained specimen for each infection site will be included in the study 
microbiology manual (see Appendix 6).  For subjects with cIAI, an appropriately obtained specimen for 
determination  of microbiological  response  is defined as a specimen  obtained using an adequate technique 
(eg, surgical procedure (laparotomy or laproscopic), percutaneous drainage (where in place for less than 24 hours) or wounds where the subject has a superficial or deep surgical wound reported at any point during the follow -up period).  From expectorated or induced sputum, an adequate specimen is one with 
≤10 squamous  epithelial cells and >25 polymorphonuclear  neutrophils  per Low Power  Field  (LPF)  upon a 
Gram -stain; throat secretions are considered to be inadequate; other specimens such as endotracheal 
aspirate, BAL, mini- BAL, and PSB are considered to be adequate.  For blood, two sets of blood cultures 
should be collected (ie, 4 bottles) from 2 different sites for aerobic and anaerobic incubation.  One set of 
blood cultures  must  be obtained through a venipuncture.  Collect samples,  ideally  over a period of 2 hours 
at least 10 to 20 minutes apart from separate sites.  
 
If a pathogen is assessed  as persistence or persistence with increasing  MIC  at the EOT  visit, 
this assessment will be carried forward to the TOC visit.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  88  
 7.1.2.1. Microbiological Response  Assessment  
The per-subject  and per-pathogen microbiological response at the EOT  and TOC  visits  will 
be assessed based on the pathogen(s) isolated from the study qualifying baseline and 
post- baseline cultures  per the definitions outlined below.  
Per-pathogen Microbiological Assessments after  Completion of All  Follow Up Visits  
Microbiological response will be assessed separately for each pathogen after completion of all follow-up visits  using the definitions listed  in Table  10. Microbiological responses other 
than “indeterminate” will be classified as “favorable” or “unfavorable.” Favorable microbiological response assessments include “eradication” and “presumed eradication.” Unfavorable microbiological response assessments include “persistence”, “persistence with increasing MIC”, and “presumed persistence.” Subjects with a microbiological response assessment  of “indeterminate” will be considered to be non- evaluable for the micro -ITT and 
ME analysis sets.  Classifications such as “superinfection” and “new infection” will be 
considered separately (see “emergent infections” below).  
Per-subject  (Overall)  Microbiological Response  Assessments  
Overall microbiological response will also be assessed as “favorable” or “unfavorable” for each subject.  Subjects  will be determined  to have a favorable microbiological response if all 
baseline pathogens for that subject have a favorable outcome (eradicated or presumed eradicated) at the appropriate time point (EOT, TOC).  If the outcome for any pathogen is 
unfavorable (persistence, persistence with increasing MIC, or presumed persistence), the subject will be considered to have an unfavorable microbiological response. 
Per-resistance Type Microbiological Response  Assessments  
Microbiological response (per subject  and per pathogen) will be presented  for the subgroup 
of subjects with a pathogen in the given resistance group (eg, ATM-non- susceptible,  
ESBL-positive, carbapenamase-positive, and MBL -positive). Per-pathogen microbiological 
response will be presented separately for ATM-non-susceptible, ESBL-positive, 
carbapenamase-positive, and MBL-positive pathogens. 
Emergent  Infections  
New  pathogens that appear  after Baseline are categorized  in Table 11 and  will be 
summarized separately.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  89  
  
Table 11.  Definition  of Emergent  Infection  Categories  
 
Emergent 
infection  Definition  
Superinfection  Emergence of a new pathogen(s) associated with emergence or 
worsening of signs and symptoms of infection and a requirement for 
additional antibiotics  during the period up to and including the EOT  visit.  
New  infection  Emergence of new pathogen(s) associated  with emergence or worsening 
of signs and symptoms of infection and a requirement for additional antibiotics in the time period after the EOT visit.  
Abbreviations:  cIAI=complicated  intra-abdominal  infection; EOT=end  of treatment; HAP=hospital -acquired 
pneumonia; VAP=ventilator -acquired pneumonia.  
 
7.2. Safety  Assessments  
Safety  and tolerability  assessment  will be undertaken on individual subject  and cohort basis 
through a determination  of SAEs  and AEs based  on signs and symptoms, examinations and 
laboratory tests. If deterioration in a laboratory value is associated with clinical signs and symptoms, the clinical diagnosis (or sign or symptom) will be reported as an AE and the associated laboratory result or vital sign will be considered as additional information. For 
details  on AE  definition  and reporting see Section 8 . If the findings meet the criteria for an 
SAE, procedures for reporting such events should be followed (refer to Section 8.1.4.1).  
7.2.1. Laboratory Safety Assessments  
Blood and urine samples  for determination  of clinical  chemistry,  hematology, and urinalysis 
will be taken  at the times  indicated  in the Schedule of Activities  (see Table 1  and Section  6). 
Blood and urine samples  collected  for safety  analyses  will be sent to the central  laboratory 
for analysis. The results of safety laboratory sampling will be made available to the 
investigators. Investigators are to review central laboratory results and to confirm and document any significant results. The laboratory safety variables to be measured at the central laboratory are displayed in Table 12 . 
Local  laboratory results,  including safety  parameters  will be used for eligibility  determination 
(ie, serum creatinine for calculation of CrCL, serum or urine β -hCG for pregnancy test, AST, 
ALT, ALP, TBili, and hematology as listed in Section 4.2) and subject management throughout the study. Local laboratory test results will be entered in the CRF  
(see Section  6.1.1).  
For HAP/VAP subjects, arterial blood gases are required for ventilated subjects, recommended for non ventilated subjects at Screening visit to calculate APACHE II score; for cIAI subjects, arterial blood gases are to be collected as clinically  indicated at Screening 
visit to calculate APACHE II score.  Where ABGs are not available at screening, serum 
bicarbonate is to be used to calculate APACHE  II score  as per Appendix 5. For all subjects,  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  90  
 arterial  blood gases  are also  collected  as clinically  indicated  at Baseline,  during treatment 
period and at EOT. 
Liver  function tests and CrCL  must be closely  monitored  throughout the study. Further 
details for the monitoring of liver function tests are described in Section 8.5.2. Further 
details regarding the calculation of the CrCL are described in Appendix 3. Further safety samples may be collected if clinically indicated at the discretion of the 
Investigator and analyzed in the local laboratory of the study site. The date, time of 
collection  and results  (values, units and reference  ranges)  will be recorded  on the appropriate 
CRF.  
The following safety  laboratory  variables  will be measured:  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  91  
  
Table 12.  Laboratory Safety Variables  
 
Clinical chemistry  Hematology  Arterial blood  
gasesb Urinalysis  
Albumin   Partial  pressure  of 
oxygen (PaO 2)  
Total  protein  Hematocrit  Partial  pressure  of 
carbon dioxide 
(PaCO 2) Appearance (color, 
clarity)  
ALT  Hemoglobin  pH Bilirubin  
AST INR (at baseline and 
as clinically indicated)  Oxygen saturation  Glucose  
ALP Platelet  count  Bicarbonate (HCO 3) Ketones  
Bilirubin (total, direct  and indirect)  Red blood cell count   Leukocyte esterase  
Bicarbonate  WBC  count (total and 
differential)   Nitrite  
Blood urea nitrogen    pH 
Calcium, total   Protein  
Chloride    Specific gravity  
Serum creatininea   Urobilinogen  
Glucose (nonfasting)     
Inorganic 
phosphorus     
Potassium     
Sodium     
Abbreviations:  ALP=alkaline  phosphatase;  ALT=alanine aminotransferase;  AST=aspartate aminotransferase; 
CrCL=creatinine clearance; INR=international normalized ratio; WBC=white blood cells.  
a. Following  each determination  of serum  creatinine  until TOC  (inclusive),  also the estimate  CrCL  will be 
calculated. 
b. For HAP/VAP subjects,  arterial blood gases are required for ventilated subjects, recommended for non 
ventilated subjects at Screening visit to calculate APACHE II score; for cIAI subjects, arterial blood gases 
are only collected  as clinically  indicated  to calculate APACHE  II score  at Screening  visit.  For all subjects, 
arterial blood gases are collected as clinically indicated at Baseline, during treatment period and at EOT.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  92  
 The Investigator should make an assessment of the available results with regard to clinically 
relevant abnormalities and criteria for intensified monitoring and/or discontinuation of study drug (see Section 6.3 and 8.5.2).  The laboratory results should be signed and dated and 
retained  at center  as source data for laboratory  variables.  For information  on how AEs based 
on laboratory tests should be recorded and reported, see Section 8.4.3. 
7.2.2. Physical Examination  
A complete physical examination will be performed as scheduled in the Schedule of 
Activities ( Table 1 ) and include an assessment of the following: general appearance 
including site of infection,  skin, head  and throat  (head,  eyes,  ears, nose, and throat),  lymph 
nodes, respiratory, cardiovascular (CV), abdomen including wound examination, musculoskeletal, and neurological systems. 
If clinically abnormal findings emerge or there is worsening of any condition compared to 
the physical examination  at Screening,  these findings should be documented as  AEs  on the 
respective page of the CRF.  
Height and weight will be measured at the Screening visit, and the body mass index will be 
calculated as the ratio of weight in kg/(height in cm/100)
2. If these assessments cannot be 
performed due to the subject’s clinical condition, they may be done later (as soon as 
possible). After the Screening visit, weight should be measured as clinically indicated. If 
these assessments cannot be performed due to the subject's clinical condition, they may be done later (as soon as possible). For the purpose of assessing eligibility, a subject's weight obtained during the current or most recent  hospitalization  may  be used if the subject's clinical 
condition at the time of screening does not allow this assessment to be performed. 
A detailed focused (infection-related abdominal or respiratory signs and symptoms per 
indication) assessment  will be performed  at Screening, at Baseline,  daily  during treatment 
with IV study treatment, at the EOT, TOC and LFU visits (see Table 1 ). 
The following infection -related  focused  physical examinations will be conducted:  
• For HAP/VAP  subjects,  a pulmonary assessment,  which  includes auscultation, will be 
performed.  
• For cIAI subjects, abdominal signs and symptoms will be assessed and postoperative abdominal and wound examinations  will be performed. Surgical  wound examination 
should occur  daily  even  if inspection is limited  by the presence of a negative pressure 
wound therapy device. A thorough wound evaluation should occur when a full dressing change is performed. 
7.2.3. ECG  
Standard 12-lead ECGs (triplicates for each recording time point) will be recorded and assessed at Baseline and Day 3 during the treatment period (see Table 1 ). The ECG on 
Day 3 should be performed  at maximum plasma  concentration  (C
max) which  is immediately 
(within 30 minutes) after an infusionis completed. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  93  
 The date of ECG  must be recorded  in the CRF.  
The ECGs  should be standard  12-lead ECGs  with a lead II rhythm strip with the subject  in 
the supine position after  the subject  has rested  in this position for 10 minutes. If clinically 
indicated, additional ECG recordings can be made at the discretion of the Investigator as 
unscheduled assessments. A single independent third party using uniform techniques will carry out formal analysis and reporting of ECG data for purposes of the study. 
7.2.4. Vital Signs  
Vital sign measurements (including BP, heart rate and body temperature) should be assessed 
at Screening,  Baseline,  daily  (twice  daily  for body temperature)  while  the subject  is receiving 
IV study treatment, at EOT and at TOC visits; for subjects with HAP/VAP, respiratory rate 
(breath per minute) and peripheral O
2 saturation will be collected at Screening, Baseline, 
daily  while the subject is receiving IV study treatment, at EOT and TOC visits (see Table 1). 
Vital signs should be measured and documented at least once daily, preferably at a similar 
time each day.  However, if any significant excursions occur, those measurements should 
also be captured.  
The Investigator should make an assessment of the available results with regard to clinically 
relevant  abnormalities.  The results  should be signed and dated  and retained  at study center  as 
source data.  For information on how AEs based on vital signs should be recorded and 
reported, see Section 8.4.3. 
7.2.4.1. Pulse  and Blood  Pressure  
Supine BP and heart rate should be measured using a semiautomatic BP recording device 
with an appropriate cuff size or by direct  measurement  via arterial  catheter.  The subjects  will 
be required to rest in a supine position for at least 10 minutes prior to heart rate and BP 
measurements.  
7.2.4.2. Body Temperature  
Body temperature will be measured using an automated thermometer. The subject’s body temperature will be evaluated at least twice a day (suggested at least 8 hours apart) and the actual  time of body temperature collection  will be recorded.  Fever  will be defined  as a body 
temperature ≥ 38°C.  For each individual subject, the method of temperature measurement 
ideally should be consistent for the duration of the study. At the TOC visit only a single body temperature measurement is required. The actual time of body temperature collection will be recorded.  
7.2.5. Pregnancy  Testing  
For female subjects of childbearing potential, a serum or urine pregnancy test, with 
sensitivity  of at  least 25 mIU/mL  for β-hCG will be performed  locally  at screening  (Visit 1). 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  94  
 A negative pregnancy  test result  is required  before  the subject  may receive the investigational 
product. Pregnancy  tests will also be done when potential pregnancy is otherwise suspected. 
Pregnancy tests may also be repeated if requested by institutional review boards 
(IRBs)/ethics committees (ECs) or if required by local regulations. 
Urine pregnancy tests must be sensitive to at least 25 mIU/mL for β -hCG and will be 
conducted with the test kit provided by the central  laboratory in accordance with  instructions 
provided in its package insert. An indeterminate or positive urine pregnancy test will be 
confirmed by a serum pregnancy test performed either locally or by the central laboratory. 
In the case of a positive confirmed  pregnancy, the subject  will be withdrawn from 
administration of investigational product. 
7.2.6. Other Safety Assessments  
7.2.6.1. Chest  X-ray/ CT Scan  
For HAP/VAP subjects only, a chest X- ray or a CT scan will be taken at Screening (if not 
available within  48 hours prior to randomization), and  as clinically  indicated  during the study 
(see Table 1 ). 
7.2.6.2. Acute Physiology and Chronic Health Evaluation  
At Screening, cIAI and HAP/VAP subjects will be assessed by using the Acute Physiology 
and Chronic Health Evaluation (APACHE) II score (see Appendix 5).  Subjects with cIAI 
will also be stratified  at randomization based  on APACHE  score.  ABGs  will be collected  at 
Screening to calculate APACHE II score (see Table 1 ) as required for ventilated subjects, 
recommended for non- ventilated subjects with HAP/VAP and as clinically indicated for 
subjects with cIAI.  Where ABGs are not available at screening, serum bicarbonate is to be 
used to calculate APACHE II score.  
7.3. Microbiology  
Cultures o f abdominal site infections (for cIAI subjects only)  
Specimens must be obtained for culture from an initial qualifying surgical procedure performed  within  24 hours before  or after randomization and sent to the local  laboratory for 
microbiological culture.  This will be treated as the baseline culture.  
Additional specimens will be collected for culture, as clinically appropriate at the time of repeat  surgical procedures or from  the wound, during the treatment  period, and at EOT  and 
TOC (see Table 1 ), if surgical procedure/intervention permits. 
All specimens  will be sent to the local  laboratory for microbiological culture,  and isolates 
will be sent to the central laboratory. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  95  
 Respiratory  specimen  for Gram -stain/culture  (for HAP/VAP  subjects  only)  
Cultures from  respiratory  specimens  obtained within  48 hours prior to randomization may be 
used. Repeat respiratory specimens at Baseline are not required, unless a Screening sample 
was obtained from  a non-ventilated subject and the subject is subsequently ventilated  (or has 
bronchoscopy). In this case, an appropriate respiratory specimen should be obtained via 
BAL, miniBAL, PSB sample or endotracheal aspirate prior to the first dose of study treatment.  
Respiratory specimens will also be collected during the treatment period if clinically indicated  and at EOT  and TOC  (see Table 1 ) if at all possible. If treatment is discontinued 
early,  an attempt to obtain an appropriate respiratory  specimen  for culture should be made, 
ideally after stopping the study treatment and before the new treatment is administered. 
All specimens will be sent to the local laboratory for microbiological culture, and isolates 
will be sent to the central laboratory. A Gram -stain needs to be performed and an unstained 
Gram -stain  slide  (dried  glass  mount) of each respiratory  specimen  (expectorated  and induced 
sputum only) must also be sent to the central reference laboratory. 
Collection  
of Blood for Culture (for all subjects)  
All subjects require 2 sets of blood cultures (1 anaerobic and 1 aerobic bottle in each set) 
within 48 hours prior to randomization. Blood cultures should be performed at Baseline prior to first dose of study treatment  if blood cultures  are not available within  48 hours prior 
to randomization. For subjects who are found to be bacteremic, blood cultures should be repeated at least every 3 days until clearance of bacteremia is documented.  If a negative 
culture report has not been achieved by the time of the EOT visit, a set of repeat blood cultures should be obtained at the EOT visit. Blood cultures should also be obtained as clinically indicated (see Table 1 ). 
All specimens  will be sent to the local  laboratory for microbiological culture,  and isolates 
will be sent to the central laboratory. 
Further details  are provided in Appendix 6 . 
7.4. Pharmacokinetics  
PK sampling  will be employed to achieve further information on the PK of ATM -AVI in the 
subject population. 7.4.1. Collection  of Plasma  Samples  for Analysis of Aztreonam -Avibactam  
A total of 6 blood samples  (2 mL/sample  to provide approximately 1.0 mL  of plasma)  for PK 
and/or PK/PD evaluation should be collected into appropriately labeled tubes containing 
sodium fluoride/potassium oxalate (gray  top) from  subjects  assigned  to the ATM -AVI ±MTZ 
treatment arm.  Samples will be collected from the subject’s arm opposite to that into which 
study drugs (ATM-AVI) are infused and/or via use of a concurrent multi- lumen central line, 
and will be labelled,  stored  and shipped as detailed  in the Laboratory Manual.  Three samples  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  96  
 should be taken  on both Day 1 and Day 4 of study treatment.  To provide greater  flexibility, 
Day 4 PK samples can be collected on Day 4 ± 1 day [Note: A blood sample (5 mL) for 
estimation of serum creatinine will also be collected on Days 3 or 5 and sent to the central 
laboratory if PK samples are collected on Days 3 or 5]. 
All subjects  randomized  to ATM -AVI will have 3 blood samples  collected  for determination 
of study drug in plasma for both Day 1 and Day 4 (a total of 6 samples per subject). These 
samples will be taken as scheduled in the Schedule of Activities ( Table 1 ) and at the times 
presented in Table 13 as well as in Figure 3 and Figure 4 below. Where this presents 
difficulty to the site, priority should be given to collection of sample 2 on Day 1 and all 
3 samples on Day 4. Where possible, Day 1 samples 1 and/or 3 should also be collected. The time of sample collection for sample 3 on both Days 1 and 4 is different depending on 
the CrCL  value of either  >30 mL/min  or >15 mL/min  to ≤30 mL/min,  ie, whether  the subject 
is receiving q6h or q8h maintenance dosing (see Table 13 ). 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  97  
  
Table 13.  Pharmacokinetic ATM -AVI Sample  Collection  Time  Points  
 
Day Sample  time 
Day 1 All subjects  randomized  to ATM -AVI:  (3 samples/subject)  
Sample  1: Within  5 minutes  before  the end of the loading dose infusion 
(25 to 30 min after the start of the loading dose infusion). 
Sample  2: Within  15 minutes  before the end of the extended  loading dose 
infusion (3.25 to 3.5 hours after the start of the loading dose 
infusion).  
Sample  3: Within  1 hour before  the start of the first maintenance 
infusion:  
For subjects on q6h dosing: 2 to 3 hours after stopping the extended  loading dose (5.5 to 6.5 hours after the start of the 
loading dose infusion). 
For subjects on q8h dosing: 4 to 5 hours after stopping the 
extended  loading dose (7.5 to 8.5 hours after the start of the 
loading dose infusion). 
Day 4 All subjects  randomized  to ATM -AVI:  (3 samples/subject)  
Sample  1: Within  15 minutes  before the end of the IV  infusion 
(2.75 to 3 hours after the start of the IV infusion). 
Sample  2: 30 to 90 minutes after stopping the IV infusion (3.5 to 
4.5 hours after the start of the IV infusion). 
Sample  3: Within  1 hour before  the start of the next maintenance 
infusion:  
For subjects on q6h dosing: 2 to 3 hours after stopping the IV 
infusion (5 to 6 hours after the start of the IV infusion). 
For subjects on q8h dosing: 4 to 5 hours after stopping the IV 
infusion (7 to 8 hours after the start of the IV infusion). 
Abbreviations:  ATM -AVI=aztreonam -avibactam;  IV=intravenous(ly);  q6h = every  6 hours; 
q8h = every 8 hours.  
ATM -AVl 
C3601002 
 Final  Protocol  Amendmen t 2, 18 May 2022   
PFIZER  CONFIDENTIAL  
Page  98  
 
 
Figure 3   ATM -AVI Pharmacokinetic  Sample Collection Time -Point s for Subjects with  CrCL  >30mL /min (Q6h 
Maintenance Dose) 
 
 Dayl   
 
■ l•I Extended LD II maintenance  
• • • • • • • • • • • • 
-1 0 0.5 1 2 3 4 5 6 7 8 9    
 
• • • 
 11 12 10 
PK Sample  time  from start  of LD !] = 25-30 min fJ = 3.25-3.5 hr 11111  = 5.5-6 
Day4 ,., ' - 
• • • • • • • • 
0 1 2 3 4 5 6 7 5 hr 
• 
9    
• 
8 • 
10 • 
11 • 
12 
 PK Sample  time from  start of IV infusion  2.75-3 hr 
•= 3.5-4.5 hr  
 
= 5-6 hr  
  
 PK Sample number  ••• ATM -AVI Infusion I Hours   
Abbre viations:  ATM -AVI= aztreonam -avibactam ; CrCL = creatinine clearance; IV= intravenous (ly); LD = loading dose; PK= pharmacokinetics; 
q6h = every 6 how -s. 
ATM -AVl 
C3601002 
 Final  Protocol  Amendmen t 2, 18 May 2022   
PFIZER  CONFIDENTIAL  
Page  99  
 
-··-  •  • • • 
 
• • • • • • • • • • • • • 
• • 
 •  
Figure 4   ATM -AVI Pharmacokinetic  Sample  Collection Time -Point s for Subjects  with CrCL  >15 to30 mL/min (Q8h 
Maintenance Dose) 
 
Dayl  
 •  
 
[) D Extended LO  
M  maintenance  • • • • • 
-1 0 0.5 1 2 3 4 5 6 7 8 9 10 11 12 
 
PK Sample time from start of LO I! = 25 - 30 min fl =3.25 - 3.5 hr Ill.II  =7.5-8.5 hr 
 
Day4  
,., • - 
0 1 2 3 4 5 6 7 8 9 10 11 12 
 
PK Sample time from  start of IV  infusion   = 2.75 - 3 hr  =3.5-4.Shr - =7-8hr 
PK Sample number  ATM- AVI Infusion  Hours  
Abbre viations : ATM -AVI= aztreonam -avibactam ; CrCL = creatinine clearance; IV= intravenous (ly); LD = loading dose ; PK= pharmacokinetics; 
q8h = every 8 how-s. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  100  
 The date, starting and stop time of infusion and exact time of sample collection must be 
recorded  in the CRF  for each sample.  If a deviation  from  the protocol is experienced  due to 
technical difficulties, eg, with the administration of  the infusion or PK sampling, the details 
of the deviation have to be recorded in the CRF. 
The plasma  samples  will be analyzed,  and the resulting  data will be used in PK analysis.  A 
PK/PD analysis will be performed if adequate microbiological response data are collected. 
PK/PD analyses will be reported separately.  
7.4.2. Determination  of Drug  Concentration  
Samples  for determination  of ATM  and AVI concentration in plasma  will be analyzed  using 
an appropriate validated bioanalytical method in compliance with Pfizer & vendor standard operating procedures (SOPs). Full details of the bioanalytical methods used will be 
described in a separate bioanalytical report.  
The PK samples must be processed and shipped as indicated in the instructions provided to the investigator site to maintain sample integrity.  Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shipping conditions), including any actions taken, must be documented and reported to the sponsor. On a case-by- case basis, the sponsor may make a determination as to whether sample 
integrity has been compromised. Any deviation from the specified sample handling procedure resulting  in compromised sample  integrity  will be considered  a protocol deviation. 
Incurred  sample  reproducibility  analysis,  if any, will be performed  alongside the bioanalysis 
of the PK samples and reported in a separate bioanalytical report. 
Additional analyses may be conducted on the biological samples to further investigate the 
presence and/or identity  of drug metabolites  and validate  the analytical  method. Results  from 
such analyses may be reported separately from the CSR.  
7.4.3. Storage and Destruction  of Pharmacokinetic Samples  
PK samples  will be disposed of 12 months after the Bioanalytical  Report finalization  unless 
requested for future analyses.  
Any residual back-up PK samples may be used for future CCI  (in 
this case, residual back -up PK samples will be shipped to Sponsor assigned biostorage; see 
details in the Laboratory Manual). This is optional and will require additional informed 
consent from subjects (See Section 7.6).  
7.5. P harmacogenomics: not applicable  
Pharmacogenomics  samples  will not be taken  during the study. 
7.6. Biological Samples  
The subject’s  consent to  the use of donated biological samples  is mandatory. Optional  
CCI  samples will utilize the PK samples, so no additional draw of blood is needed. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  101  
 Samples for safety, microbiological and PK analyses will be collected as per the inclusion 
criteria,  Schedule of Activities  (Table 1) and PK sampling  schedule ( Table 13).  The volume 
of blood to be drawn from each subject is displayed in Table 14. All samples will be 
processed and analyzed using sensitive and validated bioanalytical methods. 
The number of samples taken, as well as the volume required for each analysis, may be 
changed during the study as new data on ATM- AVI become available.  Aspects of the 
subject  management  may require additional samples,  which  might also increase the volume 
of blood drawn. 
 
Table 14.  Volume  of Blood to Be Drawn  from  Each  Subject  
 
Assessment   Sample  volume 
(mL)  Number  of 
samples  Total volume (mL)  
Safety  Clinical chemistry  5 Minimum 8, maximum 11
a Minimum 40,  
maximum 55  
Hematology  2.5 Minimum 6, maximum 9
a Minimum 15,  
maximum 22.5  
Pregnancy  testb  2.5 Minimum 0,  
maximum 1 Minimum 0,  
maximum 2.5  
Pharmacokinetic sampling   2 6 12 
Blood culture   10 - 15 Minimum 4 40 - 60 
Arterial  blood 
gases   2 Minimum 0,  
maximum 1 Minimum 0,  
maximum 2 
Totalc    107 – 154 
Abbreviation:  β-hCG= β-human chorionic  gonadotropin;  CrCL=creatinine clearance;  EOT=end  of treatment; 
TOC=test of cure. 
a. Number of samples depends on clinical response (duration of treatment: 5 – 14 days).  Sampling time 
points:  Screening  (local  lab and central  lab), Baseline,  study  Days  4, 7, 10, and 13; EOT,  within  24 hours 
after end of last infusion); TOC, Day 28 ± 3 days.  In addition samples on clinical chemistry panel are 
required on Day 2 and Day 3 for serum creatinine for estimation of CrCL.  
b. Determination  of urine  or serum  β-hCG  for women  of childbearing  potential at Screening  (Visit 1) only.  
c. If the subject  is found  to be bacteremic, the total volume  required  for blood culture  will increase by a 
further 60 mL for each follow up sample being drawn.  
 
7.6.1. Storage, Re-use and Destruction  of Biological Samples  
Samples will be stored until the end of the study and then destroyed; unused PK samples 
(with consent) will be stored for up to 15 years for CCI analysis;  microbiology isolates 
will be kept at least five years after the study drug is submitted to the regulatory authorities 
for marketing approval. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  102  
 7.6.2. Labelling  and Shipment  of Biological Samples  
The Principal  Investigator ensures  that samples  are labelled  and shipped in accordance with 
the Laboratory Manual and the Biological Substance, Category B Regulations (materials 
containing or suspected to contain infectious substances that do not meet Category A criteria), see Appendix 2 ‘International Airline Transportation Association (IATA) 
6.2 Guidance Document’. 
Any samples identified as Infectious Category A materials are not shipped and no further samples  will be taken  from  the subject  unless agreed  with Pfizer  and appropriate labelling, 
shipment and containment provisions are approved. 
Samples must be collected, labelled, processed, analyzed, stored and transported to the 
relevant  storage site, as indicated  in the Laboratory Manual.  Tubes will be labelled  with the 
study number, sample description and date and time of collection. The date and time of the 
sample  collection  will be recorded  in the source documents and in the appropriate section  of 
the CRF.  
An isolate ID number will be allocated to all pathogen isolates obtained.  Samples of all 
isolates will be sent to the central reference laboratory  (see Section 7.3).  PK samples will be 
shipped periodically  from  the study centers  to the responsible (Pfizer -approved) laboratory at 
agreed intervals.  
Samples should be shipped in batches if possible. Logistics should be coordinated between 
involved parties  to ensure that samples  will arrive  during working hours. A requisition  sheet 
should accompany the shipment that details the study number, center number, enrollment 
number, date of sample collection, and a unique ID for each of the samples in the shipment. 
7.6.3. Chain  of Custody  of Biological Samples  
A full chain  of custody is maintained  for all samples  throughout their lifecycle.  
The Investigator at each center keeps full traceability of collected biological samples from 
the subjects  while  in storage at the center  until shipment or disposal (where  appropriate) and 
keeps documentation of receipt of arrival. 
The sample  receiver  keeps  full traceability  of the samples  while  in storage and during use 
until used or disposed of or until further shipment and keeps documentation of receipt of 
arrival.  
Pfizer  keeps  oversight of the entire  life cycle through internal  procedures,  monitoring of 
study sites and auditing of external laboratory providers. 
Samples  retained  for further use are registered  in the Sponsor assigned  biostorage during the 
entire life cycle.  
ATM -AVl 
C3601002 
 Final  Protocol Amendmen t 2, 18 May 2022   
PFIZER  CONFIDENTIAL  
Page  103  
 
 
 
 
 
 
 
 
 
I   
I  
I  

ATM -AVl 
C3601002 
 Final  Protocol Amendmen t 2, 18 May 2022   
PFIZER  CONFIDENTIAL  
Page  104  
  
 
8. ADVERSE  EVENT  REPORTING  
8.1. Requirements  
The table below  summarize s the requiremen ts for recording safety events  on the  CRF and for 
repo1iing safety  events on the Clinical  Trial  (CT)  Serious Adverse  Event  (SAE ) Repo1i  Fo1m 
to Pfizer Safety . These requirements are  delineat ed for 3 types  of events: (1) SAEs; (2)  
non-serious adve rse events  (AEs);  and (3) exposure  to the investigational product  under 
study during pregnancy or bre astfeedin g, and occupati onal exposure.  
 
Safety  Event  Recorded  on the CRF  Reported on the CT SAE 
Report Form to Pfizer 
Safety  Within 24 Hours  of 
Awareness  
SAE All All 
Non-serious AE All None 
Expos ure to the 
investigational product 
under study during  
pregnancy or All (regardless of whether 
assoc iated wi th an AE) , 
except occupational  
exposure  Expos ure during  pregnancy , 
expos ure via br eastfeeding, 
occupatio nal exposure  
(regardless of whether 
breastfeeding , and 
occupational  exposure   associated  with an AE) 
All observed o r volunteered events  regardless of treatment group or suspected causal 
relationship  to the investigational  produc t(s) will be repo1ied as described in the following 
paragraphs.  
Events listed in the table above  that requir e repo1iing to Pfizer  Safety  on the CT SAE  Repo1i 
Fonn within 24 hours of awareness of the event by the  investigator a re to be repo1i ed 
regardless  of whether the event is dete1mined b y the investigator to be related to an 
investigational product under study. In paiiicular , if the SAE is fatal  or life-threatening, 
notification  to Pfizer Safety  must be made immediat ely, i1Te spective  of the extent  of available 
event  info1mation. This time frame also applies to additional new (follow -up) info1mation on 
previously  fo1wai·ded repo1is.  In the rare situation that the investigato r does  not beco me 
imm ediately aware of the occmTence of  an event, the in vestigator must report the event 
within 24 hours after  leaining of it and  docume nt the time of his/her first awareness  of the 
event.  
For each event,  the investigator must pursue and obtain adequate info1mati on both to 
dete1mine the  outcome and to assess w hether it meets  the criteri a for classification  as an SAE 
(see the Serious Adverse Events Section 8.2.3 below).  In addition, the in vestigator may be 
requested by Pfizer Safety  to obtain specific follow- up info1mati on in an expedited fashion. 
This infonn ation is more detai led than that recorded  on the CRF.  In gene ral, this will include  

ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  105  
 a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and independent determination of possible causality. Any information relevant to the event, such as concomitant medications and illnesses, must be provided. In the case of a 
subject  death,  a summary  of available autopsy findings must be submitted  as soon as possible 
to Pfizer Safety.  Any pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory data) are to 
be sent to Pfizer Safety ONLY upon request. 
As part of ongoing safety reviews conducted by the sponsor, any non- serious AE that is 
determined  by the sponsor to be serious will be reported  by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may be requested from the investigator to provide clarity and understanding of the event in the context of the clinical study.  
8.1.1. Additional  Details  on Recording  Adverse Events  on the CRF  
All events detailed in the table above will be recorded on the AE page(s) of the CRF. It 
should be noted that the CT SAE Report Form for reporting of SAE information is not the same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology and the same AE term should be used on both the CRF  and the CT SAE  Report 
Form for reporting of SAE information. 
8.1.2. Eliciting  Adverse Event  Information  
The investigator is to record  on the CRF  all directly  observed AEs and all AEs spontaneously 
reported by the study subject/legally acceptable representative. In addition, each study 
subject/legally  acceptable representative will be questioned about the occurrence of AEs in a 
non-leading manner. 
8.1.3. Withdrawal from  the Study  Due to Adverse Events  (see also the Subject 
Withdrawal Section)  
Withdrawal  due to AEs should be distinguished from  withdrawal  due to other causes, 
according to the definition of AE noted below, and recorded on the CRF. When  a subject withdraws from  the study because of an SAE,  the SAE  must be recorded  on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.  
8.1.4. Time Period for Collecting AE/SAE Information  
The time period for actively eliciting and collecting AEs and SAEs (“active collection period”) for each subject  begins from  the time the subject  provides informed  consent, which 
is obtained before the subject’s participation in the study (ie, before undergoing any study- related  procedure and/or receiving  investigational product), through the treatment 
period and including the LFU visit. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  106  
 For subjects who are screen  failures,  the active  collection  period ends when  screen  failure 
status is determined.  
8.1.4.1. Reporting  SAEs  to Pfizer Safety  
All SAEs  occurring in a subject  during the active collection  period are reported  to Pfizer 
Safety on the CT SAE Report Form. 
SAEs  occurring in a subject  after the active collection  period has ended  are reported  to Pfizer 
Safety if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety. 
Follow up by the investigator continues throughout and after the active collection  period and 
until the event  or its  sequelae resolve or stabilize  at a level  acceptable to  the investigator, and 
Pfizer concurs with that assessment.  
8.1.4.2. Recording  Non-serious  AEs  and SAEs  on the  CRF  
During the active  collection  period, both non- serious  AEs and SAEs  are recorded  on the 
CRF.  
Follow-up by the investigator may be required until the event or its sequelae resolve or 
stabilize  at a level  acceptable to the investigator, and Pfizer  concurs  with that assessment.  
Any AEs/SAEs  that are unresolved at the subject’s  last AE/SAE  assessment  in the study are 
followed up by the Investigator for as long as medically indicated, but without further recording in the CRF. 
8.1.5. Causality Assessment  
The investigator’s assessment  of causality  must be provided for all AEs (serious and 
non-serious);  the investigator must record  the causal  relationship  on the CRF,  and report  such 
an assessment in accordance with the SAE reporting requirements, if applicable. An 
investigator’s causality assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused  or contributed to  an AE; generally  the facts 
(evidence) or arguments to suggest a causal relationship should be provided. If the 
investigator does not know whether or not the investigational product caused the event, then the event will be handled as “related to investigational product” for reporting purposes, as defined by the sponsor. If the investigator's causality assessment is “unknown but not related” to investigational product, this should be clearly documented on study records. 
In 
addition, if the investigator determines  that an SAE  is associated  with study procedures, 
the investigator must record  this causal  relationship in the source documents and CRF,  and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  107  
 8.1.6. Sponsor’s  Reporting  Requirements  to Regulatory Authorities  
AE reporting, including suspected  unexpected  serious adverse reactions,  will be carried  out 
in accordance with applicable local regulations.  
8.2. Definitions  
8.2.1. Adverse Events  
An AE is any untoward medical occurrence in a study subject administered a product or 
medical  device;  the event  need  not necessarily  have a causal  relationship  with the treatment 
or usage. Examples of AEs include, but are not limited to: 
• Abnormal test findings;  
• Clinically  significant signs and symptoms;  
• Changes in physical examination  findings;  
• Hypersensitivity;  
• Drug  abuse;  
• Drug  dependency.  
Additionally, AEs may include signs and symptoms  resulting  from:  
• Drug  overdose;  
• Drug  withdrawal;  
• Drug misuse;  
• Drug interactions;  
• Extravasation;  
• Exposure during pregnancy (EDP);  
• Exposure via breastfeeding;  
• Medication  error;  
• Occupational  exposure.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  108  
 8.2.2. Abnormal Test Findings  
Abnormal objective test findings should be recorded  as AEs when  any of the following 
conditions are met: 
• Test result  is associated  with accompanying symptoms; and/or  
• Test result  requires  additional diagnostic testing  or medical/surgical  intervention; 
and/or  
• Test result  leads  to a change in study dosing (outside of any protocol- specified  dose 
adjustments) or discontinuation from the study, significant additional concomitant 
drug treatment, or other therapy; and/or 
• Test result  is considered  to be an AE by the investigator or sponsor.  
Merely repeating an abnormal test, in the absence of any of the above conditions, does not constitute  an AE. Any abnormal test result  that is determined  to be an error  does not require 
recording as an AE. 
8.2.3. Definitions  of Serious  Adverse Events  
A serious adverse event  is any  untoward medical occurrence at any  dose that: 
• Results  in death;  
• Is life-threatening (immediate  risk of death);  
• Requires  inpatient hospitalization or prolongation of existing hospitalization; 
• Results  in persistent  or significant disability/incapacity  (substantial disruption of the 
ability to conduct normal life functions); 
• Results  in congenital anomaly/birth  defect. 
Or that is considered to be: 
• An important medical event.  
Medical  and scientific  judgment is exercised  in determining  whether  an event is an important 
medical event.  An important medical event may not be immediately life -threatening and/or 
result in death or hospitalization. However, if it is determined that the event may  jeopardize 
the subject or may require intervention to prevent one of the other AE outcomes, the 
important medical event should be reported as serious. 
Examples of such events are intensive treatment in an emergency room or at home for 
allergic  bronchospasm; blood dyscrasias  or convulsions that do not result  in hospitalization; 
or development of drug dependency or drug abuse. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  109  
 8.2.4. Hospitalization  
Hospitalization is defined as any initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility, or any prolongation of an existing admission. Admission also includes transfer within the hospital to an acute/intensive care unit (eg, from the psychiatric wing to a medical floor, medical floor to a coronary care unit, or neurological floor to a tuberculosis unit). An emergency  room visit does not necessarily  constitute  a hospitalization; 
however, the event leading to the emergency room visit is assessed for medical importance. 
Hospitalization  does not include the following:  
• Rehabilitation facilities;  
• Hospice facilities;  
• Respite  care (eg, caregiver  relief);  
• Skilled  nursing facilities; 
• Nursing homes;  
• Same- day surgeries  (as outpatient/same -day/ambulatory procedures).  
Hospitalization  or prolongation of hospitalization  in the absence  of a precipitating  clinical 
AE is not in itself an SAE.  Examples include: 
• Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory abnormality); 
• Social  admission (eg, subject has no place to sleep);  
• Administrative  admission  (eg, for yearly  physical examination);  
• Protocol- specified  admission  during a study (eg, for a procedure required  by the study 
protocol);  
• Optional admission  not associated  with a precipitating  clinical  AE (eg, for elective 
cosmetic surgery);  
• Hospitalization  for observation without a medical  AE; 
• Preplanned  treatments  or surgical  procedures.  These  should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  110  
 Diagnostic and  therapeutic noninvasive and  invasive procedures, such  as surgery, should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE. For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements  are met, and the resulting  appendectomy should be recorded  as treatment of the 
AE. 
8.3. Severity  Assessment  
 
If required on the AE page of the CRF, the investigator will use the adjectives MILD, MODERATE,  or SEVERE to describe the maximum intensity  of the AE. For purposes of 
consistency, these intensity grades are defined as follows: 
MILD  Does  not interfere with subject's usual function.  
MODERATE  Interferes  to some extent  with  subject's usual function. 
SEVERE  Interferes  significantly  with subject's usual function. 
Note  the distinction  between  the severity  and the seriousness of an AE. A severe event  is not 
necessarily an SAE.  For example, a headache may be severe (interferes significantly with 
the subject's usual function) but would not be classified as serious unless it met one of the criteria for SAEs, listed above.  
8.4. Special Situations  
8.4.1. Protocol- Specified  Serious  Adverse Events  
There are no protocol-specified SAEs in this study. All SAEs will be reported to Pfizer 
Safety  by the investigator as described  in previous sections,  and will be handled as SAEs  in 
the safety database.  
8.4.2. Adverse Events Based on Signs and Symptoms  
All AEs spontaneously reported by the subject  or care provider or reported  in response to the 
open question from the study personnel: ‘Have you had any health problems since the previous visit/you were last asked?’, or revealed by observation will be collected and recorded in the CRF.  When collecting AEs, the recording of diagnoses is preferred (when 
possible) to recording a list of signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be recorded separately. 
8.4.3. Adverse Events  Based  on Examinations and Tests  
The results  from  protocol mandated  laboratory tests and vital signs will be summarized  in the 
CSR.  Deterioration as compared to Baseline in protocol-mandated laboratory values, vital 
signs and ECG should therefore only be reported as AEs if they fulfil any of the AE criteria 
or are the reason for discontinuation of treatment with the IP. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  111  
 If deterioration in a laboratory value/vital sign is associated with clinical signs and  
symptoms, the clinical diagnosis (or sign or symptom) will be reported as an AE and the 
associated  laboratory result/vital sign will be considered  as additional information. Wherever 
possible the reporting Investigator uses the clinical, rather than the laboratory term (eg, anemia versus low hemoglobin value). In the absence of clinical signs or symptoms, clinically relevant deteriorations in non -mandated parameters should be reported as AE(s). 
Deterioration  of a laboratory  value,  which  is unequivocally due to disease progression, 
should not be reported as an AE/SAE. 
Any new or aggravated  clinically  relevant  abnormal medical  finding at a physical 
examination  as compared  with the  baseline assessment  will be  reported  as an AE. 
8.4.4. Exceptions  from  Standard Adverse Events  Collection  
Where there is deterioration in the condition for which the IV study treatment is being used, 
there may be uncertainty as to whether this is lack of efficacy, disease progression or constitutes an AE. In such cases, unless the Pfizer or reporting physician considers that the study treatment contributed to the deterioration or local regulations state to the contrary, the deterioration  should be compared  with the definitions below and considered to be either  lack 
of effect ( Section 8.4.4.1) or disease progression ( Section 8.4.4.2) and not an AE. 
8.4.4.1. Lack  of Effect  
Insufficient  therapeutic effect  will be captured  as an efficacy  outcome. Instances  of, or 
discontinuation due to  insufficient therapeutic effect  (ie, lack  of efficacy)  should not be 
collected as AEs.  A clinical failure should not be recorded as an AE. 
8.4.4.2. Disease  Progression  
Disease progression can be considered as a worsening of a subject’s condition attributable to the disease for which the IP is being studied. It may be an increase in the severity of the disease under study and/or increases in the symptoms of the disease. Expected progression of the disease under study and /or expected progression of signs and symptoms of the disease under study, unless more severe in intensity or more frequent than expected for the subject’s condition should not be reported as an AE. Any event or extended hospitalization that is unequivocally due to disease progression must not be reported  as an SAE  unless it is believed 
that the study drug actively contributed to the progression of the disease (ie, not by way of insufficient therapeutic effect).  Events, which are unequivocally due to disease progression, 
should not be reported as an AE/SAE during the study unless the outcome is fatal within the active collection period. If disease under study has a fatal outcome during the study or within the active collection period, then the event leading to death must be recorded as an SAE on the AE CRF, and SAE Report Form. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  112  
 8.4.5. Potential  Cases  of Drug -Induced Liver Injury  
Humans exposed to a drug who show no sign of liver injury (as determined by elevations in 
transaminases)  are termed  “tolerators,” while  those who show transient  liver injury, but adapt 
are termed “adaptors.” In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome. These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver injury, commonly referred to as drug-induced liver injury (DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal (
× ULN) should be monitored more frequently to determine if they are an “adaptor” 
or are “susceptible.”  
In the majority of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) precede TBili elevations  (>2 
× ULN)  by several  days or weeks.  The 
increase in TBili typically occurs while AST/ALT is/are still elevated above 3 × ULN  
(ie, AST/ALT and TBili values will be elevated within the same lab sample).  In rare 
instances, by the time TBili elevations are detected, AST/ALT values might have decreased. This occurrence is still regarded  as a potential DILI.  Therefore,  abnormal  elevations  in either 
AST OR ALT in addition to TBili that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law criteria) cases and should always be considered 
important medical events, even before all other possible causes of liver injury have been 
excluded.  
The threshold of laboratory  abnormalities  for a potential DILI  case depends on the subject’s 
individual baseline values and underlying conditions. Subjects who present with the following laboratory abnormalities  should be evaluated  further as potential DILI (Hy’s  law) 
cases to definitively determine the etiology of the abnormal laboratory values: 
• Subjects  with AST/ALT  and TBili baseline values  within  the normal range who 
subsequently present with AST OR ALT values >3 
× ULN AND a TBili value  
>2 × ULN with  no evidence of hemolysis and an alkaline phosphatase value  
<2 × ULN or not available;  
• For subjects with baseline AST OR ALT OR TBili values above the ULN, the following threshold values  are used in the definition  mentioned above,  as needed, 
depending on which values are above the ULN at baseline: 
• Preexisting  AST  or ALT  baseline values  above the normal range:  AST  or 
ALT values >2 times the baseline values AND >3 
× ULN; or >8 × ULN 
(whichever is smaller).  
• Preexisting  values  of TBili  above the normal range: TBili level  increased  from 
baseline value by an amount of at least 1 × ULN or if the value reaches >3 × ULN (whichever is smaller).  
Rises in AST/ALT and TBili separated by more than a few weeks should be assessed individually based  on clinical  judgment; any case where uncertainty  remains  as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  113  
 The subject should return to the investigator site and be evaluated as soon as possible, 
preferably  within  48 hours from  awareness  of the abnormal results.  This evaluation  should 
include laboratory tests, detailed history, and physical assessment. 
In addition to repeating  measurements  of AST  and ALT  and TBili,  laboratory tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma- glutamyl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), total bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels. Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses  at the time of the recognized  initial abnormalities  to determine  etiology. A detailed 
history, including relevant information, such as review of ethanol, acetaminophen (either by itself or as a coformulated product in prescription or over-the-counter medications), recreational drug, supplement (herbal) use and consumption, family history, sexual history, travel history, history of contact with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, biliary tract) may be warranted.  
All cases  demonstrated  on repeat  testing  as meeting  the laboratory criteria  of AST/ALT  and 
TBili elevation defined above should be considered potential DILI (Hy’s law) cases if no other reason for the Liver Function Test (LFT) abnormalities has yet been found. Such 
potential DILI (Hy’s law) cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.  
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of reasonable investigations have been  received  and have excluded  an alternative  etiology. 
8.4.6. Exposure to the Investigational Product  During  Pregnancy  or Breastfeeding,  and 
Occupational Exposure 
Exposure to the investigational product under study during pregnancy or breastfeeding  and 
occupational exposure are reportable to Pfizer Safety within 24 hours of investigator 
awareness.  
8.4.6.1. Exposure During Pregnancy  
For both unapproved/unlicensed products and for marketed  products, an exposure during 
pregnancy (EDP) occurs if:  
• A female becomes,  or is found to be, pregnant either  while  receiving  or having been 
exposed (eg, because of treatment or environmental exposure) to the investigational product; or the female  becomes  or is  found to  be pregnant after  discontinuing and/or 
being exposed to the investigational product; 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  114  
 • An example of environmental exposure would be a case involving direct 
contact  with a Pfizer  product in a pregnant woman  (eg, a nurse reports  that she 
is pregnant and has been exposed to chemotherapeutic products). 
• A male  has been  exposed (eg, because of treatment or environmental exposure) to the 
investigational product prior to or around the time of conception and/or is exposed during his partner’s pregnancy. 
If a subject or subject’s partner becomes or is found to be pregnant during the subject’s treatment with the investigational product, the investigator must report this information to Pfizer Safety on the CT SAE Report Form and an EDP supplemental form, regardless of whether an SAE has occurred. In addition, the investigator must submit information 
regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject reports that she is pregnant and has been exposed to a cytotoxic product by inhalation or spillage)  to Pfizer  Safety  using the EDP  supplemental form.  This must be done irrespective 
of whether  an AE has occurred  and within  24 hours  of awareness  of the exposure. The 
information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy). 
Follow-up is conducted to obtain general information on the pregnancy and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a follow- up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrity  of the neonate can be assessed  at the time of birth. In the event  of a termination,  the 
reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless pre-procedure test findings are conclusive for a congenital  anomaly  and the findings are 
reported).  
If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine  fetal demise,  neonatal death,  or congenital anomaly  [in a 
live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs. 
Additional information  about pregnancy outcomes that are reported  to Pfizer  Safety  as SAEs 
follows:  
• Spontaneous abortion includes miscarriage and missed  abortion;  
• Neonatal  deaths  that occur within  1 month of birth  should be reported, without regard 
to causality, as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the investigational product. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  115  
 Additional information regarding the EDP may be requested by the sponsor. Further 
follow-up of birth outcomes will be handled on a case-by- case basis (eg, follow -up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the 
investigator will provide the subject  with the Pregnant Partner  Release of Information Form 
to deliver to his partner. The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information Form to provide to his partner.  
8.4.6.2. Exposure During  Breastfeeding  
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of an associated  SAE,  to Pfizer  Safety  within  24 hours of the investigator’s awareness,  using the 
CT SAE Report Form. An exposure during breastfeeding report is not created when a Pfizer drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration,  the SAE is reported  together with  the exposure during breastfeeding.  
8.4.6.3. Occupational Exposure  
An occupational exposure occurs when, during the performance of job duties, a person (whether  a healthcare professional or otherwise)  gets in unplanned direct  contact  with the 
product, which may or may not lead to the occurrence of an AE. 
An occupational exposure is reported  to Pfizer  Safety  within  24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a subject enrolled in the study, the 
information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file.  
8.4.7. Medication  Errors  
Other  exposures to the investigational product under study may occur in clinical  trial settings, 
such as medication errors. 
 
Safety Event  Recorded  on the CRF  Reported on the CT SAE 
Report Form to Pfizer Safety  Within  24 Hours  of 
Awareness  
Medication  errors  All (regardless  of whether 
associated with an AE)  Only  if associated  with an 
SAE 
Medication  errors  may result  from  the administration  or consumption of the investigational 
product by the wrong subject, or at the wrong time, or at the wrong dosage strength. 
Medication  errors  include: 
• Medication  errors  involving subject  exposure to the investigational product;  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  116  
 • Potential medication  errors  or uses outside of what  is foreseen  in the protocol that do 
or do not involve the participating subject. 
Such  medication  errors  occurring  to a study participant  are to be captured  on the medication 
error page of the CRF, which is a specific version of the AE page.  
In the event of a medication dosing error, the sponsor should be notified immediately.  
Whether or not the medication error is accompanied by an AE, as determined by the 
investigator, the medication  error is recorded  on the medication  error page of the CRF  and, if 
applicable,  any associated  AE(s),  serious and non-serious, are recorded  on an AE page of the 
CRF.  
Medication  errors  should be reported  to Pfizer  Safety  within  24 hours on a CT  SAE  Report 
Form only when associated with an SAE . 
8.4.7.1. Overdose  
Overdose is defined as a dose of study drug administered to a subject in excess of that specified in Section 5.6. Overdose does not automatically make an AE/SAE but if the consequences of the overdose are accompanied  by an AE or serious for example death  or 
hospitalization, the event is AE or SAE and should be reported as such. 
Avibactam  alone and in combination with another β-lactam  partner  antibiotic  CAZ  
(CAZ -AVI) was  studied in healthy  volunteers at doses  up to  2000 mg  of AVI  in single and 
multiple  dose regimens  in Phase 1 clinical  pharmacology studies, including a thorough QT 
study, with no safety signals or trends identified for AVI (see IB). If an overdose or intoxication on the IV study treatment occurs in the course of the study, 
then the Investigator or other site personnel will inform  Pfizer  immediately  when  he or she 
becomes aware of it.  
Overdose should be reported  to Pfizer Safety  within  24 hours  on a CT SAE  Report Form 
only when associated with an SAE . 
Recording an overdose will be done according  to the following:  
• A
n overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant  AE modules in the CRF  and on the medication  error CRF  module. Relevant 
information regarding any corresponding SAE(s) related to the overdose must be forwarded to Pfizer safety in CT SAE Report Form for data entry in the safety database.  
• An overdose without associated  symptoms is only reported  on the medication  error 
CRF module. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  117  
 8.5. Management  of Laboratory Safety  
If necessary, ATM may be cleared from the serum by hemodialysis and/or peritoneal 
dialysis.  ATM has been shown to be cleared from the serum by continuous arteriovenous 
hemofiltration.  AVI may also be cleared  from  the serum  by hemodialysis (55% of the AVI 
dose was removed in 4 hours in a group of subjects with ESRD). 
8.5.1. Renal  Function  
CrCL will be monitored at Screening, Baseline, Day 2 through Day 4 (daily) (and Day 5 if 
PK sample collected on Day 5) and as clinically indicated and dose of study drug will be adjusted accordingly throughout the study. Determination of creatinine will be part of each 
safety laboratory until TOC inclusive, ie, every 3 days until end of IV study treatment (as defined  in Table 1),  followed  by calculation  of CrCL  at the central  laboratory. For eligibility 
assessment at Screening and renal function monitoring for dose adjustment of study drug at subsequent visits,  CrCL  needs  to be calculated  at the study site, based  on the creatinine value 
determined at local laboratory (see Section 6 and Appendix 3).  
If subsequent to randomization and while still on IV study treatment, a subject’s estimated 
CrCL  falls below the threshold for study inclusion (ie, estimated CrCL ≤ 15 mL/min)  and/or 
there is a requirement  to start renal  replacement  therapy,  the Investigator should discontinue 
ATM -AVI or MER±COL investigational therapies.  
8.5.2. Monitoring  of Liver- related  Laboratory Parameters  
If a subject  reaches  an ALT or AST  >3 x ULN and has not met the discontinuation criteria, 
the following enhanced monitoring and subject follow- up will be instigated: 
• C
ollection  of clinical  and historical information  to determine  the cause of ALT and/or 
AST elevations (and completing the relevant CRFs modules); 
• Frequency  of liver function tests,  and INR,  should be increased  to daily  monitoring 
(using local laboratory data and recorded as unscheduled visits) until the liver 
function tests recover to ≤3 x ULN.  
In the absence of any alternative  explanation for an increase in the following abnormalities, 
individual subjects of both treatment arms should be discontinued from study treatment if 
any of the following criteria are met (also see Section 8.4.5):  
• ALT  or AST  >8 x ULN;  
• ALT  or AST  >3 x ULN and either  TBili >2 x ULN  or INR  > 1.5; 
• ALT or AST >3 × ULN and with appearance of symptoms and signs suggestive of new or progressive liver disease (eg, new or worsening fatigue, nausea, vomiting, right upper quadrant pain or tenderness,  fever,  rash,  and/or eosinophilia [eosinophils 
>2 x ULN]).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  118  
 With  regards  to any cases  of Potential Hy’s  Law (PHL) (occurrences  of AST  or ALT  
>3 x ULN together with TBili >2 x ULN), the Pfizer medical monitor will initially  review 
the case (as described in Appendix 4) and then the case will be referred for independent 
clinical  hepatologist review.  The independent clinical  hepatology review  will be unblinded 
to study treatment allocation.  
9. DATA ANALYSIS/STATISTICAL  METHODS  
Detailed  methodology for summary  and statistical analyses  of the data collected  in this study 
is outlined here and further detailed in a statistical analysis plan (SAP), which will be 
maintained by the sponsor. The SAP may modify what is outlined in the protocol where appropriate; however, any major modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment.  
9.1. Sample Size Determination  
The study will randomize up to approximately 425 subjects in a 2:1 randomization ratio 
(approximately 283 subjects to ATM- AVI ± MTZ and approximately 142 subjects to 
MER  ±COL)  with serious  infections proven or strongly suspected  to be caused  by MDR  
pathogens, including those producing MBLs. Current literature indicates that the prevalence 
of infections caused by pathogens producing MBLs could range from 17% to 31% ( Azim et 
al. 2010; De  et al. 2010; Lascols  et al. 2011; Mouloudi et  al. 2010 and  Walsh  et al. 2011),  but 
we anticipate a more conservative estimate for prevalence of 8 -10% in the study. 
As no formal  hypothesis testing  will be performed  for this study, no power calculation  was 
carried out to assess the number of subjects required for each treatment arm.  The planned 
sample size is considered sufficient to estimate the overall clinical cure rates in each arm. 
The smaller numbers of subjects in these groups will be reflected in the precision of the estimate of clinical cure rate.  
9.2. Definitions  of Analysis Sets 
9.2.1. Efficacy Analysis Set  
9.2.1.1. Intent -To-Treat  (ITT)  Analysis Set 
The ITT analysis  set will include all randomized  subjects  regardless  of receipt  of study drug. 
Subjects in the ITT analysis set will be analyzed according to the treatment they are randomized to. The ITT analysis set will be used to evaluate the primary, secondary and tertiary objectives.  
9.2.1.2. Clinically  Evaluable (CE) Analysis Set 
The CE analysis  set is defined  as all subjects  who:  
• Meet  the definition  of the ITT  analyses.  
• Meet  disease criteria for diagnosis of cIAI,  or HAP/VAP.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  119  
 • Received at least 48 hours of study treatment (ATM- AVI ± MTZ or MER ± COL) or 
received  <48 hours of study treatment  before discontinuing study drug due to an AE. 
• Did not receive concomitant antibiotic treatment with potential activity against any 
baseline pathogens between  the time of the first dose of study treatment  and the time 
of TOC.  This does not include those subjects who have received protocol- allowed 
antibiotics, or have failed study treatment and require additional antibiotics to treat their infection.  
• Had no important protocol deviations that may affect  the assessment  of efficacy  (to 
be defined in the SAP). 
• Did not have a clinical outcome of  indeterminate at TOC.  
• Do not have monomicrobial infections due to non-eligible pathogens (any Acinetobacter  spp., Pseudomonas aeruginosa) and do not have only Gram -positive 
pathogens.  
Subjects in the CE analysis set will be analyzed according to the treatment they are 
randomized  to. The CE analysis set will be used to evaluate selected  primary, secondary and 
tertiary objectives.  
9.2.1.3. Microbiological Intent -To-Treat  (micro -ITT)  Analysis Set 
The microbiological Intent- To-Treat (micro -ITT) analysis set is a subset of the ITT analysis 
set and includes all subjects who have at least 1 Gram -negative pathogen in an adequate 
initial/prestudy culture.  Subjects with inherently resistant pathogens (monomicrobial 
infections due to any Acinetobacter spp.), and those subjects with only Gram-positive 
pathogens will be excluded  from  the micro -ITT analysis  set. The micro -ITT analysis  set will 
be used to evaluate selected secondary and tertiary objectives.  
9.2.1.4. Microbiologically  Evaluable (ME)  Analysis Set 
The ME analysis  set includes all subjects  included in both micro -ITT and CE analysis  sets, 
and had at least 1 Gram -negative pathogen. The ME analysis set will be used to evaluate 
selected secondary and tertiary objectives.  
9.2.1.5. Modified  Intent -To-Treat  Analysis Set  
The modified ITT (MITT) analysis set will include all randomized subjects who receive any amount of study drug. Subjects in the MITT analysis set will be analyzed according to the treatment  they received.  The MITT  analysis  set will be used in the sensitivity  analysis  of the 
primary endpoint. 
9.2.1.6. Microbiological Modified  Intent -To-Treat  (micro -MITT)  Analysis Set  
The m
icrobiological modified  ITT (micro -MITT)  analysis  set is a subset of the micro -ITT 
analysis set and includes all subjects who receive any amount of study drug. The 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  120  
 micro -MITT  analysis  set will be used in sensitivity  analysis  of microbiological response 
endpoints.  
9.2.2. Safety Analysis Set  
The safety  analysis  set will be used for reporting  safety  data and  will include all subjects  who 
received any amount of IV study treatment. Subjects in the safety analysis sets will be 
analyzed according to the treatment they receive.  
9.2.3. Population Pharmacokinetic (popPK)  Analysis Set 
The population pharmacokinetic (popPK) analysis set will include all subjects who have at 
least 1 plasma  concentration  data assessment  available for ATM -AVI±MTZ  and will be used 
to report all PK data.  
9.2.4. Other Analysis Sets 
9.2.4.1. All Subjects  Analysis Set 
This analysis  set will compromise  all subjects  enrolled  into the study and will be used for 
reporting of disposition. 
9.3. Outcome Measures for Analyses  
9.3.1. Primary  Outcome Variable  
The primary efficacy outcome measure is the proportion of subjects with clinical cure at 
TOC  in the ITT  and CE analysis sets. For the US regulatory submission, the ITT analysis  set 
will be used for the primary analysis while CE analysis set will be the secondary analysis. The proportion of subjects  with clinical  cure for the ITT analysis  set is defined  as the number 
of subjects with clinical cure at TOC divided by the number of subjects in the ITT analysis set. Details are included in the SAP.  
9.3.2. Secondary Outcome Variables  
The secondary outcome measures  are: 
• Proportion of subjects  with clinical  cure at TOC  visit in the micro -ITT and ME 
analysis sets.  
• Proportion of subjects  with clinical  cure at 
the TOC  visits  by infection  type in the ITT 
and CE analysis sets.  
• Proportion of subjects  with clinical  cure at the TOC  visit for subjects  with 
MBL -positive pathogens in the micro- ITT and ME analysis sets.  
• P roportion of subjects  with a favorable per-subject  microbiological response at the 
TOC visit in the micro -ITT and ME analysis sets.  
• Proportion of subjects  who died on or before  28 days after randomization in the ITT 
and micro -ITT analysis sets.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  121  
 • PK of ATM  and AVI  in subjects  with cIAI or HAP/VAP  infections.  
• PK/PD  relationship  between  exposure and clinical  and microbiological response for 
ATM -AVI.  
9.3.3. Tertiary Outcome Variables  
• Proportion of subjects  with clinical  cure at the EOT visit in the ITT, micro -ITT, CE 
and ME analysis sets.  
• Proportion of subjects  with clinical  cure at the EOT  visit by infection  type in the ITT 
and CE analysis sets.  
• Proportion of subjects  with clinical  cure at the EOT visit for subjects  with 
MBL -positive pathogens in the micro- ITT and ME analysis sets.  
• Proportion of subjects with clinical cure at the EOT and TOC visits by pathogen 
resistance type (eg, ATM -non- susceptible,  ESBL- positive, carbapenamase- positive, 
etc) in the micro -ITT and ME analysis sets.  
• Proportion of subjects  with a favorable per-subject  microbiological response at the 
EOT visit in the micro -ITT and ME analysis sets.  
• Proportion of subjects  with a favorable per-pathogen microbiological response at the 
EOT and TOC visits in the micro -ITT and ME analysis sets.  
• Proportion of subjects  with a favorable per- subject  microbiological response by 
pathogen resistance type (eg, ATM-non-susceptible, ESBL-positive, carbapenamase-positive, MBL - positive) at the EOT  and TOC  visits  in the micro -ITT 
and ME analysis sets.  
• Proportion of subjects  with a favorable a per-pathogen microbiological response by 
per-resistance type (eg, ATM -non-susceptible, ESBL-positive, 
carbapenamase-positive, MBL -positive) at the EOT  and TOC  visits  in the micro -ITT 
and ME analysis sets.  
9.3.4. E
xploratory Outcome Variables  
The exploratory outcome measures assessing  the outcomes are:  
• Summary  of total score  for the composite endpoint of symptom- based  objective 
clinical measures (ITT and CE analysis sets).  
• Proportion of subjects  who died  on or before  14 days after randomization.  
• For the health  utilization objective:  
• Length of hospital stay, including any readmissions up to TOC  (days);  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  122  
 • Length of ICU stay (days);  
• Transferred  to the ICU (Yes/No);  
• Length of study treatment (days);  
• Mechanical  ventilation  (Yes/No)  for HAP/VAP  subjects;  
• Length of mechanical  ventilation  (days) for HAP/VAP  subjects;  
• Subsequent unplanned surgical  intervention after treatment  success  vs failure 
(up to the TOC visit) for cIAI subjects. 
9.3.5. Safety Variables  
The following safety  data will be collected:  AEs,  physical  examination, vital signs, ECGs 
and laboratory values. 
9.4. Methods  for Statistical  Analyses  
All data will be presented by treatment arm.  Descriptive statistics (number, mean, standard 
deviation [SD],  median,  minimum,  and maximum)  will be provided for continuous variables, 
and counts and percentages will be presented for categorical variables.  
No formal  hypothesis testing  will be performed  for this study. Any comparisons between 
treatment arms will only be assessed as evidence of an effect, no formal statistical 
comparisons will be made.  
Methodology for dealing with missing data will be specified in the SAP.  
Important protocol deviations are defined  as any important variations from  the protocol that 
could affect the assessment of efficacy and will be defined in the SAP.  An important 
protocol deviation may include: 
1. Those who entered the study even though they did not satisfy  the entry  criteria.  
2. Those who developed withdrawal  criteria  from  IP or from  study or for both during the 
study but were not withdrawn. 
3. Those who received  the wrong treatment  or dose.  
4. Those who received an excluded concomitant treatment.  
5. Those identified through review of all protocol deviations reported during the study.  
9.4.1. Analysis of the Primary  Variable  
The primary descriptive efficacy analysis (for non- US countries) will be the estimate of the 
clinical  cure rate and 95% confidence interval  (CI) in each treatment arm (ATM -AVI ±MTZ  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  123  
 and MER ± COL) in the ITT and CE co -primary analysis sets.  The estimate of the clinical 
cure rate and 95% CI in each treatment arm in the ITT analysis set will be the primary 
analysis  for the US. Single  arm CIs will be computed  using Jeffrey’s  method  (Brown  et al. 
2001; Cai 2005).  The number and percentage of subjects who had a clinical response of 
clinical cure, clinical failure, and indeterminate in each treatment arm will be tabulated for the ITT and CE analysis sets at the TOC visit.  
The primary  descriptive analysis  will be conducted using the clinical  response assessment 
determined by a blinded independent adjudication committee ( Section 9.7).  The 
Investigator’s assessment of clinical response will also be summarized in the ITT and CE analysis sets at the TOC visit.  In case of any discrepancy between the Investigator’s and 
adjudication committee’s clinical response assessment, the adjudication committee’s assessment will prevail.  
Difference in clinical cure rate between treatment arms at TOC visit (ATM -AVI ± MTZ 
minus MER  ±COL)  and corresponding two-sided  95% CI will be calculated  for the ITT and 
CE analysis sets.  The two -sided 95% CI for the observed difference in the cure rates  
(ATM -AVI ± MTZ group minus MER ± COL group) will be computed using the method 
proposed for unstratified  designs by Miettinen  and Nurminen and  an additional supporting 
descriptive analysis  will be conducted  using the stratified  Miettinen  and Nurminen  method 
(Miettinen and Nurminen 1985), if each stratum has at least 3 subjects per each treatment 
group.  
9.4.2. Analysis of the Secondary/Tertiary  Variable(s)  
Secondary and tertiary efficacy outcome measures will be assessed and presented using the same methods as described in Section 9.4.1. For descriptive secondary/tertiary outcome measures, number and percentage in each treatment arm will be tabulated.  Summaries will 
be presented  for the overall  population, and also split by infection  type (cIAI  or HAP/VAP), 
and by resistance group (eg, ESBL status, carbapenemase status, and MBL status). 
The final PK data will be pooled with data from other studies to conduct a popPK analysis 
(using Nonlinear Mixed Effects Modelling [NONMEM]). Using these parameter estimates 
(mean  PK parameters  including inter individual variance  estimates),  Monte- Carlo  simulation 
will be undertaken and potential PK/PD relationships will be explored. ATM and AVI 
plasma concentrations versus time will be depicted graphically in the CSR. Full details of 
the PK and PK/PD analysis will be given in the popPK Analysis Plan. These results will be 
reported separately.  
The proportion of subjects  who died on or before 28 days after randomization will be 
presented for the overall population, and also split by infection type. 
9.4.3. Subgroup Analysis  
Subgroup analysis  may include subject  characteristics,  disease severity,  prior antibiotic  use, 
infection type and pathogen resistance type. More details on the subgroup analyses will be 
provided in the SAP. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  124  
 9.4.4. Interim  Analysis  
No formal interim analysis will be conducted for this study. However, as this is an 
open- label  study, the sponsor may conduct reviews  of the data which  will include no 
summaries  of data by treatment arm during the course of the study for the purpose of safety 
assessment, and/or to support clinical development. 
9.4.5. Supportive Analyses  
Additional descriptive analyses  of the primary  endpoint (clinical  cure rate) will be performed 
for the effect of protocol-allowed additional antibiotics (eg, Gram- positive antibiotics, 
aminoglycosides).  
An additional descriptive analysis  will be performed  for clinical  cure at TOC  using the MITT 
population which comprises subjects who were randomized and received any amount of IV 
study drug. 
Additional descriptive analyses  will be performed  for the secondary and tertiary  outcomes of 
clinical cure rate and microbiological favourable response rate at EOT and TOC using the 
micro -MITT which is a subset of the micro-ITT comprising those subjects who have 
received any amount of IV study drug. 
Sensitivity analyses will be performed using the modified Intent- To-Treat and 
microbiological modified Intent- To-Treat.  The modified Intent- To-Treat and 
microbiological modified Intent- To-Treat are subsets of the Intent -To-Treat and 
microbiological Intent- To-Treat  respectively  and include all randomized  subjects  who 
receive any amount of intravenous study drug. Details  of sensitivity  analyses will be fully  documented in the SAP.  
9.4.6. Exploratory Analysis  
Subjects  will be summarized  by the value of their composite score of symptom- based 
objective clinical measures.  
The proportion of subjects  who died on or before  14 days after randomization  will be 
presented by treatment arm.  
Further details  on the analysis  methods for response endpoint utilizing  objective measures  of 
clinical response and evaluation of health resource utilization will be detailed in the SAP. 9.4.7. Analysis Methods  for Safety  Variables  
AEs will be summarized  by means  of counts summaries  by preferred  term separately  for the 
study periods (treatment period [from  first dose to EOT],  from  EOT  to LFU,  and for the full 
study period [from first dose to LFU].) All AEs and treatment emergent adverse events 
(TEAEs) will be listed (including prior to first dose). Deaths, AEs leading to 
discontinuation, and SAEs will be summarized. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  125  
 Laboratory data for hematology and clinical  chemistry  will be summarized.  The frequency 
of changes with respect to normal ranges between baseline and each post- treatment time 
point will be tabulated.  Frequencies of clinically noteworthy values (defined in the SAP) 
occurring during the clinical study will also be given. Shifts from normal to abnormal 
between baseline and each post -baseline time point will be evaluated for all laboratory 
parameters.  
The incidence of markedly abnormal values  and changes  from  baseline  in the ECG 
parameters will be summarized by treatment arm.  
Other  safety  variables  will be summarized  as appropriate. Further details  will be provided in 
the SAP.  
9.5. Data  Monitoring  Committee  
This study will use an external data monitoring committee (E -DMC).  
The E-DMC  will be responsible for ongoing monitoring of the safety  of subjects  in the study 
according to the E- DMC Charter.  The recommendations made by the E- DMC to alter the 
conduct of the study will be forwarded to Pfizer for final decision. Pfizer will forward such 
decisions, which may include summaries of aggregate analyses of endpoint events and of safety data that are not endpoints, to regulatory authorities, as appropriate. 
Programming and statistical personnel separate from the Sponsor study team will be 
responsible for producing the E- DMC  analyses.  The Sponsor study team  will not receive any 
unblinded summary analyses intended for the E- DMC review.  
9.6. Independent  Clinical Hepatologist Review  of Potential  Hy’s  Law Cases  
With regards to any cases of potential Hy’s Law (PHL), the Pfizer Medical Monitor will initially  review the case (as described in Appendix 4) and then the case will be referred for 
independent clinical  hepatologist review.  The independent clinical  hepatology review  will be 
unblinded to study treatment allocation. The independent clinical hepatologist also will be available for consultation for cases of liver enzyme test abnormalities not specifically  
meeting the criteria for PHL or qualifying as liver -related SAEs.  
9.7. Independent  Adjudication Committee  
An independent adjudication committee  consisting  of at  least  three  experts  will be convened 
at regular intervals  during the study. This independent adjudication committee  is the central 
blinded assessor (see Section 5.2).  
A charter will be in place for the adjudication committee.  The adjudication committee will 
be blinded to study treatment and will review the clinical response assessments at EOT and TOC  visits.  In case of a discrepancy  with the Investigator’s assignment of clinical  response, 
the adjudication committee’s assessment will prevail for the analysis.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  126  
 In addition, for cIAI subjects  classified  as a clinical failure,  and all cIAI subjects  classified  as 
a cure who undergo another procedure (eg, another surgical procedure) subsequent to 
randomization, the adjudication committee will review the adequacy of the surgical source control. All cIAI subjects assessed by the adjudication committee as having inadequate initial infection source control (ie, the cIAI procedure performed was not considered to be adequate to control the source of infection) will be reclassified as having an indeterminate clinical response and will be excluded from the clinically evaluable (CE) and Microbiologically Evaluable (ME) analysis sets. 
10. QUALITY CONTROL  AND QUALITY ASSURANCE  
Pfizer  or its agent  will conduct periodic monitoring visits  during study conduct to ensure that 
the protocol and Good Clinical Practices (GCPs) are being followed. The monitors may 
review source documents to confirm that the data recorded on CRFs are accurate. The 
investigator and institution will allow Pfizer monitors/auditors or its agents and appropriate regulatory authorities direct access to source documents to perform this verification. This 
verification may also occur after study completion. 
During study conduct and/or after study completion, the investigator site may be subject to 
review  by the IRB/EC,  and/or to quality  assurance audits performed  by Pfizer,  or companies 
working with or on behalf of Pfizer, and/or to inspection by appropriate regulatory authorities.  
The investigator(s) will notify Pfizer or its agents immediately of any regulatory inspection 
notification  in relation  to the study. Furthermore,  the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the inspection and will allow Pfizer or its 
agent, whenever feasible, to be present during the inspection. The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and  the subject's medical  records.  The investigator will promptly  provide copies  of the 
inspection findings to Pfizer or its agent. Before response submission to the regulatory authorities, the investigator will provide Pfizer or its agents with an opportunity to review and comment on responses to any such findings. 
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits  and possible audits or inspections and that sufficient  time is devoted to the 
process.  
11. DATA HANDLING  AND RECORD KEEPING  
11.1. Case  Report Forms/Electronic Data Record  
As used in this protocol, the term CRF  should be understood to refer to either  a paper  form  or 
an electronic data record or both, depending on the data collection method used in this study. 
A CRF is required and should be completed for each included subject. The completed 
original CRFs  are the sole property of Pfizer  and should not be made available in any form  to 
third parties, except for authorized representatives of Pfizer or appropriate regulatory authorities, without written permission from Pfizer.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  127  
 The investigator has ultimate responsibility for the collection and reporting of all clinical, 
safety, and laboratory data entered on the CRFs and any other data collection forms (source documents) and ensuring that they are accurate, authentic/original, attributable, complete, consistent, legible, timely (contemporaneous), enduring, and available when required. The 
CRFs must be signed by the investigator or by an authorized staff member to attest that the data contained  on the CRFs  are true. Any corrections  to entries  made  in the CRFs  or source 
documents must be dated, initialed, and explained (if necessary) and should not obscure the original entry. 
In most cases,  the source documents are the hospital or the physician subject chart.  In these 
cases, data collected on the CRFs must match the data in those charts.  
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site  and at Pfizer  that clearly  identifies  those data that 
will be recorded on the CRF, and for which the CRF will stand as the source document. When  participant  data are to be deleted,  the investigator will ensure that all copies  of such 
data are promptly and irrevocably deleted from all systems. 11.2. Record  Retention  
To enable evaluations and/or inspections/audits from regulatory authorities or Pfizer, the 
investigator agrees to keep records, including the identity of all participating subjects (sufficient information to link records, eg, CRFs and hospital records), all original signed informed consent documents, copies of all CRFs, safety reporting forms, source documents, and detailed records of treatment disposition, and adequate documentation of relevant correspondence (eg,  letters,  meeting  minutes,  and telephone call reports).  The records  should 
be retained by the investigator according to the ICH guidelines, according to local regulations, or as specified in the clinical study agreement (CSA), whichever is longer. 
If the investigator becomes  unable for any reason  to continue to retain  study records  for the 
required period (eg, retirement, relocation), Pfizer should be prospectively notified. The 
study records must be transferred to a designee acceptable to Pfizer, such as another 
investigator, another institution, or an independent third party arranged by Pfizer. 
Investigator records must be kept for a minimum of 15 years after completion or 
discontinuation of the study  or for longer if required  by applicable local  regulations. 
The investigator must obtain Pfizer's  written  permission  before  disposing of any  records, 
even if retention requirements have been met. 
11.3. Data  Protection  
All parties  will comply with all applicable laws,  including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data. Participants’  personal data will be stored at the study site in either an encrypted electronic 
and/or paper  form  and will be password protected  or secured  in a locked room, as  applicable  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  128  
 to ensure that only authorized study staff have access. The study site will implement 
appropriate technical and organizational measures to ensure that the personal data can be recovered  in the event  of disaster.  In the event  of a potential personal data breach,  the study 
site will be responsible for determining  whether  a personal data breach  has in fact occurred 
and, if so, providing breach notifications as required by law.  
To protect the rights and freedoms of participants with regard to the processing of personal data, participants will be assigned a single, participant- specific numerical code.  Any 
participant  records  or data sets that are transferred  to the sponsor will contain  the numerical 
code; participant names will not be transferred.  All other identifiable  data transferred  to the 
sponsor will be identified by this single, participant- specific code. The study site will 
maintain a confidential list of participants who participated in the study, linking each participant’s numerical code to their actual identity and medical record ID. In case of data transfer,  the sponsor will protect  the confidentiality  of participants’  personal data consistent 
with the clinical study agreement and applicable privacy laws.  
Information  technology systems used to collect,  process,  and store  study- related  data are 
secured by technical and organizational security measures designed to protect such data against accidental or unlawful loss, alteration, or unauthorized disclosure or access. 
The sponsor maintains  standard  operating procedures  on how to respond in the event  of 
unauthorized access, use, or disclosure of sponsor information or systems. 
 
 
12. ETHICS  
12.1. Regulatory and Ethical  Considerations  
This study will be conducted  in accordance with  the protocol and  with  the following:  
• Consensus ethical  principles  derived  from  international guidelines, including the 
Declaration of Helsinki and CIOMS International Ethical Guidelines; 
• Applicable ICH  GCP  guidelines;  
• Applicable laws and regulations, including applicable privacy  laws.  
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents (eg, 
advertisements)  must be reviewed  and approved by the sponsor, submitted  to an IRB/EC by 
the investigator, and reviewed and approved by the IRB/EC before the study is initiated.  
Any amendments to the protocol will require IRB/EC approval before implementation of changes  made to the study design, except  for changes  necessary  to eliminate  an immediate 
hazard to study participants. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  129  
 Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation  except  for changes  necessary  to eliminate  an immediate  hazard  to 
study participants. 
The investigator will be responsible for the following:  
• Providing written  summaries  of the status  of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC;  
• Notifying the IRB/EC of SAEs  or other significant safety  findings as required  by 
IRB/EC procedures;  
• Providing oversight of the conduct of the study at the site and adherence to requirements  of 21 CFR,  ICH  GCP  guidelines, the IRB/EC,  European regulation 
536/2014 for clinical  studies,  European Medical  Device  Regulation 2017/745 for 
clinical device research, and all other applicable local regulations.  
12.1.1. Reporting  of Safety  Issues and Serious  Breaches  of the Protocol or ICH  GCP  
In the event  of any prohibition or restriction  imposed  (ie, clinical  hold) by an applicable 
regulatory authority in any area of the world, or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the study intervention, Pfizer should be informed immediately. 
In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken  by the investigator to  protect  the study participants  against  any immediate  hazard,  and 
of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator becomes aware of.  
12.2. Subject Information and Consent  
All parties  will ensure protection of subject  personal  data and will not include subject  names 
or other identifiable data in any reports, publications, or other disclosures, except where required by law. 
When study data are compiled for transfer to Pfizer and other authorized parties, subject 
names, addresses, and other identifiable data will be replaced by numerical codes based on a numbering system provided by Pfizer in order to de -identify  study subjects.  The investigator 
site will maintain a confidential list of subjects who participated in the study, linking each subject’s numerical code to his or her actual identity. In case of data transfer, Pfizer will 
maintain  high standards of confidentiality  and protection  of subjects’ personal data consistent 
with applicable privacy laws. 
The informed consent documents and any subject recruitment materials must be in 
compliance with ICH GCP,  local  regulatory requirements,  and legal  requirements, including 
applicable privacy laws.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  130  
 The informed  consent documents used during the informed  consent process and  any subject 
recruitment materials must be reviewed and approved by Pfizer, approved by the IRB/EC 
before use, and available for inspection. 
The investigator must ensure that each study subject or his or her legally acceptable 
representative is fully  informed  about the nature and objectives  of the study and possible 
risks associated with participation.  
Whenever consent is obtained from a subject’s legally acceptable representative, the subject’s assent (affirmative agreement) must subsequently  be obtained when the subject has 
the capacity to provide assent, as determined by the IRB/EC. If the investigator determines 
that a subject’s decisional capacity is so limited he/she cannot reasonably be consulted, then, as permitted by the IRB/EC and consistent with local regulatory and legal requirements, the subject’s assent may be waived with source documentation of the reason assent was not obtained. If the study subject  does not provide his or her own consent, the source documents 
must record  why the subject  did not provide consent (eg, minor, decisionally  impaired  adult), 
how the investigator determined that the person signing the consent was the subject’s legally acceptable representative, the consent signer’s relationship to the study subject (eg, parent, spouse), and that the subject’s assent was obtained or waived. If assent is obtained verbally, 
it must be documented in the source documents. 
The investigator, or a person designated  by the investigator,  will obtain written  informed 
consent from each subject or the subject's legally acceptable representative before any  
study- specific activity  is performed.  The investigator will retain  the original of each subject's 
signed consent document. 12.3. Reporting  of Safety  Issues and Serious  Breaches  of the Protocol or ICH  GCP  
In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable 
regulatory authority in any area of the world, or if the investigator is aware of any new information  that might influence the evaluation of the benefits  and risks  of the investigational 
product, Pfizer should be informed immediately. 
In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken by the investigator to protect the study subjects against any immediate hazard, and of any serious breaches  of this protocol or of ICH  GCP  that the investigator becomes  aware of. 
13. DEFINITION OF END OF  TRIAL  
13.1. End of Trial  in a Member State  
End of trial in a Member State of the European Union is defined as the time at which it is deemed that a sufficient number of subjects have been recruited and completed the study as 
stated  in the regulatory application  (ie, clinical  trial application  [CTA]) and ethics  application 
in the Member State.  Poor recruitment (recruiting less than the anticipated number in the 
CTA) by a Member State is not a reason for premature termination but is considered a 
normal conclusion to the study in that Member State . 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  131  
 13.2. End of Trial  in All Other  Participating  Countries  
End of trial in all other participating  countries is  defined  as last subject last visit (LSLV).  
14. SPONSOR  DISCONTINUATION CRITERIA  
Premature termination  of this study may occur  because of a regulatory authority  decision, 
change in opinion of the IRB/EC, or investigational product safety problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue development of 
ATM -AVI at any time.  
If a study is prematurely terminated, Pfizer will promptly notify the investigator.  After 
notification,  the investigator must contact  all participating  subjects  and the hospital pharmacy 
(if applicable) within 7 days. As directed by  Pfizer, all study  materials must be collected and 
all CRFs completed to the greatest extent possible.  
15. PUBLICATION OF STUDY RESULTS  
15.1. Communication of Results  by Pfizer  
Pfizer fulfills its commitment to publicly disclose clinical trial results through posting the results  of studies on www.clinicaltrials.gov  (ClinicalTrials.gov),  the European  Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.  
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and complete  manner and are reported  regardless  of the outcome of the study or the country in 
which the study was conducted. 
www.clinicaltrials.gov  
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov  for Pfizer -sponsored 
interventional studies (conducted in subjects) that evaluate the safety and/or efficacy of a 
Pfizer  product, regardless  of the geographical location  in which  the study is conducted. US 
Basic Results  are submitted  for posting within  1 year  of the primary  completion  date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric populations.  
PCD  is defined  as the date that the final subject  was examined  or received  an intervention for 
the purposes of final collection of data for the primary outcome, whether the clinical study concluded according to the prespecified protocol or was terminated. 
EudraCT  
Pfizer posts European Union (EU) Basic Results on EudraCT for all Pfizer-sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results  are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  132  
 www.pfizer.com  
Pfizer posts Public Disclosure Synopses (clinical study report synopses in which any data 
that could be used to identify  individual subjects  has been  removed)  on www.pfizer.com  for 
Pfizer -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov. 
15.2. Publications  by Investigators  
Pfizer supports the exercise of academic freedom and has no objection to publication by the 
principal investigator (PI) of the results of the study based on information collected or generated  by the PI, whether  or not the results  are favorable to the Pfizer  product. However, 
to ensure against inadvertent disclosure of confidential information or unprotected inventions, the investigator will provide Pfizer an opportunity to review any proposed publication or other type of disclosure of the results  of the study (collectively,  “publication”) 
before it is submitted or otherwise disclosed. 
Publication  of the results  of the study will be in accordance with Pfizer  and 
COMBACTE -CARE publication policies. 
The investigator will provide any publication to Pfizer  at least 30 days before  it is submitted 
for publication or otherwise  disclosed. If any patent  action  is required  to protect  intellectual 
property rights, the investigator agrees to delay the disclosure for a period not to exceed an 
additional 60 days. 
The investigator will, on request, remove any previously undisclosed confidential 
information  before  disclosure,  except  for any  study- or Pfizer  product- related  information 
necessary to the appropriate scientific presentation or understanding of the study results. 
If the study is part of a multicenter study, the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that any subsequent publications by the PI will reference that primary publication. However, if a joint manuscript has not been  submitted  for publication within  12 months of completion  or termination  of the study at 
all participating sites, the investigator is free to publish separately, subject to the other requirements of this section. 
For all publications relating to the study, the institution will comply with recognized ethical 
standards concerning publications and authorship, including Section II - “Ethical Considerations in the Conduct and Reporting of Research” of the Uniform Requirements for Manuscripts Submitted  to Biomedical  Journals, http://www.icmje.org/index.html#authorship, 
established by the International Committee of Medical Journal Editors.  
Publication of study results is also provided for in the CSA between Pfizer and the institution.  In this section  entitled  Publications by Investigators, the defined  terms  shall  have 
the meanings given to them in the CSA. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  133  
 If there is any conflict between the CSA and any attachments to it, the terms of the CSA 
control. If there is any conflict  between  this protocol and the CSA,  this protocol will control 
as to any issue  regarding  treatment  of study subjects, and the CSA  will control as to all other 
issues.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  134  
 16. REFERENCES  
1. Azim  A, Dwivedi  M, Rao PB, Baronia AK, Singh RK, Prasad  KN, et al. Epidemiology 
of bacterial colonization at intensive care unit admission with emphasis on extended- 
spectrum beta- lactamase- and metallo -beta- lactamase-producing Gram- negative 
bacteria—an Indian experience. J Med Microbiol 2010;59:955-60. 
2. Metronidazole 500 mg/100 ml Intravenous Infusion. UK Summary of Product Characteristics;  Baxter  Healthcare Ltd. Caxton Way,  Thetford, Norfolk, IP24  3SE UK: 
Available from https://www.medicines.org.uk/emc/medicine/30191  
3. Brown  LD, Cai TT, DasGupta A. Interval  estimation  for a binomial proportion. 
Statistical Science 2001, 16 (2):101-117. 
4. Cai TT. One-sided  confidence  intervals  in discrete  distributions. J Stat Plan Inference 
2005;131(1):63- 68. 
5. Cockcroft DW,  Gault  HM. Prediction  of creatinine  clearance from  serum  creatinine. 
Nephron. 1976;16:31-41. 
6. Colomycin (Colistimethate  Sodium 2 MIU  Powder for Injection, Infusion or Inhalation) 
(UK Summary of Product Characteristics). Teva UK Ltd. Available from https://www.medicines.org.uk/emc/product/9664/smpc  
7. Crandon JL, Nicolau DP: Human Simulated Studies of Aztreonam and Aztreonam -Avibactam  to Evaluate Activity  against  Challenging Gram -Negative 
Organisms, Including Metallo -β- Lactamase Producers.  Antimicrob  Agents  Chemother. 
2013 Jul; 57(7): 3299–3306. 
8. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, et al. High- 
dose, extended -interval  colistin  administration  in critically  ill patients:  Is this the right 
dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720-1726. 
9. Dewan  A, Shoukat M. Evaluation of risk of nephrotoxicity with high dose, extended - 
interval colistin administration. IJCCM. 2014;18:427-430. 
10. De AS, Kumar SH, Baveja SM. Prevalence of metallo -β-lactamase producing 
Pseudomonas aeruginosa and Acinetobacter  species  in intensive care areas  in a tertiary 
care hospital. Indian J Crit Care Med 2010;14:217-9. 
11. EMA  Guideline on the evaluation of medicinal  products indicated  for treatment  of 
bacterial infections. European Medicines Agency 2011, London, UK 
(EMA/CPMP/EWP/558/95 Rev 2, 15 December 2011). 
12. EM
A  Addendum to the guideline on the evaluation  of medicinal  products indicated  for 
treatment of bacterial infections. European Medicines Agency 2013, London, UK (EMA/CPMP/351889/2013, 24 October 2013). 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  135  
 13. European Medicines  Agency Assessment  Report. Polymyxin- based  medicines. 
European Medicines Agency 2014, London, UK ( EMA/707128/2014, 
23 October  2014).  
14. European Medicines Agency completes review of polymyxin- based medicines. 
Recommendations issued  for safe use in patients  with serious infections resistant  to 
standard antibiotics. European Medicines Agency 2014, London, UK 
(EMA/643444/2014, 24 October 2014). 
15. ER Squibb & Sons Limited.  Azactam  (ATM) 1g or 2g Powder for Solution for Injection 
or Infusion (vial).  United  Kingdom Summary  of Product Characteristics.  Uxbridge, UK: 
The Company, eMC  2014. Available  at http://www.medicines.org.uk/emc/medicine/549 
(last accessed: 15 August 2016). 
16. European Commission EudraLex Volume 4: EU Guidelines to Good Manufacturing Practice,  Medicinal  Products for Human  and Veterinary  Use. Annex  13: Investigational 
Medicinal Products, 03 February 2010. 
17. European Commission: Community  register  of medicinal  products for human  use. 
Product information Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion. Accessed on 24 November 2016. Available at 
http://ec.europa.eu/health/documents/community- register/html/h1109.htm.  
18. Guidance for Industry: Drug Induced Liver  Injury: Premarketing  Clinical Evaluation,  
U.S. Department  of Health  and Human  Services,  Food and Drug  Administration,  Center 
for Drug Evaluation and Research (CDER), July 2009. 
19. Guidance for Industry: Hospital- Acquired  Bacterial  Pneumonia and 
Ventilator -Associated Bacterial Pneumonia: Developing Drugs for Treatment, U.S. 
Department  of Health  and Human  Services,  Food and Drug  Administration,  Center  for 
Drug Evaluation and Research (CDER), May 2014, Revision 2. 
20. Guidance for Industry: Complicated  Intra -Abdominal Infections: Developing Drugs for 
Treatment, U.S. Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research (CDER), February 2015. 
21. Guidance for Industry: Antibacterial Therapies for Patients With an Unmet Medical Need  for the Treatment  of Serious Bacterial  Diseases,  U.S. Department  of Health  and 
Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), August 2017. 
22. Highlights of prescribing information. U.S. Department  of Health  and Human  Services, 
Food and Drug Administration, January 2017. Available at 
https://www.allergan.com/assets/pdf/avy caz_pi (last accessed: 29 March 2017).  
23. Antibiotic  Guidelines 2015-2016, treatment  Recommendations  for Adult Inpatients. 
Available at:  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  136  
 http://www.hopkinsmedicine.org/amp/guidelines/Antibiotic_guidelines.pdf  (last 
accessed: 24 March 2017). 
24. Management of Adults With Hospital-acquired and Ventilator- associated Pneumonia: 
2016 Clinical Practice Guidelines by the Infectious  Diseases  Society  of America and the 
American Thoracic Society. Accessed 02 September 2016. Available at 
http://www.idsociety.org/Guidelines/Patient_Care/IDSA_Practice_Guidelines/Infection  
s_by_Organ_System/Lower/Upper_Respiratory/Hospital - 
Acquired_Pneumonia_(HAP)/.  
25. See http://www.imi.europa.eu/  (last accessed:  20 March  2017).  
26. Innovative Medicines  Initiative  ND4BB  Topic 5: Clinical development of antibacterial 
agents for Gram -negative antibiotic resistant pathogens. 
http://www.imi.europa.eu/webfm_send/913 (last accessed: 15 August 2016). 
27. Jaruratanasirikul  S, Sriwiriyajan  S, Punyo J. Comparison of the Pharmacodynamics  of 
Meropenem in Patients with Ventilator -Associated Pneumonia following 
Administration by 3-Hour Infusion or Bolus Injection. Antimicrobial Agents and Chemotherapy Apr. 2005: 1337-1339. 
28. Jaruratanasirikul S, Limapichat T, Jullangkoon M, Aeinlang N, Ingviya N, Wongpoowarak W. Pharmacodynamics  of meropenem  in critically  ill patients  with 
febrile neutropenia and bacteraemia. Int J Antimicrob Agents. 2011;38:231-236. 
29. Johnson AP,  Woodford N. Global spread  of antibiotic  resistance:  the example of New 
Delhi  metallo -β-lactamase (NDM) -mediated  carbapenem  resistance.  J Med Microbiol 
2013, 62 (Pt4): 499–513. 
30. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator- associated Pneumonia: 
2016 Clinical Practice Guidelines by the Infectious  Diseases  Society  of America  and the 
American Thoracic Society. Clin Infect Dis. 2016;63:e61-e111. 
31. Knaus WA,  Draper  EA, Wagner  DP, Zimmerman  JE. APACHE  II: a severity  of disease 
classification system. Crit Care Med 1985 Oct;13(10):818-29. 
32. Keel RA, Sutherland CA, Crandon JL, Nicolau DP. Stability of doripenem, imipenem and meropenem  at elevated  room temperatures.  Letters  to the editor, Int J Antimicrobial 
Agents 2011, 37: 174-85. 
33. Lascols  C, Hackel  M, Marshall  SH, Hujer  AM, Bouchillon S, Badal  R, et al. Increasing 
prevalence and dissemination of NDM -1 metallo -β-lactamase in India: data from the 
SMART study (2009). J Antimicrob Chemo 2011;66(9):1992-7. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  137  
 34. Li C, Kuti JL, Nightingale CH, Nicolau  DP. Population Pharmacokinetic  Analysis and 
Dosing Regimen Optimization of Meropenem in Adult Patients. J Clin Pharmacol 
2006;46:1171- 78. 
35. Lucasti  C, Popescu  I, Ramesh  MK, Lipka J, Sable  C. Comparative study of the efficacy 
and safety of ceftazidime/avibactam plus Metronidazole versus meropenem in the treatment of complicated intra -abdominal infections in hospitalized adults: results of a 
randomized, double-blind, Phase II  trial. J Antimicrob Chemother 2013;68(5):1183-92. 
36. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CC, et al. Multidrug resistant, extensively drug-resistant and pandrug- resistant bacteria: an 
international expert  proposal for interim standard  definitions for acquired  resistance. 
Clin Microbiol Infect 2012; 18: 268–281. 
37. Mattie  H. Clinical pharmacokinetics of aztreonam.  An update. Clin Pharmacokinet. 
1994; 26(2): 99-106. 
38. MERREM  (US prescribing information). Wilmington,  Delaware:  AstraZeneca 
Pharmaceuticals LP; 2016. 
39. MERONEM  IV 1g UK Summary  of Product Characteristics;  Pfizer  Ltd.; Available 
from https://www.medicines.org.uk/emc/product/9834/smpc  
40. Moellering  RC. NDM -1 — A Cause for Worldwide Concern. N Engl J Med 2010; 363 
(25):2377- 2379.  
41. Miettinen  O, Nurminen M. Comparative Analysis of Two Rates.  Statistics  in Medicine 
1985: 213-226. 
42. Morrill  HJ, Pogue JM, Kaye KS, LaPlante KL. Treatment  Options for Carbapenem 
Resistant Enterobacteriaceae Infections. Open Forum Infect Dis. 2015;2:1-15. 
43. Mouloudi E, Protonotariou E, Zagorianou A, Josifidis E, Karapanagiotou A, Giasnetsova T, et al. Bloodstream infections cause by metallo -β-lactamases/Klebsiella 
pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010;31(12):1250-6. 
44. Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of Clinical Microbiology. Washington DC; American  Society  for Microbiology; 2007 
(Available upon request). 
45. Narayanan N, Johnson L, MacDougall C. Beyond Susceptible and Resistant, Part III: Treatment  of Infections  due to Gram -Negative Organisms  Producing Carbapenemases. 
J Pediatr Pharmacol Ther. 2016;21:110-119. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  138  
 46. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, et al. Framework for 
optimisation  of the clinical use of colistin  and polymyxin B: the Prato  polymyxin 
consensus. Lancet Infect Dis. 2015 Feb;15:225-34. 
47. Nordmann P, Poirel  L. Strategies  for identification  of carbapenemases -producing 
Enterobacteriaceae. J. Antimicrob Chemother. 2013;68 (3):487-489. 
48. Payen D, De Pont AC, SakrY, Spies C, Reinhart K, Vincent JL A Positive Fluid Balance is Associated  With  a Worse Outcome in Patients  With  Acute  Renal  Failure. 
Critical Care 2008; 12:R74. 
49. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem  dosing in critically  ill patients  with sepsis and without renal  dysfunction: 
intermittent bolus versus continuous administration?  Monte Carlo  dosing simulations 
and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142–150. 
50. Solomkin JS, Mazuski  JE, Bradley  JS; Rodvold KA, Goldstein  EJC,  Baron  EJ, et al. 
Diagnosis and Management  of Complicated  Intra-abdominal Infection in Adults and 
Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clinical Infectious Diseases 2010;50:133–64. 
51. Tängdén T, Giske CG. Global dissemination of extensively drug- resistant 
carbapenemase-producing Enterobacteriaceae:  clinical  perspectives  on detection, 
treatment and infection control. J Intern Med. 2015;277:501-512. 
52. Tarral  A, Merdjan  H. Effect  of Age and Sex on the Pharmacokinetics  and Safety  of 
Avibactam in Healthy Volunteers. Clin Ther. 2015; 37:877-886. 
53. Tsala M, Vourli S, Kotsakis S, Daikos GL, Tzouvelekis L, Zerva L, et al. Pharmacokinetic-pharmacodynamic modelling  of meropenem  against  VIM -producing 
Klebsiella pneumoniae isolates: clinical implications. J Med Microbiol.  
2016;65:211 -218. 
54. Vinks AA, van Rossem  RN,  Mathôt RA, Heijerman  HG, Mouton JW. Pharmacokinetics 
of aztreonam in healthy  subjects and patients with cystic fibrosis and evaluation of dose 
exposure relationships using monte carlo simulation. Antimicrob Agents Chemother. 2007 Sep; 51(9): 3049-55. 
55. Walsh  TR, Weeks  J, Livermore  SM, Toleman  MA. Dissemination  of NDM -1 positive 
bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11(5):355-62. 
56. Aztreonam  2 g for injection  (USP).  Fresenius  Kabi  USA,  LLC;  Lake Zurich  IL 60047, 
USA  
57. Metronidazole 500 mg/ 100 mL;  BAXTER HEALTHCARE  (SHANGHAI)  CO., LTD;  
No. 388, Tingzhu Road, Jinshan District, Shanghai 201506, CHINA  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  139  
 58. Metronidazole 500 mg/ 100 mL; Hospira, Inc, Lake Forest,  IL 60045, USA 
59. Colistimethate  sodium (equivalent to 150 mg colistin  base activity  per vial) (USP); 
Fresenius Kabi USA, LLC; Lake Zurich IL 60047, USA 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  140  
 Appendix  1. Abbreviations  
This following is  a list of abbreviations that may  be used in the protocol.  
 
 
Abbreviation or 
special term  Explanation  
 
A-aDO 2 Alveolo- arterial  oxygen difference  
ABG Arterial  blood gas 
ADR  Adverse drug reaction  
AE Adverse event  
ALP Alkaline  phosphatase  
ALT  Alanine aminotransferase  
AmpC  A Class  C β-lactamase (Amp=ampicillinase)  
APACHE  Acute Physiology and Chronic Health Evaluation  
APS Acute Physiology Score  
AST Aspartate aminotransferase  
ATM  Aztreonam  
ATM -AVI Aztreonam -avibactam  
ATM -AVI±MTZ  Aztreonam -avibactam±metronidazole  
AUC  Area under the plasma concentration  versus time curve  
AUC (0-24,ss)  Steady  state area under the curve between  time zero and 24 hours 
after dose  
AVI Avibactam  
BAL  Bronchoalveolar lavage  
BP Blood pressure  
BPM  Beats  per minute  
β-hCG β-human chorionic gonadotropin  
CAZ  Ceftazidime  
CAZ -AVI Ceftazidime -avibactam  
CBA  Colistin base activity  
CE Clinically  evaluable  
CHE  Chronic Health Evaluation  
cIAI Complicated  intra -abdominal infection  
CI Confidence interval  
CIOMS  Council for International  Organizations of Medical  Sciences  
CK Creatine Kinase  
CLSI  Clinical Laboratory Standards  Institute  
Cmax Maximum plasma concentration  
COL  Colistin (colistimethate sodium) 
COMBACTE -CARE  Combatting  Bacterial  Resistance in Europe – 
Carbapenem -res istance  
A consortium which  consists of 19 academic  and 3 pharmaceutical 
partners focusing on carbapenem resistance in Europe 
CrCL  Creatinine  clearance  
CRE  Carbapenem -resistant  Enterobacteriaceae  
CRF Case Report Form  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  141  
 Abbreviation or 
special term  Explanation  
 
CRO  Contract Research Organization  
CSA  Clinical Study  Agreement  
CLSI  Clinical and Laboratory Standards Institute  
CSP Clinical Study  Protocol  
CSR Clinical Study  Report  
CT Threshold concentration  
CT Clinical Trial  
CTA  Clinical trial application  
CT scan Computerized tomography scan 
CTX  Cefotaximase  
CTX -M A type of Class  A β-lactamase (CTX=cefotaximase)  
CV Cardiovascular  
CYP  Cytochrome P 450 
DBP  Diastolic  blood pressure  
DDI Drug -drug interaction  
DGR  Dangerous Goods Regulations  
DILI Drug  Induced Liver Injury 
EC Ethics  Committee,  synonymous to Institutional Review  Board 
(IRB) and Independent Ethics Committee (IEC) 
ECG  Electrocardiogram  
EDC  Electronic  data capture  
E-DMC  External data monitoring committee  
EDP Exposure during pregnancy  
EFPIA  European Federation  of Pharmaceutical  Industries and 
Associations  
EMA  European Medicines  Agency  
ELD  Extended loading dose 
EOT  End of treatment  
ESBL  Extended-spectrum β-lactamase  
ESRD  End-stage renal  disease  
EU European Union  
EudraCT  European Clinical Trials  Database  
FDA  Food and Drug Administration  
FiO 2 Fraction  of inspired oxygen  
FSH Follicle  stimulating hormone  
GCP  Good Clinical Practice  
GCS  Glasgow Coma Scale  
GGT  Gamma -glutamyl Transferase  
GMP  Good Manufacturing Practice  
HAP  Hospital- Acquired  Pneumonia  
HCO 3 Hydrogencarbonate or bicarbonate  
HIV Hu man immunodeficiency virus  
HL Hy’s  Law 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  142  
 Abbreviation or 
special term  Explanation  
 
IATA  International Airline Transportation Association  
IB Investigator’s Brochure  
IC50  Half maximal inhibitory  concentration  
ICF Informed  Consent Form  
ICH International Conference on Harmonization  
ICU Intensive care unit 
ID Identifier  
IMI Innovative Medicines  Initiative  
IND Investigational new drug 
INR International normalized ratio 
International 
Co-ordinating 
Investigator  If a study is conducted in several countries the International Co-ordinating Investigator is the Investigator co-ordinating the 
investigators and/or activities internationally.  
IP Investigational Product  
IRB Institutional Review  Board  
ITT Intent -To-Treat  
IU International units  
IUD Intrauterine device  
IV Intravenous(ly)  
IRT Interactive  response technology  
KPC  Klebsiella pneumoniae carbapenemase  
LD Loading dose 
LDH Lactate dehydrogenase  
LFT Liver  Function Test 
LFU Late Follow- up 
LH Luteinizing  hormone  
LPF Low Power  Field  
LSLV  Last Subject Last Visit  
MAP  Mean  arterial  pressure  
MBL  Metallo -β-lactamase  
MDR  Multidrug resistant  
ME Microbiologically  Evaluable  
MedDRA  Medical Dictionary  for Regulatory Activities  
MER  Meropenem  
MER  ±COL  Meropenem  ±colistin  
MIC Minimum inhibitory  concentration  
MITT  Modified Intent -To-Treat  
Micro -ITT Microbiological  Intent -To-Treat  
Micro -MITT  Microbiological modified  Intent- To-Treat 
MTZ  Metronidazole  
N/A Not applicable  
NDM  New  Delhi  Metallo -β-lactamase  
NONMEM  Nonl
 inear Mixed  Effects  Modelling  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  143  
 Abbreviation or 
special term  Explanation  
 
NP Nosocomial pneumonia  
O2 Oxygen  
OAT  Organic anion transporter  
OXA A type of Class  D β-lactamase (OXA=oxacillinase)  
PACL  Protocol Administrative  Change Letter  
PaCO 2 Partial  pressure  of carbon dioxide in arterial  blood  
PaO 2 Partial  pressure  of oxygen in arterial  blood  
PCD  Primary  completion date  
PD Pharmacodynamic  
PHL Potential Hy’s  Law 
PHT Pulmonary hypertension  
PI Principal  investigator  
PK Pharmacokinetic  
pO2 Partial  pressure of oxygen  
popPK  Population pharmacokinetic  
PSB Protected -specimen  brush 
PT Prothrombin Time  
PTA Probability  of target attainment  
q6h Every  6 hours  
q8h Every  8 hours  
SAC  Scientific Advisory  Committee  
SAE Serious adverse event  
SAP Statistical Analysis Plan 
SBP Systolic  blood pressure  
SD Standard  deviation  
SmPC  Summary  of Product Characteristics  
SOA Schedule of Activities  
SOAP  Sepsis  Occurrence in  Acutely  Ill Patients  
SRSD  Single Reference Safety  Document  
TBili Total bilirubin  
TCS Tata Consultancy  Services  
TEAE  Treatment -emergent  adverse event  
TOC  Test of Cure  
UK United  Kingdom  
ULN Upper limit of normal  
UN United  Nations  
US United  States  
VAP  Ventilator -associated  pneumonia  
VIM  Verona Integron encoded  metallo -β-lactamase  
WBC  Whi te blood cells  
WHO  World Health Organization  
WHOdrug  World  Health Organization drug dictionary  
WP2b  Work  package 2b 
 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  144  
  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  145  
 Appendix  2. International Airline  Transportation Association (IATA)  6.2 Guidance 
Document  
Labelling  and shipment  of biohazard samples  
The IATA classifies biohazardous agents into 3 categories. For transport purposes the 
classification of infectious substances according to risk groups was removed from the Dangerous Goods Regulations (DGR) in the 46
th edition (2005). Infectious substances are 
now classified  either  as Category  A, Category  B or Exempt. There  is no direct  relationship 
between Risk Groups and categories A and B. 
Category A Infectious  Substances  are infectious substances  in a form  that, when  exposure 
to it occurs, is capable of causing permanent disability, life -threatening or fatal disease in 
otherwise healthy humans or animals. Category A pathogens are eg, Ebola, Lassa fever 
virus:  
• are to be packed and  shipped in accordance with  IATA  Instruction 602.  
Category B Infectious  Substances  are infectious substances  that do not meet  the criteria  for 
inclusion in Category A. Category B pathogens are eg, Hepatitis A, B, C, D, and E viruses, 
Human immunodeficiency virus (HIV) types 1 and 2. They are assigned the following United Nation (UN) number and proper shipping name: 
• UN 3373 – Biological Substance,  Category  B; 
• are to be packed  in accordance with UN3373 and IATA  650. 
Exempt  - all other materials  with minimal risk of containing pathogens:  
• Clinical study  samples  will fall into Category B or exempt under IATA regulations;  
• Clinical study samples  will routinely be packed  and transported at ambient 
temperature in IATA 650 compliant packaging; 
• Biological samples  transported in dry ice require additional dangerous goods 
specification for the dry -ice content;  
• IATA  compliant courier  and packaging materials  should be used for packing  and 
transportation and packing should be done by an IATA certified person, as applicable;  
• Samples routinely transported by road or rail are subject to local regulations which require that they are also packed and transported in a safe and appropriate way to contain any risk of infection or contamination by using approved couriers and packaging/containment materials at all times.  The IATA 650 biological sample 
containment standards are encouraged  wherever  possible when  road or rail transport 
is used. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  146  
 Appendix  3. Calculation  of Estimated  Creatinine Clearance 
Calculation of the estimated creatinine clearance 
Estimated CrCL will be calculated using the following Cockcroft- Gault formula ( Cockcroft 
and Gault 1976).  The weight obtained at Screening1 should be used to qualify for entry  into 
the study. In order to determine the need to adjust the dose and/or dosing interval of IV 
study treatment to be administered, the subject’s estimated CrCL must be calculated using the most recent  serum  creatinine  value that was obtained at the local  laboratory, the subject’s 
most recent actual (not ideal) body weight, and the Cockcroft- Gault formula.  
Cockcroft- Gault  formula:  
Estimated  CrCL  is calculated by  Cockcroft -Gault as follows:  
For serum creatinine in mg/dL:  
estimated  CrCL  = [(140  – age) × weight in kilograms]/[72 × serum  creatinine  in mg/dL] 
[× 0.85 if female]  
For serum  creatinine  in μmol/L: 
estimated  CrCL  = [(140  – age)  × weight in  kilograms × constant]/[serum creatinine in  
µmol/L]  
where  constant = 1.23 for males  and 1.04 for females  
 
   
 
    
 
     
 
  
 
 
1 For the purpose  of assessing  eligibility,  a patient's  weight  obtained  during  the current  hospitalization  may be 
used if the patient's clinical condition at the time of screening does not allow  this assesment to be performed.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  147  
 Appendix  4. Actions Required  in Cases  of Increases  in Liver Biochemistry  and 
Evaluation of Hy’s Law 
1. Introduction  
This Appendix describes the process to be followed in order to identify and appropriately 
report cases of HL.  It is not intended to be a comprehensive guide to the management of 
elevated  liver biochemistries.  Specific guidance on the managing liver abnormalities  can be 
found in Section 8.5.2 of the protocol. 
During the course of the study the Investigator will remain vigilant for increases in liver 
biochemistry. The Investigator is responsible for determining  whether a subject  meets  PHL 
criteria at any point during the study. 
The Investigator participates, together with the Pfizer Medical Monitor, in review and 
assessment  of cases  meeting  PHL  criteria  to agree whether  HL criteria  are met.  HL criteria 
are met if there is no alternative explanation for the elevations in liver biochemistry other than DILI caused by the IP. 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting AE and SAE  according to the outcome of the review  and assessment  in line with 
standard safety reporting processes. 
2. Definitions  
Potential  Hy’s  Law (PHL) 
• Subjects  with AST/ALT  and TBili baseline values  within  the normal range who 
subsequently present with AST OR ALT values >3 
× ULN AND a TBili value  
>2 × ULN with  no evidence of hemolysis and an alkaline phosphatase value  
<2 × ULN or not available;  
• For subjects with baseline AST OR ALT OR TBili values above the ULN, the 
following threshold values  are used in the definition mentioned above,  as needed, 
depending on which values are above the ULN at baseline: 
• Preexisting  AST  or ALT  baseline values  above the normal range:  AST  or 
ALT values >2 times the baseline values AND >3 × ULN; or >8 × ULN 
(whichever is smaller).  
• Preexisting  values  of TBili  above the normal range: TBili level  increased  from 
baseline value by an amount of at least 1 × ULN or if the value reaches  
>3 × ULN (whichever  is smaller).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  148  
 Hy’s Law (HL)  
The case with laboratory  abnormalities  defined  in Potential Hy’s  Law (PHL) as above, where 
no other reason, other than the IP, can be found to explain the combination of increases, 
eg, elevated  ALP  indicating  cholestasis,  viral  hepatitis,  another drug. 
For PHL  and HL the elevation  in transaminases  must precede or be coincident  with (ie, on 
the same day) the elevation in TBili, but there is no specified timeframe within which the elevations in transaminases and TBili must occur.  
A PHL  case becomes  a confirmed  HL case only after all results  of reasonable investigations 
have been received and have excluded an alternative etiology. 
3. Identification  of Potential  Hy’s  Law Cases  
In order to identify cases of PHL  it is important to perform a comprehensive review of 
laboratory data for any subject  who  meets  any of the following identification  criteria  in 
isolation or in combination: 
• ALT  >3 x ULN;  
• AST  >3 x ULN;  
• TBili > 2 x ULN.  
A central  laboratory  will be used. When  a subject meets  any of the identification  criteria,  in 
isolation or in combination, the central laboratory will immediately send an alert to the 
Investigator (also sent to the Pfizer Medical Monitor).  
The Investigator will also remain  vigilant for any local  laboratory reports  where the 
identification criteria are met where this is the case the Investigator will:  
• Notify  the Pfizer Medical Monitor;  
• Request a repeat of the test (new blood draw) by the central laboratory;  
• Complete  the appropriate unscheduled laboratory  CRF  module(s) with the original 
local laboratory test result.  
When  the identification  criteria  are met from  central  or local  laboratory results  the 
Investigator will without delay: 
• Determine  whether the subject  meets  PHL  criteria  (see 2. Definitions  within  this 
Appendix for definition) by reviewing  laboratory reports  from  all previous visits 
(including both central and local laboratory results). 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  149  
 Sites  will also use local  laboratories.  The Investigator will promptly review  each new 
laboratory report and if the identification criteria are met the investigator will:  
• Notify  the Pfizer Medical Monitor;  
• Determine whether the subject meets PHL criteria (see 2. Definitions within this 
Appendix for definition) by reviewing  laboratory reports from  all previous visits;  
• Promptly  enter  the laboratory data into the laboratory CRF.  
4. Follow -up 
4.1 Potential  Hy’s  Law Criteria  not met 
If the subject does not meet PHL criteria the Investigator will: 
• Inform  the Pfizer Medical Monitor that the  subject has not met PHL criteria; 
• Perform  follow-up on subsequent laboratory results  according  to the guidance 
provided in the CSP. 
4.2 Potential  Hy’s  Law Criteria  met 
If the subject  does meet  PHL  criteria  the Investigator will: 
• Determine  whether PHL  criteria  were  met at any study visit prior to starting  study 
treatment  (See 6 Actions  Required  When  Potential Hy’s  Law Criteria  are Met 
Before and After Starting Study Treatment ); 
• Notify  the Pfizer Medical Monitor who will then inform the central Study Team.  
The Pfizer  Medical  Monitor contacts  the Investigator, to provide guidance, discuss and agree 
an approach  for the study subjects’  follow-up and the continuous review  of data.  Subsequent 
to this contact the Investigator will: 
• Monitor the subject  until liver biochemistry  parameters  and appropriate clinical 
symptoms and signs return  to normal or baseline levels,  or as long as medically 
indicated;  
• Investigate  the etiology of the event  and perform  diagnostic investigations as 
discussed with the Pfizer Medical Monitor; 
• Complete  the relevant  CRF  modules as information  becomes  available;  
• If  at any time (in consultation with the Pfizer  Medical  Monitor) the PHL  case meets 
serious criteria, report it as an SAE using standard reporting procedures. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  150  
 5. Review  and Assessment  of Potential Hy’s  Law Cases  
The instructions in this Section  should be followed for all cases  where PHL  criteria  are met.  
No later than 3 weeks after the biochemistry abnormality was initially detected, the Pfizer 
Medical Monitor contacts the Investigator in order to review available data and agree on whether  there is an alternative  explanation for meeting  PHL  criteria  other than DILI  caused 
by the IP. The Pfizer Safety Risk Lead will also be involved in this review together with other subject matter experts as appropriate.  
According to the outcome of the review  and assessment,  the Investigator will follow the 
instructions below. 
If there is an agreed alternative explanation for the ALT or AST and TBili elevations, a 
determination  of whether  the alternative  explanation  is an AE will be made  and subsequently 
whether the AE meets the criteria for a SAE:  
• If the alternative  explanation is not an AE, record  the alternative  explanation  on the 
appropriate CRF; 
• If the alternative  explanation is an AE/SAE,  record  the AE /SAE  in the CRF 
accordingly and follow the Pfizer standard processes. 
If it is agreed  that there is no explanation that would explain  the ALT  or AST  and TBili 
elevations other than the IP: 
• Report an SAE  (report  term ‘Hy’s  Law’)  according  to Pfizer  standard  processes:  
• The ‘Medically  Important’  serious criterion  should be used if no other  serious 
criteria apply;  
• As there is no alternative  explanation for the HL case,  a causality  assessment  of 
‘related’ should be assigned. 
If, there is an unavoidable delay,  of over 3 weeks,  in obtaining the information necessary  to 
assess whether or not the case meets the criteria for HL, then it is assumed that there is no alternative explanation until such time as an informed decision can be made:  
• Report an SAE  (report  term ‘Potential Hy’s  Law’)  applying serious criteria  and 
causality assessment as per above;  
• C
ontinue follow-up and review according to agreed plan. Once the necessary 
supplementary information is obtained, repeat the review and assessment to determine whether HL criteria are met.  Update the SAE report according to the 
outcome of the review  amending the reported  term if an alternative  explanation  for 
the liver biochemistry elevations is determined.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  151  
 6. Actions  Required  When Potential  Hy’s  Law Criteria  are Met Before  and After 
Starting Study Treatment  
This section  is applicable to subjects  who meet  PHL  criteria  on study treatment  having 
previously met PHL criteria at a study visit prior to starting study treatment.  
At the first  on study treatment  occurrence of PHL  criteria  being  met the Investigator will: 
• Determine  if there has been  a significant change in the subjects’  condition# compared 
with the last visit where PHL criteria were met#: 
• If there is  no significant change no action  is required;  
• If there is a significant change notify the Pfizer  Medical  Monitor, who will inform 
the central Study Team, then follow the subsequent process described 
4.2 Potential  Hy’s  Law Criteria  met of this Appendix.  
# A ‘significant’ change in the subject’s condition refers to a clinically relevant change in any of the individual 
liver biochemistry parameters (ALT, AST or TBili) in isolation or in combination, or a clinically relevant 
change  in associated  symptoms.  The determination  of whether  there  has been  a significant change  will be at the 
discretion of the Investigator; this may be in consultation with the Pfizer Medical Monitor if there is any 
uncertainty.  
 
7. Actions  Required  for Repeat  Episodes  of Potential  Hy’s  Law 
This section  is applicable  when  a subject  meets  PHL  criteria on study treatment and has 
already met PHL criteria at a previous on study treatment visit.  
The requirement  to conduct follow-up, review  and assessment  of a repeat  occurrence(s)  of 
PHL  is based on the nature of the alternative cause identified for the previous occurrence.  
The Investigator should determine  the cause for the previous occurrence of PHL  criteria 
being met and answer the following question: 
• Was the alternative cause for the previous occurrence of PHL criteria being met  
found to be the disease under study, eg, chronic or progressing malignant disease, 
severe infection  or liver disease,  or did the subject  meet  PHL  criteria  prior to starting 
study treatment and at their first on study treatment visit as described in 6 Actions Required When Potential Hy’s Law Criteria are Met Before and After Starting Study Treatment ? 
If No
:  follow the process  described  in 4.2 Potential  Hy’s  Law Criteria  met of this 
Appendix  
If Yes: 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  152  
 Determine  if there has been  a significant change in the subject’s  condition# compared  with 
when PHL criteria were previously met: 
• If there is  no significant change no action  is required;  
• If there is a significant change follow the process  described  in 4.2 Potential  Hy’s 
Law Criteria met of this Appendix.  
# A ‘significant’ change in the subject’s condition refers to a clinically relevant change in any of the individual 
liver biochemistry parameters (ALT, AST or TBili) in isolation or in combination, or a clinically relevant 
change  in associated  symptoms.  The determination  of whether  there  has been  a significant change  will be at the 
discretion of the Investigator; this may be in consultation with the Pfizer Medical Monitor if there is any uncertainty.  
 
References  
FDA  2009  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  153  
 Appendix  5. Acute Physiology and Chronic  Health  Evaluation - APACHE  II Score 
APACHE II Classification System  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  154  
  
APACHE  II Score  Form 
(Knaus et al 1985)31 
Subject ID #   D ate of Assessment   
 
 
PHYSIOLOGIC 
VARIABLE  HIGH ABNORMAL  RANGE  LOW  ABNORMAL  RANGE  
(Check  one range  per variable and write  the severity  score  in the column  to the right  
+4 +3 +2 +1 0 +1 +2 +3 +4 Severity 
Score  
1. Temperature – Rectal  (°C) 
(add 0.5oC to oral temp,  1.0oC to axillary  
temp)   
≥41  
39–40.9   
38.5– 38.9  
36–38.4  
34–35.9  
32–33.9  
30–31.9  
≤29.9  
2. Mean  arterial  pressure 
(mm Hg)  ≥160 130– 159 110– 129  
70–109  
50–69  
≤49  
3. Heart  rate (ventricular 
response) (bpm)  ≥180 140– 179 110– 139  
70–109  
55–69 40–54 ≤39  
4. Respiratory rate 
(non-ventilated  or ventilated) 
(breaths per minute)   
≥50  
35–49   
25–34  
12–24  
10–11  
6–9   
≤5  
5. Oxygenation  
A-aDO 2 or PaO 2 (mm  Hg) 
a) FiO 2 ≥0.5:record  A-aDO 2  
≥500  
350– 499  
200– 349   
<200      
b) FiO 2 <0.5:record  only PaO 2     >70 61–70  55–60 <55  
6. Arterial  pH* – If no ABGs 
record  Serum  HCO 3 below  ≥7.7 7.6–7.69  
7.5–7.59 7.33– 7.49  
7.25– 7.32 7.15– 7.24 <7.15   
7. Serum  Sodium (mmol/L)  ≥180 160– 179 155– 159 150– 154 130– 149  120– 129 111– 119 ≤110  
8. Serum  Potassium  (mmol/L)  ≥7 6–6.9  5.5–5.9 3.5–5.4 3–3.4 2.5–2.9  <2.5  
9. Serum  Creatinine (mg/dL)  
(Double points  for acute renal  failure)  ≥3.5 2–3.4 1.5–1.9  0.6–1.4  <0.6    
10. Hematocrit  (%) ≥60  50–59.9 46–49.9 30–45.9  20–29.9  <20  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  155  
  
 
PHYSIOLOGIC 
VARIABLE  HIGH ABNORMAL  RANGE  LOW  ABNORMAL  RANGE  
(Check  one range  per variable and write  the severity  score  in the column  to the right  
+4 +3 +2 +1 0 +1 +2 +3 +4 Severity 
Score  
11. White Blood Count 
(total/mm3) (in 1000s)  ≥40  
20–39.9 15–19.9 3–14.9  
1–2.9  
<1  
12. Glasgow Coma Scale 
(Score = 15 minus  actual 
GCS)  (Best GCS in the 24 hours prior to screening)  (15 – GCS 
total)  
Eye Verbal  Motor  GCS total = (Eye + Verbal + Motor)  
A. Total  Acute  Physiology Score 
(APS)  Total  severity points  indicated for  in the  column to the right  
*Serum  HCO 3 (venous -mmol/L) 
Not preferred, use if no ABGs ≥52 41–51.9  
32–40.9 22–31.9  
18–21.9 15–17.9 <15  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  156  
 
 
APACHE  II Score Form  continued 
 
 
 
Abbreviations:  A-aDO 2 = alveolo -arterial  oxygen difference;  ABG  = arterial  blood gas; APS = Acute  Physiology Score;  CHE  = Chronic  Health  Evaluation;  CV 
= cardiovascular;  FiO 2 = fraction  of inspired  oxygen;  GCS  = Glasgow Coma  Scale;  HCO 3 = hydrogencarbonate  or bicarbonate;  PaO 2 = partial pressure  of 
oxygen in arterial blood; PHT = pulmonary hypertension.  
 
APACHE  II Score Worksheet  provided to be used to calculate  the APACHE  II score.  
• Abstract  data from  the 24 hour interval  prior to screening  or during screening. 
• Enter  the value for each line item.  Calculate APACHE  II score using most recent  local  laboratory results. 
APACHE II Worksheet instruction 
A - Physiological components  
• Document one score for each  of the physiological variables.  Then  calculate and document the total Acute Physiological Score 
(APS).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  157  
  
• The following will be accepted  as core temperatures:  rectal,  esophageal, bladder, tympanic, or central.  If the only temperature 
data available is from the oral or axillary routes, convert the temperature to an APACHE II core value using the following 
conversion factors: 
• Actual  oral temperature (°C)  + 0.5°C=  Rectal  (core)  temperature;  
• Actual axillary  temperature (°C) + 1.0°C = Rectal (core) temperature.  
• For the MAP  value,  use arterial  line data if available,  otherwise calculate the MAP  from  the cuff pressure using the following 
formula:  
MAP = 1/3 (SBP – diastolic blood pressure [DBP]) + DBP 
(Example:  BP 90/60, MAP  = 1/3 (90 - 60) + 60 = 10 + 60 = 70) 
Note:  If a DBP was  not obtained, do not calculate a MAP, record  “not done”.  
• Oxygenation  
• in case the FiO 2 is >50%, calculate the alveolo -arterial  oxygen difference (A-aDO 2) using the following formula,  use 
ABGs results:  
A-aDO 2=[(FiO 2 (713)- (partial  pressure of carbondioxide (PaCO 2)/0.8)] - PaO 2 
(Example: FiO 2=0.6; PaO 2=56; and PaCO 2=26 
(0.6 x 713) minus (26 : 0.8) minus 56 
427 - 32.5 = 395.3 - 56 = 339.3 = A- aDO 2 (mm  Hg) 
To calculate use FiO 2 (in decimal),  PaCO 2 (mm  Hg) and PaO 2 (mm  Hg). 
• If the FiO 2 is <50%, record  the lowest  PaO 2. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  158  
  
• In case there is no ABG available  assume  normal oxygenation (Variable score = 0). 
• Serum creatinine (μmol/L): double point score for acute renal failure. Creatinine conversion from μmol/L  to mg/dL to be: 
88.4 µ mol/L=  1 mg/dL.  
• WBC  Count. Record  WBCs  in 1000s (eg, a WBC  count of 30000 cells/mm3  would be recorded  as 30). 
• Arterial  PH should be substituted  by serum  bicarbonate (HCO3)  if there are no ABGs  available in the previous 24 hours. 
B – Age Points 
• Circle  the appropriate point for the subjects  age range. 
C - Chronic Health Points 
If the subject has a history of severe organ system insufficiency or is immunocompromised assign chronic health points as follows: 
• For nonoperative or emergency postoperative subjects: 5;  
• For elective  postoperative patients: 2; 
• Subject  does NOT  have a history of severe organ system  insufficiency  and is NOT  immunocompromised: 0. 
They will receive the points only once (which means even if they have 2 criteria, the maximum is either 2 or 5). 
GLASGOW COMA SCALE  
For the Glasgow Coma Scale (GCS)  score,  determine the lowest  (worst) number for each  of the three  factors  in the scale (eye opening, 
verbal response, and motor response). Add together these 3 numbers, and then subtract this number from 15 to get the final GCS 
score.  The subject's neurological status during a single neurological assessment should be evaluated. 
Since it is not possible to assess the GCS in subjects who are sedated and paralyzed, by convention the GCS is regarded as no rmal, 
unless it is known that there was a brain  injury prior to sedation. In that case the last measured  GCS  is to be used; if there  is no brain 
injury prior to sedation the GCS is 15, thus the neurologic score will be 0. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  159  
 Appendix  6. Microbiological Assessments  
All microbiological assessments will be initiated at the local laboratory for specimen 
collection,  shipment of isolates,  and analysis  of isolates  according  to the sections below and 
as outlined in more detail in the microbiology laboratory manual. All microbiological 
isolates (except anaerobic bacterial pathogens isolated from subjects with respiratory infections) must be shipped to the central reference laboratory for confirmation of microbiological assessments.  An unstained Gram- stain slide of each respiratory specimen 
from induced sputum and expectorated sputums must also be sent to the central reference laboratory.  
All specimens should be processed according to recognized methods that culture for both aerobic and anaerobic organisms ( Murray et al. 2007) following the standard operating 
procedures of the clinical  microbiology laboratory at each study center.  All cultured  isolates 
should be kept by the local laboratory at –20°C or colder (preferably at -70°C) until the end of the study or when contacted by the central reference laboratory. 
1. Specimen  collection  
a. Intra -abdominal specimens: Intra -abdominal specimens  should be obtained for culture 
at initial qualifying surgical procedure (performed within 24 hours before or after 
randomization). If additional surgical procedures are performed, additional 
abdominal site specimens should be obtained for microbiological culture. An 
adequate abdominal specimen (such as tissue or aspirate suitable for isolation of both aerobic and anaerobic bacteria) should be obtained from all subjects and sent to the local laboratory for culture, identification, and in vitro susceptibility testing.  If 
treatment is discontinued early because the subject is failing therapy and the subject requires a second surgery, an appropriate specimen for culture should be obtained, ideally after stopping the initial treatment but before the new treatment is administered.  The CRF should indicate whether or not a sample was obtained. 
b. Respiratory specimens: Baseline respiratory specimens (see below) must be obtained for culture within  48 hours prior to randomization and after development of signs and 
symptoms of NP (ideally before receipt of any systemic antibiotics). An adequate 
and appropriate baseline respiratory  pecimen  should be sent to the local  laboratory  for 
Gram -stain (expectorated and induced sputum only) and culture. Isolated organisms 
need to be identified, and tested for in vitro susceptibility. 
Appropriate specimens  from  ventilated  subjects include:  
• endotracheal  aspirate;  
• BAL;  
• mini- BAL;  
• PSB sample.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  160  
 Appropriate specimens  from  non- ventilated  subjects include:  
• expectorated or induced sputum;  
• BAL;  
• mini- BAL;  
• PSB sample.  
Note that there may be non -ventilated subjects who develop HAP and subsequently 
require intubation and mechanical ventilation. If such subjects require ventilation 
prior to the first dose of study treatment, a specimen appropriate for the subject should be obtained even if the patient has already provided a sputum sample. In 
addition, subjects  undergoing bronchoscopy prior to the first dose of study treatment 
should provide a respiratory  specimen  during the procedure even  if a sputum sample 
or endotracheal aspirate has already been obtained. 
To be adequate,  respiratory  specimen  from  expectorated  or induced sputum must 
show <10 squamous epithelial cells and >25 polymorphonuclear neutrophils per Lower Power Field (LPF) upon a Gram- stain.  
When  clinically  indicated, pleural  fluid  should be sampled  for Gram - stain,  culture 
identification, in vitro susceptibility testing; isolates should be sent to the central laboratory for confirmation. Additionally, (when indicated) cell counts, pH and lactate dehydrogenase (LDH)  of pleural  fluid  as well as serum  LDH should also  be 
obtained. It is not necessary to submit a Gram-stain slide of pleural fluid to the central laboratory.  
If treatment is discontinued early because the subject is failing therapy or other reasons, an appropriate respiratory specimen for culture should be obtained, ideally after stopping the initial treatment  but before the new treatment is administered.  The 
CRF should indicate whether or not a sample was obtained. 
In some circumstances,  subjects  may have multiple  respiratory  specimens  obtained 
after the onset of signs and symptoms of pneumonia within 48 hours prior to 
randomization. The baseline respiratory culture is defined as the last respiratory culture obtained via BAL, mini-BAL or PSB prior to randomization. If BAL,  
mini- BAL  or PSB specimens  are not available,  the baseline respiratory  culture will be 
defined as the last respiratory culture obtained via endotracheal aspirate prior to randomization. If none of these are available, the baseline culture is defined as the 
last sputum culture obtained prior to randomization. In case a repeat respiratory 
specimen is obtained after randomization, but prior to the first dose of study treatment, this will be defined as baseline.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  161  
 The status  and/or results  of the baseline respiratory  culture (ie, whether  the results  are 
pending or known; pathogen(s) identification and/or the susceptibility profile of the 
identified pathogens) should be used to determine whether the protocol requirements for open- label Gram -positive or Gram- negative agents have been met as described in 
Section 5.10. Only baseline cultures should be used for determining the need for open- label agents.  
c. Blood specimen: Blood cultures should be performed prior to the first dose of study treatment  (if blood cultures  are not available within  48 hours prior to randomization) 
and thereafter as clinically indicated.  Two sets of blood should be collected 
(ie, 4 bottles)  from  2 different  sites for aerobic and  anaerobic incubation. Each  bottle 
should be inoculated with 10 to 15 mL of blood for a total of 40 to 60 mL per collection.  One set of blood cultures must be obtained through a venipuncture. 
Collect samples, ideally  over a period of 2 hours at least 10 to 20 minutes apart  from 
separate sites.  If a subject is on antibiotics, blood cultures should ideally be taken 
immediately before the next dose.  Organisms isolated from blood cultures obtained 
within 48 hours prior to randomization or at Screening/Baseline will be assigned a microbiologic response similar  to those given for pathogens isolated  from  cultures  of 
abdominal or respiratory specimens (see Table 10 for list of response categories).  
Details  concerning the collection  of blood cultures  are provided in the laboratory 
manual.  
2. Shipment of isolates  
The central reference laboratory will supply the local laboratory with all media containing transport vials and instructions for shipment of isolates to the central reference laboratory. The central reference laboratory will monitor and verify resistant isolates reported by the local  laboratory. All shipment documentation for samples  sent from  the local  laboratory to 
the central reference laboratory should be maintained and available for review by the Contract Research Organization (CRO) representative.  
3. Analysis of isolates  
The local laboratory  must identify  all aerobic bacterial pathogens to the genus and species 
level using confirmatory, not presumptive, identification methods from blood, respiratory and abdominal specimens. The disk diffusion method as established by the Clinical and Laboratory Standards Institute (CLSI) should be used to determine susceptibility for ATM -AVI and meropenem for all isolates.  Discs  with ATM -AVI and meropenem  will be 
supplied by the central reference laboratory.  Reporting of susceptibility results on 
ATM -AVI to the Principal Investigator will be detailed in the study site manual.  The 
laboratory may perform  any additional testing  on meropenem  (eg, MIC)  and any additional 
agents as they normally do to provide susceptibility results of isolated aerobic microorganisms. Disk zone size determinations for interpretation of susceptibility for all 
isolated aerobic microorganisms will be according to CLSI methodology for comparator agents.  All aerobic isolates should be sent to the central reference laboratory for 
confirmation of identification and susceptibility testing.  Characterization of β -lactamases  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  162  
 associated with the bacterial pathogens and molecular profiling (eg, pulse- field gel 
electrophoresis,  whole genome sequencing) will be performed  or coordinated by the central 
laboratory.  
All anaerobic bacterial pathogens must be identified to at least the genus level.  If the local 
laboratory cultures and performs susceptibility testing on anaerobic organisms, it should 
follow CLSI  methodologies by either  broth microdilution  (Bacteroides  fragilis  group) or agar 
dilution MIC testing for MTZ, meropenem and possible additional comparator agents. Anaerobic isolates originating from subjects with intra-abdominal infections need to be sent to the central  reference laboratory for confirmation  of identification  and susceptibility  testing. 
Anaerobic bacterial pathogens isolated from subjects with respiratory infections do not need to be sent, but must be entered into the CRF as having an anaerobe present. 
The Investigator should record information on all specimens according to the Investigator’s 
manual supplied by the central reference laboratory. The central reference laboratory will 
confirm  pathogen identifications  and susceptibility  test results  on all clinical  isolates  reported 
and shipped by the local laboratory. If discrepancies occur between the results obtained at 
the central reference laboratory and those obtained at the study site local laboratory, a CRO representative will request that a second sample of the isolate in question be shipped. In the 
instance of differences in pathogen identification or susceptibilities, the central reference laboratory results will take precedence over the local laboratory result.  If microorganisms 
that are isolated at the local laboratory do not survive shipping to the central reference laboratory, a CRO representative will request that a second sample of the isolate in question be shipped. Local laboratory results may be used if a microorganism does not survive shipping or is not recoverable from the local laboratory. 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  163  
 Appendix 7.  Colistin Conversion Table  
 
Olistimethate Sodium  Colistimethate Sodium  Colistin -base Activity  
(IU) (mg)  (mg)*  
12 500 1 0.4 
150 000 12 5 
1 000 000 80 34 
4 500 000 360 150 
9 000 000 720 300 
Abbreviations:  CBA  = colistin  base activity; IU = international unit. 
* Based on a nominal potency of the drug substance of 12,500 IU/mg or 0.424 mg CBA/mg: both IU and mg 
CBA are expressions of potency and have only approximate relation to the mass.  The calculation for the 
conversion  of CBA  (mg) to colistimethate  sodium  (IU) for the purpose  of following  the dosing regimen  in IU, 
should be modified if the potency stated by the manufacturer is different to the nominal potency used in this 
conversion table.  
 
Reference 
European Medicines Agency completes review of polymyxin- b ased medicines. 
Recommendations issued  for safe use in subjects  with serious infections resistant  to standard 
antibiotics.  European Medicines Agency 2014, London, UK (EMA/643444/2014, 
24 O ctober  2014).  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  164  
 Appendix  8. Summary  of Changes from  Original Protocol through Amendment  
 
Document  Version  Date  Summary of Changes and Rationale  
Amendment  1 05 July 2018  • Increased sample size per FDA feedback in 
Protocol Summary/Study sites and number of 
subjects  planned, Target  Subject  Population and 
Statistical Methods, Section 3 Study Design, Section 9.1. Sample Size Determination.  
Per FDA guideline "Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment  of Serious Bacterial  Diseases  Guidance 
for Industry (August 2017)": In general, a safety database for a drug that is the subject of a streamlined development program should include approximately 300 patients at the dose and duration of therapy proposed for marketing. The 
number of subjects was increased to meet FDA guideline.  
• Increased number of countries and sites corresponding to the increase of sample size in 
Protocol Summery  and Section  1.4.1 Study Design 
and Control Group. 
• Modified wordings on the Primary  Objective and 
the 1
st two Secondary Objectives (ie, from 
“compared to” to “and”) to reflect no formal 
comparisons between treatment groups and included study analysis sets in the 1
st Secondary 
Objective to differentiate from the Primary Objective  in Protocol Summary/Table  Objectives 
and Section 2 Study Objectives. 
• Changed “aztreonam -resistant”  or 
“ATM -resistant” to “aztreonam -non- susceptible” 
or “ATM -non-susceptible” in Protocol Summary/ 
Table Objectives, Section 2 Study Objectives, Section 7.1.2.1 Microbiological Response Assessment and Section 9.3.3 Tertiary Outcome Variables for clarity.  
• Modified wordings on treatment day (eg, from  
“full day” to “day”; from “The duration of 
treatment  is 5 to 14 days for cIAI and 7 to 14 days 
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  165  
  
  for HAP/VAP” to “The recommended minimal 
duration of treatment is 5 days for cIAI and 7 days 
for HAP/VAP.  The maximal  duration of treatment 
is 14 days”) to reflect calendar day per Pfizer standard in Protocol Summary/Duration of treatment, Section 1.4.1 Study Design and Control Group, Section 1.4.3 Dose Selection for Metronidazole, Section 3 Study Design, 
Section 5.6 Administration (Dose and Treatment Regimen)  and Section  6.2.2 Visit 3 to 15: Ongoing 
Treatment  (Days  2 to 14). 
• Replaced reference to Aztreonam and Avibactam with combined test product Aztreonam -Avibactam 
in Protocol Summary/Table Investigational product, dosage form and strength and 
Table 2 Identity  of Investigational Product.  
• Deleted the reference to 1g aztreonam and 1 mIU 
colisitn in Protocol Summary/Table  
Investigational product, dosage form and strength and Table 2 Identity of Investigational Product to be consistent with study drug supply in IP Manual.  
• Added “Note: Comparators and co- administered 
drug are supplied centrally via the sponsor. In 
some instances, locally obtained commercial supplies will be utilized in accordance with local regulations” and “Note: Aztreonam, Meropenem, Colistin and Metronidazole are commercial products over- labeled  with the study clinical  label” 
in Protocol Summary Table Investigational product, dosage form and strength and Table 2- Identity  of Investigational Product for 
clarity.  
• Removed “first dose”, “second dose” and “third and subsequent doses” and added “first” before Maintenance  Dose  on Day 1 to increase clarity  on 
dose description in Protocol Summary/Table 
Aztreonam -avibactam ± metronidazole treatment 
arm, Table 3 ATM -AVI Doses in Relationship to 
CrCL, Section 5.6.1 ATM- AVI ± MTZ and  
Table 13 Pharmacokinetic ATM -AVI Sample 
Collection Time Points.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  166  
  
  • Modified wordings on creatinine clearance 
monitoring for consistency across  the protocol in 
Project Summary/Aztreonam -avibactam  
±metronidazole treatment arm.  
• Changed “randomization” to “first dose of study 
treatment” in Clinically Evaluable Analysis Set and in the use of other systemic antimicrobials in Protocol Summary/Definition of analysis sets, Section 5.10 Concomitant Treatment(s) and Section  9.2.1.2 Clinically  Evaluable (CE) Analysis 
Set to be consistent with Concomitant Treatment definition per Pfizer standard. 
• Deleted “(and wound examination for cIAI subjects)” in study procedure “Performing  focused 
physical examination (and wound examination for cIAI subjects) (see Section 7.2.2)” to avoid redundancy with Section 7.2.2 Physical Examination in Table 1 Schedule of Activities, Section 6.1.1 Visit 1: Eligibility/Screening Procedures, Section 6.2.1 Visit 2: Baseline Procedures  and Day 1 of Treatment,  Section  6.2.2 
Visit 3 to 15: Ongoing Treatment,  Section  6.2.3.1 
Visit 16: End of Treatment, Section 6.2.3.2 Visit 17: Test of Cure andVisit 18: Late Follow up 
(Day 45 ± 3 days). 
• Added “Collection  of imaging and surgical  report 
in subjects with cIAI” at every visit except Late Follow-up visit in Table  1 Schedule of Activities, 
Section 6.1.1 Visit 1: Eligibility/Screening Procedures, Section 6.2.1 Visit 2: Baseline Procedures and Day 1 of Treatment, Section 6.2.2 Visit 3 to 15: Ongoing Treatment, Section 6.2.3.1 Visit 16: End of Treatment and Section 6.2.3.2 Visit 17: Test of Cure for collecting  source data on 
case adjudication of clinical responses for cIAI subjects.  
• Added wordings of “local  lab for eligibility  criteria 
confirmation” in  footnote b of Table 1 Schedule of 
Activities, Section 6.2.1 Visit 2: Baseline Procedures and Day 1 of Treatment (Day 1) for clarity.  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  167  
  
  • Corrected  wordings  related  to the serum  HCO 3 use 
in place of arterial pH if no ABGs available in 
footnote c of Table 1 Schedule of Activities and Appendix 5 Acute Physiology and Chronic Health Evaluation.  
• Specified  acceptable time frame  of chest  X-ray/CT 
scan (within 48 hours prior to randomization) for HAP/VAP subjects in Section 6.1.1. Visit 1: Eligibility/Screening Procedures, Footnote f of Table 1 Schedule of Activities and Section 7.2.6.1 Chest X -ray/ CT Scan to be consistent with 
Section 4.1.3 Additional Inclusion Criteria (Criterion 2) for HAP/VAP subjects.  
• Specified respiratory specimen collection to increase clarity  on respiratory  specimen  reference 
time point and Baseline definition across the protocol in footnotes h and i of Table 1 Schedule of Activities, Section 6.1.1. Visit 1: Eligibility/Screening Procedures, Section 6.2.1. Visit 2: Baseline Procedures and Day 1 of Treatment, Section 7.3 Microbiology and Appendix 6 Microbiological Assessments.  
• Clarified blood sample collection for culture to avoid unnecessary  repeat  sampling  and increase 
clarity and consistency of blood specimens for culture across protocol in footnote k of Table 1 Schedule of Activities, Section 6.1.1 Visit 1: Eligibility/Screening  Procedures,  Section  6.2.2. 
Visit 3 to 15: Ongoing Treatment, Section 7.3 Microbiology and Appendix 6 Microbiological Assessments.  
• Updated  wordings on Phase 2a study descriptions 
per Phase 2a study status  in Section  1.3 Rationale 
for Conducting This Study. 
• Included local lab blood sample at Screening, corrected PK sample volume/pregnancy test frequency and updated number of samples and total blood volume accordingly in Table 14 Volume of Blood to Be Drawn  from  Each  Subject 
and Section 1.6 Benefits/Risk and Ethical  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  168  
  
  Assessment for clarity.  
• Changed colistin  infusion duration from  “30 min” 
to “30-60 min” in Figure 1 Study Outline for 
consistency across protocol. 
• Changed comparator  group name from  MER -COL 
to MER ± COL in Figure 2 Study Treatment for 
consistency across protocol. 
• Changed “duration  of the study” to “duration of 
study treatment” relevant to the statement of effective method of contraception in Exclusion Criterion 20 in Section 4.2 Exclusion Criteria (4.2.1 All Subjects) to increase the clarity and consistency on the time frame of contraception requirement across protocol. 
• Changed “prior to study entry” to “prior to screening” in Exclusion Criterion 21 to increase the clarity on the reference time point about participating  in other investigational interventional 
studies in  Section  4.2 Exclusion Criteria  (4.2.1 All 
Subjects).  
• Deleted “or female condom” in the 3
rd 
contraception method in Section 4.6.1 Contraception to accommodate globally 
acceptable contraception methods. 
• Added “or as necessitated  by the clinical  status  of 
the subject during the period of hospitalization, eg, unconscious/ventilated” as acceptable obviation of the need for contraception in Section  4.6.1 Contraception to accommodate the 
specific study population, eg, ventilated/unconscious subjects.  
• Changed “study drug” to “test product” for ATM -AVI to differentiate  from  comparator  for 
MER ± COL/The change is clarification in 
Section 4.4 Randomization Criteria and Section 5.1 Allocation to Treatment. 
• Changed “MER -positive” to “MER -resistant”  in 
Section 5.6.2 MER ±COL Treatment Arm for  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  169  
  
  clarity.  
• Added wordings on optional aminoglycosides in 
Section  5.6.3 Optional Aminoglycosides to  align 
with the texts in Protocol Summary/Meropenem 
±colistin  treatment  arm. 
• Added wordings of “and administered per local 
label” on Polymyxin B (the alternative  to Colistin) 
to provide the guidance on Polymyxin B 
administration in Section 5.6.2 MER ±COL 
Treatment Arm.  
• Changed “enrollment” to either “informed 
consent” or “the start IV study treatment” in Table 8 Prohibited Concomitant Medications to increase the clarity  on time frame  for Prohibited 
Concomitant Medications. 
• Modified definition  of “Cure”  and “Indeterminate” 
of clinical responses in Table 9 Definition of Clinical Response Categories  at the EOT  and TOC 
visits and “Indeterminate” of microbiological response in Table 10 Definition  of Microbiological 
Response Categories at the EOT and TOC Visits 
per FDA feedback for clarity. 
• Changed “100X field” to “Lower Power Field 
(LPF)” in footnote a of Table 10 Definition of Microbiological Response Categories  at the EOT 
and TOC  Visits  and Appendix 6 Microbiological 
Assessments for clarity.  
• Removed  the wordings of “(from  an 
intra-abdominal culture for cIAI subjects or an 
adequate respiratory specimen for HAP/VAP subjects)” from Table 11 Definition of Emergent Infection  Categories  to accommodate the situation 
of emergent infection arising from other sites instead of the original site of infection. 
• Deleted “and exact time” in the statement on ECG recording in CRF  in Section  7.2.3 ECG  as the time 
of each of the triplicate ECGs will be provided in the non-CRF data transfer from the vendor and it 
is not necessary to collect the time of ECGs in the  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  170  
  
  CRF.  
• Clarified PK sampling time point in reference to 
IV ATM -AVI Loading Dose, Extended Loading 
Dose and Maintenance Dose in Table 13 Pharmacokinetic ATM -AVI Sample Collection 
Time Points to be consistent with Figure 3 and ATM -AVI Pharmacokinetic Sample Collection 
Time Points for Subjects with CrCL  >30 mL/min 
(Q6h  Maintenance  Dose)  and Figure 4 ATM -AVI 
Pharmacokinetic Sample Collection Time Points 
for Subjects with CrCL >15 to ≤ 30 mL/min (Q8h 
Maintenance Dose).  
• Modified wordings on PK sample  collections  and 
drug concentration measurements to increase 
clarity in Section 7.4.1 Collection of Plasma Samples for Analysis of Aztreonam- Avibactam 
and Section 7.4.2 Determination of Drug Concentration per Pfizer Clinical Pharmacology protocol template.  
• Specified storage time frame for microbiology isolates  for clarity  in Section  7.6.1 Storage,  Re-use 
and Destruction of Biological Samples. 
• Added wordings on SAE report for fatal case due to disease  progression to align  with Pfizer  standard 
on fatal case report in Section 8.4.4.2 Disease Progression.  
• Changed “study entry” to “randomization” for the 
starting point on renal function monitoring for clarity in Section 8.5.1 Renal Function. 
• Deleted “>1.5” in 2
nd bullet point with the 
statement of “INR>1.5” in Section 8.5.2 Monitoring of Liver  related  Laboratory Parameters 
for error correction.  
• Changed “each visit” to “EOT and TOC visits” in reference to the clinical response assessments by the adjudication committee for error correction in Section  9.7 Independent Adjudication Committee.  
• Adding  wordings  on COMBACTE -CARE  
ATM -AV1 
C3601002 
Final  Protocol  Amendment  2, 18 May 2022  
PFIZER  CONFIDENTIAL  
Page  171  
  
  publication  policies  for clarity  in 15.2 Publications 
by Investigators. 
• Added “(except anaerobic bacterial pathogens 
isolated  from  subjects  with respiratory  infections)” 
in the statement for required shipment of microbiological isolates to the central reference laboratory in Appendix 6 Microbiological Assessments for clarity.  
• Clarified  Intra-abdominal specimen  collection  for 
culture to increase clarity and consistency of Intra -abdominal specimens for culture across 
protocol in Appendix 6 Microbiological Assessments.  
• Other  typographical or administrative  edits  to 
improve readability, clarity and consistency. 
Original  protocol  20 October  
2017  Not applicable  (N/A)  
 
 Signed By: Date(GMT)  Signing Capacity   
Document Approval Record 
 
 
C3601002 Protocol  Amendment  2 Clean  18May22 
C3601002 Protocol  Amendment  2 Clean  18May22  
 
PPD  23-May-2022 18 11 06 Final Approval  Document Name:  
 
Document Title:  